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Abstract 
HOX genes are a class of homeobox transcription factors that drive embryogenesis and generally 
are expressed during development and silent in the adulthood. Proliferation, invasion and 
metastasis have been related to an overexpression of HOX genes in various forms of carcinoma, 
including prostate, colorectal, melanoma, breast and ovarian. HOX genes appear to be a valid target 
for targeted therapies given their selective expression in malignant tissue. HXR9 is a cell penetrating 
peptide capable of disrupting the interaction between HOX genes and their co-factor PBX to 
prevent the activation of downstream HOX target genes (oncogenes?) and to induce selective 
apoptosis in cancer cells, in a molecular pathway that still need to be elucidated. HTL001 is a new 
version of HXR9 with a change in few aminoacids in the original sequence to enhance peptide 
synthesis, cell entry and efficacy of cell killing. HTL001 was tested on ovarian cancer cell lines and 
primary cultures. Its cytotoxicity was compared to HXR9 and it was proved that the mode of death 
was still apoptosis. The demonstrated drug efficacy in a wide range of carcinoma cell lines led us to 
test HTL001 in a new experimental platform, the precision cut tissue slice model that uses tissue 
obtained after surgery and therefore can resemble responses closer to a clinical setting. The 3D 
model was first optimised for viability and later tissue signs of apoptosis/necrosis after exposure 
with cisplatin and HTL001 evaluated. The limited cytotoxicy of HTL001 on ovarian cancer precision 
cut slices prompted us to investigate another strategy for drug delivery and the approach to insert 
multiple copies of HTL001 into a viral vector for long-term expression appeared to be a valid 
alternative that was evaluated in preliminary experiments transfecting ovarian cancer cell lines 
with different expression cassettes. Finally, the molecular pathway of HTL001 leading to apoptosis 
was investigated to identify potential biomarkers of response and targets for combinational 
therapy.  
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“Se ti è nato il gusto di scoprire non potrai che sentire il bisogno di andare più in là” 
(If the desire for discovery sparked in you, you will certainly feel the need to move forward) 
Walter Bonatti 
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CHAPTER 1 
 
1. Introduction 
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1.1.  Epidemiology of ovarian cancer 
Ovarian cancer is a common type of malignancy in the western developed countries with 7300 new 
cases and 4300 deaths registered in 2015-16. That means there is a 4% incidence and a 5% mortality 
among women in the UK according to data published by Cancer Research UK statistics [1]. Ovarian 
cancer is the 5th most common cause of death among women with a low survival rate after 5 years, 
around 35% in the UK (2011) and 47% in the USA (2008-2014)[1, 2]. The key to improve survival is 
early diagnosis and currently the majority of women are diagnosed at an advanced stage, therefore 
there is still an urgent need to find better screening tests (biomarkers) and less aggressive 
treatments for this gynaecological malignancy where resistance to conventional chemotherapy is 
a major issue and symptoms get noticeable only at an advanced stage as compared to other cancer 
types. 
1.2.  Risk factors and screening 
Ovarian cancer is a multi-factorial disease; the single cause triggering the pathology is not clear, 
but it is now accepted that age, environmental factors, lifestyle and genetics can participate both 
singularly or together in different stages of an individual’s life. The median age of women at 
diagnosis is around 55 - 64 [2, 3], with epidemiologic studies suggesting that pre-menopausal 
women with a BMI >28 are prone to develop the disease [3]. Smoking and alcohol are negative 
factors as well as the use of talcum powder in the genital tract [3]. There is a 5 - 15% of probability 
for ovarian cancer linked to a family history of breast or ovarian cancer due to the mutations of 
BRCA1 and BRCA2 or p53, onco-suppressor genes that will be further discussed in the subsequent 
paragraphs. Protective factors seems to be the use of contraceptive pills, having children and 
breast-feeding, and it is probably associated with an optimal regulation of hormones in the body 
[1]. Screening for an early diagnosis remains an unmet need; transvaginal ultrasounds and CA-125 
blood test are the two only available methods at the moment. Unfortunately, CA-125 is an 
unreliable biomarker as unrelated factors can increase the level in the bloodstream with 50% of 
false positives given. 
1.3.  Diagnosis 
A brief overview on ovarian anatomy is given to better understand ovarian cancer types and the 
F.I.G.O. Classification (International Federation of Gynaecology and Obstetrics), the worldwide 
actual classification to evaluate tumour grading that will be briefly explained later. 
24 
 
The ovaries are paired organs, oval shaped, and part of the female reproductive system. Their 
dimension is usually around 3 - 5 cm in length and they are involved in the production of gametes 
for reproduction and hormones, oestrogens and progesterone that control and drive the 
maturation of the oocytes. Ovaries are connected to the uterus through the broad ligament at the 
posterior side, while the anterior part is in touch with the terminal section of the Fallopian tubes 
plus partly the parietal peritoneum, which are usually the preferred organs for ovarian cancer 
metastasis to spread in direction of the uterus or up to the omental wall. The ovary can be divided 
into cortex (outer layer) and medulla (inner layer). The cortex surface is a cuboidal epithelium and 
it represents the germination centre of the follicles, which are supported during their maturation 
by a thick connective tissue. The medulla instead hosts a dense stromal tissue of fibroblasts, the 
neuro-vasculature and the hilum of the organ (Figure 1.3-1). 
 
 
 
Figure 1.3-1: Anatomy of the ovary.  
The ovary is an oval shaped organ with a length of 3 -5cm. The outer layer, the cortex, is a 
cuboidal epithelium and it  represents the germination centre of the follicles, which are 
supported during their maturation by a thick connective tissue. The medulla hosts a dense 
stromal tissue of fibroblasts, the neuro -vasculature and the hilum of the organ. The pict ure 
depicts the oocyte maturation from the follicular phase (1 -2) where the oocytes get ready 
to release the mature egg (3), to the luteal phase (4 -5) where the eventual unfertilised egg 
are released with the menstrual period. Taken from 
https://smart.servier.com/smart_image/ovary/  and modified (Creative Commons 
Attribution 3.0 Unported License) [4].  
 
 
For years it has been commonly accepted that the primary site of ovarian cancer origin were the 
ovaries and that shaped the current way of staging: in fact, at the time of diagnosis only one out of 
ten of ovarian cancer tumours shows alterations in the germinal cells or stromal cells from the 
1 
2 
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medulla [5]. However, nine out of ten new cases are epithelial carcinomas from the thin layer 
covering the ovaries, further subdivided according to histological characteristics (serous, mucinous, 
endometrioid and clear cells) or type. Type I (low grade) or type II (high grade) describe the 
aggressiveness of the tumours, level of cells differentiation and chromosomal changes. High grade 
serous epithelial ovarian carcinomas (HGS-EOC) type II are the most common types accounting for 
80 - 90% of the cases (Figure 1.3-2). 
Tumours are staged using F.I.G.O. classification to assess tumour spread stage: at stage I cancer is 
confined to one or both of the ovaries; at stage II tumour cells have spread in the peritoneal liquid 
or to the uterus and fallopian tubes, while at stage III lymph nodes are positive and metastasis can 
be found extra-pelvic or extra-peritoneum. 
 
 
 
Figure 1.3-2: Ovarian carcinoma classification.   
The classification is based on the histological subtypes and common alterations often 
exhibited by the different EOC types I and II. The most common and aggressive type of OC 
has an epithelial origin and serous secreting cancer cells. This type II cancer, following the 
FIGO classification, often exhibits mutations at P53 in the early stages of serous ovarian 
cancer development, suggesting that the inactivation of the gene is a pre -requisite for 
tumour progression. Type I epithelial ovarian cancers are less aggressive and sho w 
mutations at other key oncogenes or oncosuppressors as PTEN. Adapted from [6]. 
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In light of the recent discoveries, it might be possible that this classification will be revised. Two 
recent articles published in 2016 and 2017 in Cancer Discovery [7] and Nature Communication [8] 
respectively integrated and analysed an extensive amount of data from whole genome sequencing, 
DNA methylation and SNPs status from a small cohort of patients from whom micro-dissected 
tissue was taken from lesions at different sites (left or right ovary, omentum, fallopian tubes and 
serous tubal intraepithelial carcinomas, STIC). Both proposed how the primary site of ovarian 
cancer in HGSEOC could arise from STICs in the fallopian tubes from cells that acquired early 
mutations at p53 followed by other mutations in key regulator genes from the PI3K pathway 
involved in cell cycle regulation and from the homologous recombination DNA repair system genes 
BRCA1/BRCA2. These findings are in line with the theory of clonal evolution of cancer where 
tumours are a collection of mutations through time that result in cells with uncontrolled functions 
of proliferation, invasion and seeding to other metastatic sites. Identifying driving mutations 
responsible of tumour onset might change clinical practice and open new windows for early 
screening and decision regarding surgical intervention. 
1.4.  Standard therapy 
Optimal management of ovarian carcinoma, and in particular the most frequent EOC, is a 
combination of surgical cyto-reduction and platinum-based chemotherapy administered in a time 
and stage dependent manner. 
Cyto-reduction followed by 6 cycles of intra-venous administered combination therapy of 
carboplatin and paclitaxel is the standard approach to treat stage II - IV ovarian cases. PEGylated 
liposomal doxorubicin (PLD) works in some cases as an alternative treatment and in relapsed 
disease as well as for those who do not tolerate paclitaxel [9]. As 70% of the patients will relapse 
within 3 years, follow-up treatments are based on the response to the first course of platinum 
treatment: patients who relapse after more than 12 months are usually classified as platinum 
sensitive, or partially sensitive if the relapse is occurring between 6-12 months. Patients who 
relapse within 6 months are classified as platinum resistant, or refractory if they do not respond at 
all to first line treatment. For the first two categories surgery is advisable if the patient has good 
overall clinical situation and a re-challenge with carboplatin in combination with other agents 
(paclitaxel, gemcitabine, anthracycline or PLD) is now standard practise [10, 11]. This approach can 
be used for platinum resistant or refractory patients with the final aim to control symptoms and 
improve quality of life; clinical trials showed no particular superiority of any agent and a low 
response rate as well as a short improved Progression Free Disease (PFD) of a maximum of 3-4 
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months [12]. Radiotherapy or hormone therapy are alternative palliative treatments for non-
responder patients. 
1.5.  Therapeutic targets that successfully translated into clinical practice 
Conventional therapies for OC are often toxic and require extra supervision in the hospital, patients 
have to face side effects such as weight loss and alopecia, nausea, vomiting or nephrotoxicity and 
myelosuppression. Mechanisms of resistance develop generally within less than 18 months in 70% 
of the patients. Researchers are constantly exploring new approaches to improve Overall Survival 
(OS) in women with ovarian cancer and several targeted therapies have been developed over the 
years with a huge effort spent to identify good biomarkers for early detection and targets for 
therapy. A brief overview of them, focusing on few examples of the most innovative clinical trials 
will be outlined in the following paragraph. 
 
1.5.1. Anti-vascular agents 
Certainly, the best example of targeted therapy approved by the FDA and now standard practise in 
the USA for the treatment of platinum-resistant OC is Bevacizumab (BV). 
Bevacizumab (Avastin), is a monoclonal antibody developed by Roche/Genentech that blocks 
angiogenesis, inhibiting the vascular endothelial growth factor (VEGF-A) and it is administered in 
combination with chemotherapy. Use of Bevacizumab immediately after surgery and as 
maintenance following the initial treatment of ovarian cancer has been supported by two studies, 
ICON7 and GOG218 [13, 14].  
In the relapsed setting, AURELIA was the first randomised phase III clinical trial meeting the primary 
endpoint of the study and showing a benefit in terms of progression free survival (PFS) in the BV 
treated arm [15]. 
 
1.5.2. PARP inhibitors 
Another biological therapy that obtained approval by the FDA and shows encouraging results is a 
family of compounds called PARP inhibitors (PARPi). 
PARP (poly ADP-ribose polymerase) is a protein that belongs to the family of enzymes recruited in 
in case of DNA damage. Ovarian cancer frequently shows mutations at BRCA1 and BRCA2, resulting 
in a loss of the pivotal components for reparation of DNA lesions. When treating OC with 
chemotherapy in combination with PARPi, a dual synthetic lethality occurs; cancer cells gradually 
accumulates DNA breaks that the inactive homologous recombination (HR) repair system occurring 
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with BRCA1 and BRCA2 mutations cannot solve. The second lethality is given by the action of PARP 
inhibitors on PARP and the BER system leading to a further accumulation of point mutations 
potentially lethal for cancer cells. Normal cells with functional BRCAs can efficiently solve double 
strand DNA breaks and are protected by the synthetic lethality of the drugs combination. 
The benefits of one of these cytotoxic agents, Olaparib, was shown in STUDY 19, a double-blind 
phase II trial that randomised patients with platinum-sensitive recurrent serous ovarian cancer to 
receive chemotherapy and Olaparib as capsules, 400mg twice a day or placebo. The overall survival 
advantage did not reach statistical significance, but a p=0.025 in the BRCA mutated subgroup 
suggested a benefit for these patients [16]. 
 
1.5.3. Other targeted agents 
Overexpression of the human epidermal growth factor receptor (HER2) has been associated with 
solid cancers including ovarian carcinoma. In breast cancer HER2/ERBB is a biomarker for worse 
prognosis and an important target for therapy. HER2 belongs to a family of tyrosine kinases and 
becomes active only after dimerization with other members of the family (HER1, 3 or 4 or omo); 
the dimer is capable of phosphorylating proteins involved in the RAS and PI3K/AKT signalling 
pathways promoting cell proliferation and survival, therefore constituting an interesting target for 
therapy. 
Trastuzumab is one of the most representative examples of an HER2 inhibitor, an antibody 
preventing HER2 dimerization that in 2012 was approved by the US FDA for use in combination 
with Pertuzumab (same family of inhibitors) and docetaxel chemotherapy for the treatment of 
patients with HER2 positive metastatic breast cancer. Bookman et al. evaluated the effect of 
Trastuzumab as a single agent in patients with refractory or recurrent ovarian cancer in a phase II 
trial, but despite the high concentration of soluble HER2 and the absence of anti-trastuzumab 
antibodies in serum, the outcome of the trial was disappointing as they only achieved one complete 
and two partial responses with only a 2 months difference in the PFS [17]. 
 
1.5.4. Immunotherapy 
Lately immunotherapy of cancer has received great attention thanks to advances in the 
understanding of the so-called immune checkpoints, a family of co-stimulatory or co-inhibitory 
molecules expressed on immune cells and tissues that modulate immune responses.  A well-
characterised method how cancer cells escape the immune system is through an inhibitory ligand 
on their surface (PDL1), a binding partner for the PD1 receptor expressed on T cells. Release of 
cytokines and changes in the tumour microenvironment contribute to force antigen presenting 
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cells (APC) or T-cells to express CTLA-4 and its co-partner B7 that stop T lymphocytes signalling. 
Together with PD1/PDL1, they constitute an attractive target for blockade by monoclonal 
antibodies to restore T cell function (Figure 1.5-1) 
 
 
 
Figure 1.5-1: Immune-checkpoint inhibitors.  
The interaction between T-cells and tumour cells or other cells from the immune system 
(B-cells, NK cells) is t ightly regulated by the recognition of the T cell receptor (TCR) of an 
antigen presented via the MHC (mayor histocompatibility complex). Other co -stimulatory 
and co-inhibitory surface receptors (cluster of differentiation, CD) help to amplify (CD28) 
or switch-off the signal (CTLA-4, PD-1/PDL-1). Tumour cells evading the immune syste m 
generally overexpress T -cell inhibitory signals on their surface, therefore their inhibition 
using monoclonal antibodies is a new leading strategy for immunotherapy of cancer. Image 
from [18] available via license: CC -BY-NC-3.0. 
 
 
Several among them have been tested in clinical trials and a few of them have already received 
approval from FDA for treatment of solid cancers. This is the case for Ipilimumab approved in the 
US in 2011 for the treatment of inoperable or metastatic melanoma patients.  In the context of 
ovarian cancer, Ipilimumab, a mAb anti-CTLA-4, showed the stabilization of CA-125 levels in two 
metastatic ovarian carcinoma patients previously vaccinated with autologous tumour cells virally 
forced to express granulocyte macrophage colony-stimulating factor (GMC-SF) in a phase I trial 
[19]. Another example is Avelumab, an anti-PDL1 blocker whose efficacy, dosage, pharmacokinetics 
and adverse effects were evaluated in a phase Ia trial enrolling patients with metastatic or locally 
advanced solid tumours that had received more than 3 cycles of chemo, but had not been assessed 
previously for PDL1 expression [20] .  
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1.6. Challenges to identify new effective targets for OC treatment 
The recent advances in the molecular techniques to a genome sequencing level have incredibly 
broadened our understanding of molecular pathways leading to oncogenesis and are continuously 
constituting a necessary tool for identifying new candidate genes that can be used as targets for 
therapy or biomarkers of diagnosis and/or response to treatments. It has been widely recognised 
how a proper patients’ stratification based on molecular profiling is essential to obtain better 
responses. The identification of new genes to use in the future in clinical practice is an urgent 
necessity for gynaecological malignancies too. 
In an extensive work from Ciriello et al. [21], genomic and epigenetic data were combined from the 
The Cancer Genome Atlas (TCGA) database analysing 3000 tumour samples to identify common 
patterns in several solid cancers. Regarding ovarian carcinoma, the tumour was classified in the C 
class, which was described by an early mutation at tumour suppressor p53 followed by a cascade 
of events that leads to a mosaic of genetic instability often seen in cancer patients. Class C tumours 
were further subdivided whether they were showing mutations at chromosome 8 (MYC) and class 
C13 included the typical pattern seen in HGSEOC with germline or somatic alterations at BRCA1 and 
BRCA2. Mutations in the PI3K-AKT-mTOR pathway were observed as well as KRAS, CNNE1 (Cyclin 
E1), E2F3 and Aurora Kinase A (AURKA) (Figure 1.5-4). Interestingly, in the article published by the 
Cancer Genome Atlas Research Network [22], HGSEOC was categorised into descriptive subtypes 
considering differential genes’ expression; one of them, the “mesenchymal” subtype, was 
expressing high levels of HOX genes and other markers related to an expansion of the stromal 
components. 
Each emerging target will be further discussed and its potential pharmaceutical inhibitions and 
clinical trials, where available, explored in the next paragraph implementing the description of 
some of the already briefly mentioned genes in Section 1.5. 
 
1.6.1. P53 
Tumour protein 53, TP53 or simply p53, is a 53kDa protein with a pivotal role in the control of DNA 
damage status of a cell. Its protein level is tightly regulated by MDM2 in a negative feedback fashion 
with increased concentrations seen in case of DNA damage. In fact, P53 is able to “sense” the stress 
status of a cell and interact with key regulators proteins of the cell cycle progression as p21, 
GADD45 and 14-3-3α to pause the cell and let the DNA repair systems to efficiently repair the 
damage. In the case of not solvable repairing, it is again P53 that activates pro-apoptotic genes like 
APAF-1 and BAX to force the cell to undergo programmed cell death. 
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Figure 1.5-2: P53 Functions. 
P53, the guardian of the genome, is capable of sensing a variety of external or internal 
cellular stress and converting the damage into a molecular cascade. The image shows a 
non-exhaustive list of p53 functions after stress, including the cell cycle arrest via p21, 14 -
3-3 and GADD45 to allow the activation of DNA repair  systems. In the case of a persistent 
stress and un-resolvable DNA damage, it is still p53 that initiates apoptosis via BAX, NOXA 
and PUMA. MDM2 regulates p53 protein content in the cytoplasm. Image from [23] under 
CC-BY-4.0 license. 
 
 
It is not surprising that P53 has been nominated the “guardian of the genome” and it is one of the 
early mutations with loss of function that occurs in cancer leading to genomic instability, accounting 
for 95% of the cases for HGS epithelial ovarian cancer. Due to its high rate of alteration in OC in the 
early onset of tumour development as well as in other cancer types, p53 is not an ideal biomarker 
for diagnosis, but as target for therapy, strategies aim to insert the defective p53 using 
Adenoviruses or small molecules mimicking its function such as PRIMA-met [24]. 
Other approaches prevent the accumulation of defective p53 protein, which have been shown to 
interact with aberrant pathways and being oncogenic [25] . Nutlins are a classic example of inhibitor 
of MDM2 that regulates levels of p53.  
 
1.6.2. BRCA1 and BRCA2 
Germline mutations at BRCA1 and BRCA2 have been observed in 15 - 20% of the ovarian carcinoma 
patients and their alteration linked to a 50% increase in the possibility to develop ovarian cancer 
HGS type II  [22]. The screening for BRCA1 and BRCA2 is now becoming clinical practice to stratify 
patients that could respond to PARPi treatment. The indirect targeting of BRCA1 and BRCA2 
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represents nowadays one of the most promising target therapies for HGSEOC cases as described in 
Section 1.5.2. 
 
 
Figure 1.5-3: PARP inhibitors synthetic lethality. 
When administering PARP inhibitors to BRCA negative patients, tumour cells becomes 
unable to solve DBSs and undergo apoptosis. There are recent evidences of acquired 
resistance through the activation of RAD52 involved in the homologo us recombination 
(HR). The eradication of residual HR is achieved when inducing a dual synthetic lethality 
with RAD52 inhibitors. Normal cells are protected by a fully functional BRCA dependent 
repair system [26]. Image taken from [26] under Creative Commons licence CC BY-NC-ND 
4.0 
 
 
1.6.3. Other molecular targets 
c-myc belongs to a family of transcription factors with the ability to bind DNA and activate gene 
expression via a basic-helix-loop-helix structural motif. The protein plays a central role in several 
molecular pathways and to name a few it is involved in cell-cycle control, proliferation, 
angiogenesis and apoptosis [27]. In ovarian cancer, abnormalities at c-myc results in its gene 
amplifications up to 30% of the cases [21]. Its central role in several biological processes makes c-
myc an unattractive marker for diagnosis, but it is indeed a valid prognosis marker for poor 
outcome in patients demonstrating c-myc amplification [28]. The therapy targets the gene with 
siRNA [29] in platinum resistant cell lines or using small molecules inhibiting the c-myc promoter or 
binding with its cofactor MAX [30], but the limited efficacy can be explained by the amplification of 
the number of alleles of the gene that translate into abundant level of oncogenic protein. 
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The PI3K-AKT-mTOR pathway is another central molecular hub to regulate responses to growth 
factors and cytokines, therefore it is implicated in cell cycle regulation, control of apoptosis and cell 
proliferation. The ligand of the tyrosine kinase receptors activates a cascade of phosphorylation 
that switch on the PI3K protein to generate a second messenger PIP3 that in turn recruits AKT. 
Conformational changes in AKT trigger the protein to phosphorylate its several targets as mTOR for 
survival, inhibition of BAD (apoptosis) and activation of MDM2 which inhibits P53 [31]. Alterations 
in the PI3K-AKT-mTOR pathway counts for up to 46% of cases in ovarian carcinoma, in particular 
the catalytic subunit of PI3K (PI3KCA) is amplified in 38% of the cases prevalently in clear cell and 
endometrioid cancer tumours. PTEN deletions, a protein that inhibits the phosphorylation of AKT 
by PI3K, are seen in 7% of the cases and generally associated with type I tumours (see Figure 1.3-2) 
[6, 21, 22]. Therefore, this pathway remains an attractive target to small molecules inhibitors and 
researcher have explored several compounds either directing PI3K, AKT or mTOR. BKM120 
(Buparlisib) is a pan-PI3K inhibitor that blocks the catalytic unit p100α (PI3KCA) and prevents the 
formation of the second messenger PIP3. 
The GINECO group run a phase II clinical trial exploring dosage and clinical efficacy of BKM120 as 
monotherapy in stratified patients according to type I or II OC classification. A total of 64 patients 
were enrolled, but the study was stopped before the end of recruitment due to the high toxicity of 
the drug observed and low clinical efficacy [32]. 
 
 
KRAS amplifications signature for mucinous ovarian carcinoma [22], have been observed in 15% of 
OC cases in a study by Ciriello et al. [21]. KRAS belongs to a family of G-coupled proteins with an 
intrinsic GTP-ase activity. The hydrolysis from GTP into GDP induces conformational changes into 
an active KRAS able to phosphorylate RAF and PI3K creating a connection between the two 
pathways. Intermediate and final targets of this cascade of activation are MEK1/2 and ERK1 
respectively. The RAS/RAF/ERK pathway is involved in survival and proliferation. 
Several small molecules have been developed to target RAF or MEK1/2 just to name few and 
Sorafenib and Selumetinib reached phase II clinical trials. Sorafenib was developed by Bayer and 
approved by the FDA for treatment of liver and kidney cancer. 
 
 
Amplifications at CCNE1 (cyclin E) and EF23 have been registered in 20% and 13% respectively of 
OC cases [21]. High levels of cyclin E impairs the inhibitory regulation of RB (retinoblastoma) on the 
E2F family, therefore the cells are able to enter G1/S phase. A strategy under investigation to stop 
the aberrant activity of the RB signalling is the use of small molecules targeting the CDK2 protein. 
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To date there are no clinical trials testing the efficacy of CDK2 inhibitors in ovarian cancer patients, 
but in vitro pre-clinical studies are confirming that cells overexpressing CCNE1 are susceptible to 
CDK2 inhibitors and possible mechanisms of resistance to the drug are due to overexpression in 
CDK2 [33]. 
 
20% of amplification of Aurora Kinase A (AURKA) have also been observed for OC cases. AURKA is 
a key regulator kinase for the transition from late G2 phase into M (mitosis). 
Danuseritib is the most encouraging small molecule compound with a phase II clinical trial 
conducted by Schöffski et al. in 2015 [34]. Out of the 34 OC patients enrolled, only 4 had PFD after 
4 months treatment out of the at least 10 required to carry on with the second stage of the trial 
suggesting the compound only had a partial and weak response when used as monotherapy in 
heavily pre-treated patients. 
 
 
 
Figure 1.5-4: Molecular pathways generally altered in ovarian carcinoma.  
P53 mutation occurs in more than 90%  of the new cases at early disease onset , in particular 
in HGS-EOC. Mutations at P53 results in a non -functional protein unable to correctly 
control the cell cycle (through p21 and GADD45) and DNA repair systems. The homologous 
recombination pathway is also mutated in 20% of OC with defects at BRCA1 and BRCA2. 
Overexpression of the oncogene c -MYC is probably associated with P53 mutations. 
Alterations in the RAS and PIK3A (a subu nit of PI3K) lead to an aberrant signalling cascade 
in response to cytokines and growth factors resulting in increased survival. PTEN mutations 
has been registered as well with a decreased ability to inhibit  and regulate the PI3K -AKT-
mTOR pathway. An increased expression in the level of messenger cyclin E is often seen in 
type I tumours resulting in the transition to G1S phase of the cell cycle through the 
retinoblastoma Rb/E2F complex. Modified from [35]. 
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1.7. The unmet need of identifying new therapeutic targets for OC 
Given the brief overview of current standard and the new targeted therapies for the management 
of ovarian cancer, it is clear that lot of work has been done in the last decade to make possible the 
progress into clinical trials phase III for a good number of cytotoxic compounds and the approval 
by the medicine agencies FDA or EMA. Extensive pre-clinical effort is still needed to identify 
predictive biomarkers for early diagnosis or prognosis and to stratify patients to tailor the treatment 
and obtain better overall survival and quality of life. Indeed, new targets for therapies are required 
for OC, in particular for the conservative management of relapsed and refractory patients. 
 
1.7.1.  The HOX genes superfamily 
HOX genes appear to be a valid candidate for future clinical investigation and drug discovery thanks 
to the extensive research made since 1986 when the organisation and the whole paralogues had 
been identified in Drosophila and mammals [36]. HOX genes are a family of highly conserved 
transcription factors (TF) that drive and control embryogenesis across species. In mammals there 
are 39 Hox genes divided in four clusters A, B, C and D. Each cluster lays on chromosome 7, 17, 12 
and 2 respectively [37]. HOX proteins play a pivotal role in determining the anterior-posterior (A-
P) axis during development: 9 to 11 proteins are expressed for each cluster and paralogues across 
clusters might have a redundant function that still has not been entirely elucidated (Figure 1.7-1). 
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Figure 1.7-1:  HOX clusters and the principle of collinearit y. 
HOX genes are highly conserved across species and in humans they have been duplicated 
during natural gene evolution to a final number of 39 HOX genes organised in 4 clusters 
and further subdivided in paralogues 1 -13. The function is probably redundant.  
HOX genes follow the principle of collinearity where genes at the 5’ end drive the 
formation of distal organs and limbs, while structures at the 3’ end are expressed earlier.  
Adapted from [38]. 
 
 
HOX expression follows the principle of spatial and temporal collinearity, which means paralogues 
at 5’ controls the development of distal structures of limb and organs, while the timing of 
expression runs 3’ to 5’ with proximal regions forming first during organogenesis [39, 40]. Taylor et 
al. [41] discovered that during the formation of the female reproductive system the 
paramesonephric ducts (or Mullerian ducts) gives origin to the uterine tubes, uterus, and upper 
portion of the vagina. The process is driven by HOX genes: following spatial collinearity HOXA9 is 
firstly expressed in the fallopian tubes, HOXA10 in the uterus, HOXA11 in the cervix and HOXA13 in 
the upper vagina. In another study, the results from Taylor and colleagues regarding HOXA11 
function in the cervix development were confirmed. A lack of fertility in male and female mice 
carrying mutations for HOXA11- was observed: female mice had a defective uterine preventing 
implantation, but normal eggs capable of being fertilised and development of normal embryos in 
surrogate wild type mothers. Male mice had instead a non-functional tract that was disrupting 
spermatogenesis [42]. Interestingly, despite the fact that HOX genes are generally expressed during 
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embryonic development, HOXA10 and HOXA11 expression persists into the adulthood, relegated 
to the endometrium of both human and mice and regulated by oestrogens during the menstrual 
cycle and pregnancy [43]. 
 
1.7.2. Attractive characteristics of HOX genes as drug targets 
An ideal target for drug discovery should demonstrate several essential characteristics including: 
1) selective expression to pathologic tissue; 2) oncogenic functions and 3) the possibility to be 
additionally a valid prognostic marker for drug sensitivity. 
 
1.7.2.1 Hox genes temporal and spatial de-regulation in cancer   
Numerous examples from the literature have demonstrated an aberrant regulation of HOX genes 
in several cancers including prostate, colorectal, melanoma, head and neck, breast and 
gynaecological disorders as well as cancers of the blood [44-48]. 
HOX genes demonstrate none of very little expression in normal tissue and in the context of ovarian 
cancer, Cheng et al. [49] showed that the HOX genes which normally regulate Müllerian duct 
differentiation were not expressed in normal ovarian surface epithelia (OSE), but were expressed 
in epithelial ovarian cancers (EOCs) while performing immunohistochemical analysis of biopsied 
tissue. Additional data from Yamashita et al. [50] who created an expression profile of HOX genes 
in ovarian-derived samples, showed little or no expression in normal samples as well. 
The upregulation of homebox superfamily genes only in the context of cancer, makes them 
attractive targets for therapies, given the selectivity of expression limited to tumour site. 
Aberrant HOX genes expression has been documented from the comprehensive analysis on the 
entire 39 HOX genes expression in OC from the work of Yamashita et al. [50], Tait et al. [51] and 
Kelly et al. [52]. Yamashita et al. found an aberrant overexpression of HOXA10, HOXA13, HOXB4, 
HOXB7, HOXB13 and HOXC13 in cell lines and tissue compared to normal tissue, but an 
undetectable expression of HOXB1, HOXC3 and HOXC9 both in normal and cancer samples by qPCR.  
Tait et al. screened a microarray containing 65 ovarian cancer tissues and observed that the most 
up-regulated genes were HOXB2 and HOXB3, while expression of HOXA7, HOXA10 and HOXD1 was 
unchanged.  In 2016, Kelly et al. demonstrated a dysregulated pattern in cluster B from a panel of 
HGS ovarian cancer cell lines of the PEO series. HOXB3, HOXB4 and HOXB9 were significantly 
upregulated. However, an alteration in HOXs from cluster A was seen in the peritoneal liquid 
derived cell line COV318 with an HOXA9 overexpression. HOXA9 and HOXA3 were particularly 
upregulated in HGS patients’ tissues as well and the authors identified a pattern of expression for 
endometrioid samples (overexpression of HOXA7, A9, A10, A13, B1, B4, B5, B13, C9, C13, D9 and 
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D10) in an effort to link HOX profile expression to a particular tumour subtype for patients 
stratification and prognostic markers identification. 
 
Oncogenesis is a biological process often associated with abnormal organogenesis and 
differentiation. As HOX genes are involved in the correct organ development in a tightly regulated 
spatial and temporal manner, many research groups have hypothesized that homeobox genes are 
essential to maintain tissue- or organ-specificity even in adult body and they have focused on 
understanding whether the aberrant HOX regulation in cancer leading to tumour progression was 
following any principle of spatial or temporal collinearity. 
In a key paper for HOX discovery published in Nature Medicine, Chen et al. [58] confirmed previous 
results from Taylor et al. [41] regarding the tempo-spatial collinearity observed in the female 
reproductive system with a selective overexpression in mice and human tissue of HOXA9, HOXA10 
and HOXA11 with qPCR and IHC. Immunohistochemical analysis in EOC tissue showed how HOXA9 
was expressed in all EOCs subtypes. However, HOXA10 was strongly expressed in endometrioid and 
mucinous and HOXA11 staining was only observed in mucinous EOCs, suggesting the first strong 
evidence that the reactivation of HOX genes in ovarian cancer follows the development scheme of 
the Mullerian duct. Moreover, when forcing the expression of HOXA9, HOXA10 and HOXA11 in 
normal OSE cells from mice and inoculating cells in vivo, tumours resembled a HGS, endometrioid 
and mucinous carcinoma respectively. 
Similarly, Takahashi et al. [53] evaluated all Hox gene expression levels in primary oesophageal 
squamous cell carcinoma tissues and seven matched normal specimens by quantitative reverse 
transcription PCR (qRT-PCR). The normal oesophagus expressed more 3′ Hox genes and much 
higher levels when compared with the expression of 5′ Hox genes in line with the principle of spatial 
collinearity. By contrast, this pattern was lost in tumour samples, with significantly increased 
expression of the distal 5′ Hox genes. A further analysis revealed different expression levels of HOX 
genes within different status of tumour stage (T1, T2 and T3). This upregulation was most 
prominent in tumours of stage T2, suggesting also a transient temporal upregulation of HOX genes 
leading to tumour development and progression. 
 
Very little is clear about the exact Hox family regulation of expression, mainly dependent on the 
complexity to analyse a high number of HOX genes and the temporal-spatial differential expression 
organ specific. Proposed mechanisms of control of HOX genes are mainly 1) epigenetic 
modifications and 2) long non coding RNAs. 
39 
 
Epigenetic modifications are a series of residues added on the tail of histones that are packing DNA 
information with the final aim of controlling gene expression. The process is tightly regulated in 
normal cells, but becomes aberrant in cancer cells generally leading to a switch on of certain pro-
oncogenes or a switch off of tumour suppressor genes. This scenario can be observed in ovarian 
cancer as well and some evidences comes from recent the work of Wu et al. [54], where they found 
HOXA9 highly methylated in ovarian cancer cell lines and in half of the primary tumours. HOXA9 
hyper methylation was statistically associated with an early FIGO stage and endometrioid subtype. 
Methylation to a lower extent was seen in the HGS-EOC again suggesting the oncogenic role of 
HOXA9 to be in promoting a more aggressive tumour type. Discrepancies with the above arise with 
the data published by Montavon et al. [55]. HOXA9 methylation was observed in 95% out of the 80 
cases of HGS-EOC, but not detectable in normal ovarian surface epithelium (OSE). The methylation 
status of HOXA9 and another gene of the homeobox family, engrailed 1 (EN1), combined was 
proposed as a signature to discriminate HGS cancer tissue from benign with a sensitivity of 98.8% 
and a specificity of 91.7%. 
 
Long non coding RNAs (lncRNAs) are a heterogeneous family of RNA sequences found to be 
transcribed with genes, but not coding for proteins and with the function of regulating gene 
expression. From a clinical point of view, in ovarian cancer the two most attractive lncRNAs 
regulating HOX genes are HOTAIR and HOXA11-AS. HOTAIR (HOX transcript antisense RNA) is an 
antisense transcript located on chromosome 12 where the HOXC cluster is expressed. 
A recent article from Liu et al. [56] showed how HOTAIR is differentially overexpressed in cisplatin 
resistant ovarian cancer cell lines and how its upregulation is correlated with an increased cell 
proliferation as demonstrated from silencing HOTAIR with an siRNA. Downregulation of HOTAIR 
restored sensitivity to platinum therapy and reduced invasiveness and migration. It was also found 
that HOTAIR was positively regulating the expression of HOXA7 and their combined 
downregulation was supressing the tumour growth in vitro and in vivo.  
HOXA11-AS is an antisense transcript located on chromosome 7 and co-expressed with HOXA 
cluster. Richards et al. [57] showed a decreased expression of HOXA11-AS in EOC tissue compared 
to normal. Moreover cells with an ectopic expression of HOXA11-AS exhibited a reduced ability to 
proliferate and migrate. A trans regulation operated by HOXA11-AS was proposed as forced 
overexpression or knock-down of HOXA11-AS did not affect the mRNA level of the adjacent genes 
HOXA11 and HOXA13. The finding suggests the tumour suppressor role of this lncRNAs need to be 
further explored. 
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1.7.2.2 Hox genes as oncogenes   
The second and the most important feature that a good target for therapy should demonstrated is 
the role in tumour development acting as an oncogene. Many reports showed how members of 
the HOX family are involved in proliferation, differentiation, invasion, apoptosis and DNA repair; 
few examples from the literature are briefly reported here. 
The role of HOXB13 was investigated by Miao and colleagues [58] and its overexpression was 
quantified in a number of ovarian cancer cell lines and primary ovarian tumours. Knockdown of 
endogenous HOXB13 by RNA interference in human ovarian cancer cell lines correlated with 
reduced cell proliferation. However, ectopic expression of HOXB13 was altering growth rate of 
mouse embryonic fibroblasts containing genetic alterations in p53, myc, and ras in vivo. Similarly, 
HOXB13 was promoting a morphology change and anchorage independent cell proliferation in vitro 
in T1 ovarian cancer cells, a cell line generated from mouse ovarian surface epithelial cells that 
contains genetic alterations in p53, c-myc, and K-ras. 
Experiments from Naora et al. [59] group in the Simian virus 40-transformed human ovarian surface 
epithelial cell line, IOSE-29, which is a cell line with an “uncommitted phenotype”, revealed how an 
ectopic expression of HOXA7 promoted proliferation in OSE cells and also correlated with an 
increased production of bFGF, a potent growth factor. 
Functional studies Yamashita et al. [50] introducing an anti-sense sequence by electroporation 
against the particularly overexpressed HOXB7 and HOXB13 showed a decreased ability of invasion 
in matrigel assays, demonstrating again a possible role of HOXs in invasion and metastasis. 
Surprisingly, a tumour suppressor role was reported for HOXA5 only in breast cancer. HOXA5 mRNA 
levels was largely low in breast tumour tissue and when expressing of HOXA5 in epithelial cancer 
cells with wild-type p53, but not in cell lines lacking the p53 gene, the gene led to apoptotic cell 
death. Further analysis from the same group confirmed the role of caspase 2 and caspase 8 in 
mediating apoptosis [60]. 
Sukumar group [61] was the first team to identify that HOX genes can act as oncogenes playing also 
a role in DNA repair. They demonstrated that HOXB7 interacts with members of the DNA-PK 
holoenzyme (Ku70, Ku80, DNA-PKcs) involved in the NHEJ repair. Ectopic expression of HOXB7 
increased resistance to IR in the breast cancer MCF10A and knockdown of endogenous HOXB7 in 
MCF7 and MDA-MB-435 cell lines reduced the efficiency of DNA repair in vitro. 
 
1.7.2.3 Hox genes as prognostic markers 
Advantages as prognostic markers for ovarian cancer subtype identification or prediction of drug 
response have also been reported for some of the 39 members of the HOX family. 
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In one of the first studies of HOX gene expression in the context of ovarian cancer in 2001, Naora 
et al. [62] analysed the expression of HOXA7 in serous and endometrioid EOC at different stages of 
differentiation. HOXA7 RNA levels were upregulated in moderately and well differentiated cancer, 
particularly true for the serous subtype, but undetectable in the low stage cases. The finding were 
validated by immunohistochemistry where HOXA7 was expressed in the epithelium and not the 
stroma of cell surrounding tumour tissue. From the same study, in an attempt to identify new 
clinical biomarkers for early detection of OC, the serum of 24 patients was screened and it was 
found that 67% of them were generating anti-HOXA7 antibodies and 68% in a group of benign 
serous cystadenomas. 
Recent work utilising data from 630 ovarian cancer cases from the Cancer Genome Atlas linked the 
expression of HOX genes with clinic-pathologic features as FIGO stage, grade and suboptimal 
residual disease [63]. Advanced FIGO stage patients observed a high expression of HOXA1, HOXA4, 
HOXA5, HOXA7, HOXA10, HOXA11, HOXB13, HOXC13, HOXD1 and HOXD3. HOXB9, HOXB13 and 
HOXC13 overexpression correlated with the presence of residual disease due to suboptimal 
debulking surgery. Survival curves showed shorter overall survival in patients expressing high levels 
of HOXA10 and HOXB3, while HOXC5 appeared to be a protective biomarker, suggesting the role 
of HOX genes expression as a tool for chemotherapy sensitivity prediction. 
Another use of HOXs as biomarkers of response to treatment comes from the article recently 
published by Miller et al. [64]. They performed univariate and multivariate Cox regression analyses 
on an initial panel of 23 HOX genes further reduced to the 5 top genes of the initial screening. Gene 
expression was correlated with PFS and HOXA4 and HOXB3 had significant differences in PFS in the 
low and high expressing arms. In multivariate analysis the combined signature HOXA4/HOXB3 was 
able to define risk groups and optimal debulking surgery, whereas the presence of adjuvant 
chemotherapy was not affected. Authors underlined the importance of the role of HOXA4/HOXB3 
as response biomarkers in defining a sub-group of patients that relapsed after platinum treatment 
and received suboptimal surgery. 
 
1.7.3. Targeting the homeobox superfamily 
Given their selective overexpression and oncogenic functions in cancer, HOX genes have all the 
ideal features to be valuable prognostic biomarkers, as described in the previous section, and 
candidates for targeted therapies. 
In a phase II study from Matei et al. [65], platinum resistant OC patients were pre-treated with 
recurrent low doses of Decitabine, a DNA hypomethylating compound followed by carboplatin 
therapy. Nine out of seventeen patients had a PFS more than 6 months as compared to the placebo 
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arm. Among the panel of de-methylated genes positively associated with a PFD of more than 6 
months were HOXA10 and HOXA11 as measured in samples from ovarian cancer tissue and ascites. 
This is probably the first clinical trial showing how targeting HOX genes (among other genes) could 
improve clinical outcome. Another strategy to indirectly target HOX genes is the lncRNA HOTAIR 
(see previous Section 1.7.2.1) a peptide nucleic acids (PNAs) was proved to be effective in re-
sensitising resistant ovarian cells to cisplatin [66]. In the study a PNA was engineered to contain a 
nucleotide sequence conjugated to a peptide backbone capable of preventing the binding of 
HOTAIR with its partner EZH2, a histone methyl transferase and functional enzymatic component 
of the Polycomb Repressive Complex 2, PRC2. The abrogation of the interaction induced cell killing 
through IL-6 secretion and NF-κB pathway activation. 
 
One of the most promising approaches to target HOX genes for the treatment of cancer is a short 
peptide, called HXR9, developed by Morgan et al. within the Oncology Lab at the University of 
Surrey. HXR9 disrupts the binding between HOXs and their PBX co-factor and induces a selective 
apoptosis in cells overexpressing HOX genes [67]. HXR9 has shown efficacy against cancer cell lines 
derived from several solid cancers, including melanoma, ovarian, breast, prostate and 
mesothelioma [67-71] and blood cancers such as AML and malignant myeloma (MM) [72, 73]. 
A detailed description of the HOX protein structure and their co-factors is needed to understand 
the strategy behind the design of HXR9 (Figure 1.7-2). The functional region of the HOX gene is 
an 183bp DNA portion on the exon 2 that translates a 61a.a. helix – turn – helix motif called 
homeobox or homeodomain (HD) and assigns the name to the family. The HD has a DNA binding 
preference for sequences containing TAAT/TTAT that was identified via NMR studies [74, 75]. 
 
 
 
Figure 1.7-2: Schematic representation of HOX protein structure . 
The 61 a.a. long helix-turn-helix domain, which is the functional homeobox domain has 
been highlighted together with the 5 a.a. long conserved hexapeptide for the TALE family 
binding. The two regions are separated by a flexible linker. Variable regions are 
surrounding the conserved portions at N -term and C-term. HX, hexapeptide; HD, 
homeodomain.  
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Upstream of the HD, HOX paralogues 1 – 8 exhibits a conserved region, the hexapeptide HX, where 
a tyrosine (Y) is generally followed by a proline (P), tryptophan (W) and methionine (M) [76] (see 
Figure 1.7-2). The HX region is connected to the HD with a flexible linker of a few a.a. [77]. HOX 
proteins can bind DNA at target genes as homodimers or the “YPWM motif” can interact with PBX, 
a member of the TALE family, to form heterodimers. Three-amino acid-loop extension (TALE) is the 
extra three amino acids loop with sequence Y-P-Y inserted between helix 1 and helix 2 of the PBX 
homeodomain that makes it divergent from the HOX proteins homeobox [78]. 
 
 
 
Figure 1.7-3: YPWM motif.  
HOX paralogues show a conserved  region called the hexapeptide for the binding to their  
co-factor PBX. In the picture it is highlighted in light grey. Modified version from  
Shanmugam et al. [79]. 
 
 
In humans there are four PBX proteins 1 - 4 with redundant function and their partnership with 
HOX proteins stabilises them and creates a stronger affinity at target DNA.  
Pre-B cell acute lymphoblastic leukaemia, PBX, was first identified as an oncogene for ALL in the 
form of an aberrant fusion gene with another transcription factor E2A [80]. The original E2A-PRL 
found in pre-ALL neoplastic B cells was containing a portion of E2A and the homeobox region of 
PRL (later re-named PBX). Later experiments confirmed that PBX alone cannot activate 
transcription as E2A-PBX1 or PBX alone failed to binds the DNA probes in immunoprecipitation (IP) 
studies , but it required HOX collaboration to accommodate both the homeobox domains (HOX and 
PBX) on the target sequence [81]. To complicate the picture, the conserved tryptophan W in 
paralogues HOX9 is sufficient for the PBX biding despite the lack of the hexapeptide region, but not 
for HOX11-13 [82]. Besides, other members of the TALE family MEIS1 and MEIS2 have been 
characterised in humans and they can bind either PBX through a conserved PBC-A domain [78] or 
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HOX paralogues from distal region (HOX 10-13) [83].  HOX-HOX, HOX-PBX, HOX-MEIS and HOX-PBX-
MEIS are all possible combinations of cooperation (Figure 1.7-4) that can modulate differently the 
transcription process operated by HOX proteins opening to an extensive variety of target gene 
expression [84]. 
 
 
 
Figure 1.7-4: HOX proteins and their co -factors from the TALE family. 
HOX proteins can homodimerise to create weak bonds at DNA with the homeodomain (HD). 
However the partnership with PBX through the interaction between the hexapeptide (HX 
or YMPW motif) and the TALE loop stabilises the heterodimer at the DNA site.  
The preferred binding sequence conta ins TAAT or TTAT. PBX in turn can interact with MEIS 
thanks to a PBC-A conserved domain. Finally HOX protein from paralogues 10 -13 can bind 
MEIS at its C-terminus. The preferred MEIS binding sequence slightly differs from PBX, 
having nucleotides GA followed by C instead of the T in PBX. Image modified from [85]. 
 
 
1.7.3.1. The mechanism of action of HXR9 
HXR9 is an 18 a.a. peptide of 2.7 KDa with sequence: 
 
WYPWM KKHH RRRRRRRRR 
 
It contains the YPWM motif (red) to compete with HOXs paralogues 1 – 9 for the binding of PBX 
and stopping of PBX mediated functions, a linker (green) to enhance peptide flexibility and a poly-
arginine region (blue) which is the mechanism for cell entry of the compound. The theoretical 
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isoelectric point (pI), the pH at which the total charges on the aminoacids chain of a protein are 
neutral, is around 12. Therefore, the peptide is highly basic at biological pH 7 due to the presence 
of charged aminoacids such as Histidine (H), Lysine (K) and Arginine (R). The selectivity of HXR9 
towards HOX/PBX was proved using a controlled peptide CXR9 with the same poly arginine 
functional domain and linker, but containing a single amino acid change in the binding domain to 
result in a: 
WYPWM  WYPAM 
 
The inhibitory effect of HXR9 in preventing the binding and inducing apoptosis were not seen in the 
control peptide. The effective disruption of the HOX-PBX binding operated by HXR9 was confirmed 
by co-immunoprecipitation techniques. HOXD9, found to be particularly overexpressed in 
melanoma, was immunoprecipitated using an anti-PBX antibody: in the absence of any inhibition, 
and this was the case for CXR9, the antibody was able to co-immunoprecipitate HOXD9 and PBX as 
confirmed by subsequent western blot. However, the recovery of HOXD9 was not successful once 
the cells were treated with HXR9, suggesting that HXR9 sequestered PBX [67]. 
 
The arginine rich portion of HXR9 belongs to a family of so called cell- penetrating peptides (CCPs) 
first identified in the HIV-1 virus in the form of a TAT (trans-activator protein). Other members of 
the family includes Penetratin found in the homeodomain of Antennapedia (Antp) in Drosophila 
and the poly-arginine group chemically synthesised taking inspiration from TAT and Antp with 
repetition spanning from R6 to R12 [86]. There has been lots of debate in the last years to 
characterise the mechanism of cell uptake of CCPs, whether it was merely a pure diffusion through 
the double lipid layer of the membrane or an active process via endocytosis [87].  First experiments 
were affected by artefacts imposed by the fixations methods. The highly charged CCPs were 
probably interacting with the charges of methanol or paraformaldehyde giving them false positive 
cellular localisations. An extensive work from Duchardt et al. [88] demonstrated that the 
mechanism of entry of poly-arginine peptides with 9 repetitions (9R) was concentration dependent: 
at concentrations <10μM the uptake of R9 was partially reduced by selective inhibitors of clathrin 
mediated or lipid mediated endocytosis providing evidence that this was the mechanism of entry. 
At higher concentration the heparan sulphate proteoglycans of the double layer were the ones 
facilitating the cell entry and selective inhibitors for endocytosis were not effective. The cell entry 
at high concentrations observed was initially confined to particular spot in the cells, followed by a 
rapid diffusion through the cytoplasm and ending at the nucleolus in a range of minutes (10mins). 
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Other factors affect the cell uptake, thus it is complicate to predict the behaviour that the CCPs will 
have once internalised: temperature and cholesterol levels modified the uptake of an L-isomer R8 
and D-isomer R8 in CD4+ leukaemia cells. The process was particularly efficient for the D-R8 at 37°C 
with localisation at the nucleolus and with the depletion of cholesterol with a chelating agent [89]. 
While efforts have been made to understand the CCPs uptake, it is still not clear what the 
mechanism of endosomal escape is operated by the CCPs it is not clear, as the lower pH of the 
endosome compartment degraded peptides and their cargos making them biologically inactive 
[90]. 
Given their ability to efficiently and within a short time reach the cytoplasmic and then nucleolus 
compartment, CCPs have become an attractive carrier for a series of small molecules, peptides and 
nucleic acids also for cancer therapy. In the work published by Tan et al. [91], a portion of a TAT 
CCP was fused with a peptide targeting the extracellular domain of Her-2/neu (ErbB2) in breast 
cancer cells and the downstream signalling molecule STAT3. Tan et al. showed the capability to 
suppress proliferation in vitro and in xenograft models and provided one of the first examples of 
how combining CCPs and other selective peptides can efficiently improve the drug delivery.  
The successful targeting of STAT3 signalling pathway with another 9R CCP was also shown by Kim 
et al. [92]. They proved the ability of an aptide APTSTAT3-9R to bind and inhibit the phosphorylation 
of STAT3 in the range of nano-molar concentration in the B16 melanoma cell line. Cell viability and 
proliferation was reduced as confirmed by MTT assays. The peptide decreased xenograft tumours 
by half their size and extended the OS of mice for two weeks. Another elegant strategy came from 
the Wang group [93] to efficiently deliver a siRNA against the proto-oncogene Polo Like Kinase-1 
(PLK1). They designed a micelle with a shell made of polyethylene glycol (PEG) and a peptide 
susceptible to the cut of tumour overexpressing metallo-proteinases 2 (MMP-2). The shell 
protected the inner poly-arginine 9R peptide bound to the siRNA to reach the target site and 
overcame problems of systematic delivery in the blood. The poly-arginine worked as cargo for the 
siRNA for cell entry once on target tissue. The experiment also demonstrated how successfully the 
complex reached the tumour site in vivo and the siRNA was effective at silencing PLK1. 
 
Experiments to assess the efficient cell entry and cellular localisation of HXR9 were performed in 
vitro in B16 melanoma cell lines and breast cancer MDA-MB231 cells. Leukaemia cells were treated 
with 60μM of peptide and then a nuclear and cytoplasmic localisation was revealed with a FITC 
labelled anti-HXR9 antibody. In the breast cell line, the authors conjugated a fluorescent tag (FITC) 
to HXR9, treated the cells at 22μM and observed a rapid distribution of “green” in the cytoplasm 
and in the nucleolus in line with the previous experiments with CCPs with poly-arginine. However 
to date there is no study published to confirm whether the mechanism of cell entry of HXR9 is 
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primarily endocytosis or an interaction with proteoglycans, but the high concentrations used and 
the previous findings are suggesting the latter is the possible method of cell penetration [67, 68]. 
 
Despite the high efficiency of delivery into cancer cells as seen in the previous examples, CCPs have 
some unsolved limitations that prevented them from being approved by the FDA or EMA as anti-
cancer agents. First the half-life often exhibited in blood and the fast clearance at renal or liver site 
is relatively limited. For example, HXR9 has a clearance shorter than 18 hours in human serum and 
the C-term and N-term of the peptide have been designed in a D-isoform, which is the isoform not 
present in biological life, to make it more resistant to attack by proteases present inside cells and 
in serum [67]. Secondly the ubiquitous distribution of the poly-arginines in cancer and non-cancer 
cells raises questions about side-toxicity or less bioavailability at target tissues. 
 
1.7.3.2. HXR9 and molecular mechanisms leading to apoptosis 
The strategy of HOX-PBX inhibition has been described in the previous section as well as the 
mechanism of cell entry. Here, I am briefly outlining the possible correlation between HOXs 
expression and the sensitivity to the HXR9 drug, as potential predictive biomarker of response and 
the current state of understanding of the molecular pathways leading to apoptosis after treatment 
with HXR9. A linear correlation between HOX expression and drug sensitivity is highly desirable, 
because it makes possible an efficient patient stratification for delivery of the treatment in future 
clinical trials. Morgan et al. found a positive trend between the mean of whole HOX genes 
expression and the IC50 calculated via MTS assays in a panel of breast cancer cell lines, excluding 
MCF7. The finding was particularly strong and reaching a linear regression (r2 value = 0.98) when 
analysing the subgroup of HOX genes from cluster B and from paralogues 1 - 9, which are the 
paralogues binding PBX and therefore susceptible to HXR9 inhibition. Notably, when plotting 
HOXB1- B9 mean gene expression versus their theoretical IC50 a linear correlation was observed 
too in a cohort of 78 primary breast cancer tissues. However HOXs expression was not correlating 
to any clinical-pathological features as survival, tumour grade or HER2, ER (estrogen) and PR 
(progesterone) status [68]. Similarly, a linear correlation between IC50 and mRNA mean expression 
of all HOX genes was seen in vitro in squamous carcinoma cell lines, but not regarding PBX1 or PBX2 
expression and IC50 [94]. 
 
An effort to understand the molecular mechanism of HXR9 leading to cell killing has been necessary 
to identify biomarkers of response to HXR9 and/or potential targets for combination therapy.  
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The preferred mode of death induced by the small peptide seemed to be apoptosis and this was 
confirmed again by Morgan and colleagues using an Annexin V staining and the vital dye 7AAD. 
After treatment with HXR9 most of the cell lines were in a stage of late apoptosis/early necrosis as 
compared to the untreated or the CXR9 treated cells that were in contrast 100% viable. The use of 
a pan-caspase inhibitor, z-VAD, was partially able to rescue the cells from HXR9 induced apoptosis. 
The same was observed for B16 cells, melanoma and prostate [67, 69, 95]. 
Further evidence that apoptosis was the mode of death was the presence of cleaved PARP in 
ovarian SKOV3 cells [70] and the marked capsase-3 activity in the HXR9 treated melanoma cells 
detected through a fluorescent caspase-3 substrate [95].  
HXR9 delays tumour progression in vivo as well: an initial dose of HXR9 100 mg/Kg injected into the 
tail vein or subcutaneously, followed by two injections at 10 mg/Kg per week significantly reduced 
flank tumour growth in mice presenting with different tumour models: melanoma, prostate, breast 
and ovarian [68-70, 95]. For example, there was a 46% reduction tumour volume in the HXR9 
treated mice group at 32 days in the context of ovarian cancer [70]. 
Kelly et al. demonstrated how in vitro combination platinum therapy – HXR9 synergistically 
contributed to cell death, but once in vivo in a flank model using SKOV3 cells, this effect was 
minimal compared to HXR9 alone [52]. 
 
Despite the proven mode of death in vitro and in vivo with different degrees of sensitivity, the 
molecular pathway after treatment with HXR9 still needed to be further elucidated to understand 
the cascade of activation of particular proteins leading to apoptosis. 
The first study came from Morgan et al. in 2007 where the potential genes being upregulated or 
downregulated in response to treatment with HXR9 were screened [67]. Melanoma B16 cells were 
exposed for 2h to 60μM of HXR9 or CXR9 and their RNA extracted. CXR9 was included in the assay 
as the scramble control peptide not able to induce apoptosis in cancer cells.  Out of the 14,000 
mouse genes on the array, only 22 showed an overexpression when compared to CXR9 control with 
a significant threshold (P<0.05). Results were further validated at qPCR. Candidate genes were 
Dusp1 and Atf3, which showed the highest expression, followed by c-Jun and c-Fos and other 
members such as Klf4 and Smad7 to a lesser extent, suggesting that a re-activation in the mRNA 
expression (and following protein expression) of those genes would have implicated in the 
mechanism of cell death.  Up to now, most of the published research on identifying biomarkers of 
response to HXR9 focused on the oncogene c-Fos, probably because it is involved in the formation 
of the AP-1 complex in partnership with c-Jun. The AP-1 complex is a family of transcription factors 
with a highly conserved leucine zipper DNA binding domain. It includes JUN members that can 
homeodimerise with themselves or heterodimerise with FOS and ATF family proteins. The AP-1 
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complex can trigger several target genes with promoters containing either TPA (TRE-responsive 
elements) or CRE (cAMP-responsive elements), therefore it is involved in several cellular processes 
including cell proliferation, differentiation and apoptosis. Their role and function in cancer will be 
discussed in details in the results Chapter 6. 
 
 
 
Figure 1.7-5: AP1 complex signalling pathway overview . 
External stimuli like growth factors or inflammatory cytokines stimulate AP-1 activity via  
mitogen-activated protein kinases (MAPKs) ERK,  p38 and JUN amino-terminal kinase (JNK) 
families.  AP1 binding partners c -Fos and c-Jun are in turn transcriptionally regulated by a 
family of transcription factors, binding TRE elements for c -Jun and TRE/CRE elements for 
c-FOS activation. FOS and JUN fami ly members then dimerise to form the AP -1 complex. 
Their phosphorylation in the cytoplasm fosters a translocation in the cell nuclei activating 
TRE responsive genes involved in a variety of cellular functions such as proliferation, 
differentiation and apoptosis according to the type of initial stimulus. MAPKK, MAPK 
kinase; TCF, ternary complex factor; SRE, serum -response element; TRE, TPA-responsive 
element; CRE, cAMP-response element. Image adapted from [96] under a CC-BY Creative 
Commons license. 
 
 
In order to validate the previous finding in mouse melanoma cells in 2007, Morgan and 
collaborators re-confirmed the gene overexpression of c-FOS after treatment with HXR9 in vitro as 
well in vivo in a panel of human solid malignancies [67-70, 72]. 
In breast carcinoma, an increased transcript and protein level for C-FOS was shown, but not for P53 
in cells treated with HXR9 [68]. The rationale to explore the role of P53 in response to HXR9 came 
from previous studies, where a HOXA5 consensus sequence was found in the P53 promoter. In fact, 
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HOXA5 overexpression in breast cancer cell lines was associated with a tumour suppressor activity 
[97]. Excluding the role of P53 in HXR9 treated breast cancer cell lines due to its unaltered protein 
content, the possible role of c-FOS in delivering a programmed cell death was proposed.  
In a following study, prostate cancer cells DU145 were transfected with anti-cFOS siRNA prior HXR9 
exposure to establish whether increased c-FOS levels were responsible for apoptosis. Knocking 
down the FOS gene, a lower percentage of cell death was observed in cells treated with HXR9 in 
Annexin V assays. The partial protection from apoptosis suggested the mediation of c-FOS in 
promoting cell death, but an indication of the participation of other mechanisms as well [69]. 
Similar results were also confirmed by Errico et al. in the context of melanoma in vitro. A 50% 
rescue in the percentage of survival was achieved when melanoma cells were pre-treated with c-
FOS siRNA and exposed to HXR9 [95] as compared to the control group of cells without a c-FOS 
silencing. Errico et al. also added a piece to the puzzle identifying a possible HOXB7/PBX2, miR-
221&222 and c-FOS link. The experiments demonstrated that the HOX/PBX binding was 
transcriptionally activating two regulating micro RNAs (miR) which in return were targeting c-FOS 
in a feedback negative loop. By downregulating HOXB7 and PBX2 expression with siRNA, a 
decreased in the expression of miR was confirmed. The abrogation of HOX/PBX binding in 
melanoma cells treated with HXR9 led as well to a spike in the c-FOS expression and apoptosis as, 
they proposed, its expression was no longer suppressed by miR-221&222. Changes in the protein 
expression of potential c-FOS targets were analysed too: for example, the binding partner c-JUN 
for the AP1 complex showed no differences after treatment with HXR9; in contrast the anti-
apoptotic protein c-FLIP, a target of c-JUN/c-FOS presented a decreased expression. Neither 
protein expression levels of PTEN, an additional target of miRs and a key oncogene in melanoma, 
were detected after treatment with the peptide. The partial protection from cell death achieved 
silencing c-FOS and the unchanged protein expression of driver key oncogenes as P53 or PTEN are 
suggesting that the molecular mechanism triggered by the HXR9 treatment is complex and should 
be the attention of further investigation in the present work. 
 
1.7.4. Limitations of HOX genes as a target therapy: future directions 
HOX family contribution to organ development is well documented and accepted in the scientific 
community, however not clear enough is the role of HOX as transcription factors during 
oncogenesis. 
The mRNA expression of the 39 HOXs has been reported mainly upregulated in several tumour 
types, but a correlation HOX expression profile – phenotype has still not been clearly defined. The 
discrepancy found across several published articles about HOX genes expression could be explained 
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the limited number of primary material available for some studies. It is also important to 
understand at which time point of a patients’ treatment timeline the biopsy is taken: HOX genes 
are expressed according to spatial and temporal collinearity, therefore their expression could 
change with tumour progression and treatment. Finally the limitations of the qPCR in terms of 
performance and binding site of the primers and DNA quality can explain the variability observed 
in the results. 
The mechanisms underlining HOX regulation of expression are still not solved as well. Resolving the 
epigenetic modifications and the HOX genes silencing by ncRNAs and miRNAs could suggest 
indications on the use of epigenetic-modifying agents such as DNA methyltransferase (DNMT) and 
histone deacetylase (HDAC) inhibitors. Comprehensive miRNAs array analysis would be advisable 
to perform in this direction. 
Moreover, very few hits from the literature elucidated possible HOX factor interactors and mostly 
focusing on one particular HOX gene during the study. There is an urge to identify the upstream 
and downstream interactors of HOXs to be able to fully understand the molecular mechanisms of 
HOX oncogenesis.  There is an absence of comprehensive proteomic studies for homeobox proteins 
due to the complexity of analysing 39 proteins at the same time, their function and their 
interactome. The advances in the proteomic era will permit to design global proteomic analysis (i.e 
global acetylome/methylation or global phosphoproteome) to quantify HOX protein levels in 
normal and disease setting and to map gene/protein enrichment analysis. 
Nevertheless, HOX genes play a role as transcription factor binding DNA and regulating the 
promoter of downstream genes. The new technologies of chromatin immunoprecipitation-
sequencing arrays (i.e RIME) will aid to identify new targets and draw molecular pathways. 
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1.8 Summary 
The previous paragraphs described the up-to-date clinical ovarian carcinoma management and 
recent and more advanced phase III clinical trials.  Several strategies, such the use of PARPi or anti-
angiogenesis therapeutic monoclonal antibodies, are showing promising results and have been 
approved by FDA or EMA for certain type of cancers. Novel targets currently under investigation 
aim to primarily identify new biomarkers for early screening and prognosis. A proper patient’s 
stratification is in fact needed to avoid unnecessary side toxicities, costs and to increase treatment 
success rate and hence quality of life for the patients. New biomarkers discovery will also lead to 
identification of new targets for drug therapy, moving in the direction of treatment of cancer in a 
patient personalised manner. 
The exploration of new targets is still an open and exciting field and the family of homeobox 
transcription factors (HOXs) appears to be valid candidates given their selective overexpression in 
a variety of cancers, such as prostate, melanoma, colorectal, breast and ovarian associated with 
the acquisition of oncogenic functions of proliferation, invasion, differentiation and regulation of 
apoptosis and DNA repair. 
The successful ability of HXR9, a small penetrating peptide, to target the HOX proteins and their co-
factor PBX and to induce a selective apoptosis has been tested in a variety of immortalised cancer 
cells derived from different types of malignancies in vitro and in flanks tumour models in vivo. Some 
biomarkers of response to HXR9 have been identified, but the molecular pathway leading to 
programmed cell death has yet not been elucidated.  
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1.9  Hypothesis and Objectives 
The novelty of the present thesis will be exploring the therapeutic targeting of HOX/PBX interaction 
with a new generation drug (HTL001) than its previous version (HXR9). 
Assuming that the new HTL001 conserved the mechanism of targeting with its predecessor, the 
work proposed a new experimental platform in 3D to evaluate the cytoxicity of the peptide on the 
tumour tissue in a patient personalised manner.  
As well as providing an alternative approach to test cytotoxic agents in a scenario closer to a clinical 
setting, the present thesis investigated a new strategy to enhance drug delivery of HTL001 at target 
tissue.  
Finally, a comprehensive understanding of the molecular pathway leading to apoptosis after the 
HOX/PBX inhibition is still lacking, therefore my effort aimed at filling this gap and at the same time 
at identifying targets for combinational therapy.  
 
 
The thesis hypothesises are as follows: 
 
1) given the improved characteristics of the new peptide generation of HXR9, HTL001 would 
have a stronger cytotoxic efficacy on ovarian carcinoma and a prediction of its potency 
would be possible reading the HOX profiling (prognostic marker) (Chapter 3); 
 
2) there is an unmet need to improve new experimental models to test therapeutic drugs that 
can predict the response of an individual patient to a single agent and an optimisation of 
an ex vivo 3D organotypic model that uses patient tumour tissue, would provide better 
insights of drugs efficacy and guidance for a personalised medicine (Chapter 4); 
 
3) alternative strategies for HTL001 delivery, rather than relying on the polyarginine entry, 
would enhance its bioavailability at target tissue and therefore its efficacy (Chapter 5); 
 
4) a new understanding of the mechanisms leading to apoptosis will identify potential 
biomarkers of response to HTL001 treatment and possible targets for combination therapy 
(Chapter 6). 
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To test out these hypotheses the objectives of this thesis are as follows: 
 
1.a. compare the cytotoxicity of HXR9 versus HTL001 in a panel of immortalised ovarian cancer 
cell lines and primary cell cultures from patient tumour tissue and ascites using an MTS 
assay (Chapter 3); 
1.b. correlate, if possible, HOX gene expression profiling with qPCR and drug potency 
calculated from the MTS assay (Chapter 3); 
 
 
2.a. optimise the protocol of the ex vivo organotypic model, from culturing conditions to 
assessment of tissue viability using a panel of biomarkers for cell proliferation and 
apoptosis (Ki67 and cleaved caspase 3) using IHC (Chapter 4); 
 
2.b. test cytotoxic agents efficacy such as platinum therapy (cisplatin) and HTL001 on the 
optimised platform. Try to evaluate cell killing efficacy using a panel of biomarkers for cell 
proliferation (Ki67), apoptosis (cleaved caspase 3, CC3) and DNA damage (γH2A.X) using 
IHC and to correlate to clinical details as tumour grade, stage, subtype where possible 
(Chapter 4); 
 
 
3. deliver the HTL001 peptide using an adeno-associated virus (AVV2). An optimised construct 
for HTL001 expression will be designed and then inserted into a suitable expressing system 
for mammalian cell expression (preliminary studies) and subsequently sub-cloned into a 
pAVV-TetOne Inducible System for viral particles and transgene generation (Chapter 5); 
 
 
4.a. explore intrinsic and extrinsic molecular pathways of apoptosis after HTL001 treatment 
with a RT2 qPCR array profiler (Qiagen) and validate candidate genes at the protein level 
with Western Blot (Chapter 6); 
 
4.b. target with a small molecule inhibitor one of the candidate genes to obtain further insights 
and propose a molecular mechanism of action of HTL001 (Chapter 6). 
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CHAPTER 2 
 
2. Materials and methods 
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2.1. Tumour specimens 
Tissue specimens were collected after consent at the Royal Surrey County Hospital, Guildford, UK. 
Clinical details can be found in Appendix A. 
2.2. Cell lines 
Human cell lines were purchased from the European Collection of Authenticated Cell Lines (ECACC), 
excluding COS1 which was from the American Tissue Culture ATCC. 
COV318 and COS1 were cultured in Dulbecco Modified Medium (DMEM) (Sigma UK), as well as the 
tissue-derived primary cells EOC01 and EOC02, while PEA (1 and 2) and PEO (1 and 4) series and 
primary cells derived from peritoneal liquid AS01 and AS03 were passaged in RPMI-1640 (Sigma 
UK) and 2mM sodium pyruvate (Gibco); all cell lines received 10% Fetal Bovine Serum FBS (Gibco), 
antibiotics 100U/ml penicillin and 100μg/ml streptomycin (Sigma UK) and 2mM glutamine (Sigma 
UK) as additives. Cells were cultured in a humid chamber with 5% CO2. Growth media was changed 
every 2 or 3 days and passage number never exceeded 30 for immortalised cell lines and 10 for 
isolated primary cells. Split ratio was 1:2 - 1:6 for commercial cells and 1:2 for patient’ derived cells. 
A mycoplasma test (MycoAlert PLUS Mycoplasma Detection Kit, Lonza) was run monthly to ensure 
the mycoplasma free status of the cells. Cells were cryopreserved in cryovials in 5%DMSO and 100% 
heat inactivated FBS, with the exception of the PEO series where the FBS was not heat inactivated 
and stored in LN tanks. 
Table 2.2-1 below summarises the main features of the commercial cell lines used: 
 
 
Name ECACC 
catalogue 
Growth 
mode 
Oestrogen 
receptor 
status 
Cell type Description 
PEA1 10032306 Adherent Positive Epithelial; 
whirling 
pattern of 
cells 
PEA1 is a cell  line established 
from peritoneal l iquid of a 
patient with poorly 
differentiated adenocarcinoma 
prior to treatment with 
cisplatin and prednimustine.  
PEA2 10032307 Adherent Positive As PEA1 PEA2 is from the same patient 
as the PEA1 cell l ine, but it was 
collected on relapse.  
PE01 10032308 Adherent Positive Epithelial; 
islands of 
PEO1 derives from peritoneal 
ascites of a patient with a 
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polygonal 
cells 
poorly differentiated serous 
adenocarcinoma that 
previously received cisplatin,  
5-fluorouracil  and 
chlorambucil treatment.  
PE04 10032309 Adherent Positive As PEO1 PEO4 derived from the same 
patient as PEO1 showing 
resistance to treatment.  
COV318 07071903 Adherent n/a Polygonal 
and 
fusiform 
COV318 was established from 
peritoneal ascites of a patient 
with serous carcinoma.  
COS1 ATCC® 
CRL-
1650™  
Adherent n/a Fibroblast-
like, 
polygonal  
COS1 derived from a kidney of  
an African green monkey. As 
the cell  l ine has been SV40 
transformed, COS1 can be used 
with vectors containing the 
SV40.  
Table 2.2-1: List of commercial cell lines used for the project . 
All cell l ines have an ovarian carcinoma origin with the exception of COS1 which is a 
fibroblast like cell l ine from a kidney of a monkey. Cell l ines were grown in RPMI or DMEM 
medium supplemented with fetal bovine serum and antibiotics and incubated at 37°C and 
5% CO2. ECACC, European Collection of Authenticated Cell Lines.  
2.3. Tumour cells isolation 
2.3.1. From tissue 
The isolation of tumour cells from ovarian carcinoma was performed using the Tumour Dissociation 
Kit (Miltenyi Biotec) which combines an enzymatic and a mechanical gentle dissociation to obtain 
a single cell suspension that can be used for downstream applications. The enzymes H, R, A were 
reconstituted in plain RPMI-1640 media and added according to the manufacturer’s protocol to a 
further 5ml of media containing the minced tumour tissue of 2-4mm pieces in a gentleMACS C-
Tube. The sample was run through different programs on a gentleMACS Dissociator (h_tumor_01, 
(h_tumor_02, h_tumor_03) and each time incubated for 30mins in a cell culture incubator rolling 
on a MACS Rotator. The suspension was then applied to a 70μm cell strainer (Corning) to obtain a 
uniform single-cell suspension and washed with 25ml of RPMI medium before a centrifugation step 
at 300g for 5mins. The cell pellet was resuspended in the desired growth medium for further 
applications.  
 
2.3.2. From peritoneal liquid 
20-25ml of peritoneal liquid were collected in sterile tubes and spun at 1000g for 10mins to obtain 
a cell pellet. Cells were washed with Hanks’ balanced salt solution (Sigma, UK), passed through a 
70μm strainer (Corning) and again spun as before. A Red Blood Cell Lysis Solution (Qiagen, UK) was 
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added to the solution for 10 min to remove red blood cells and tumour cells were resuspended in 
working buffer for downstream applications. 
 
2.3.3. Tumour isolation 
A single cell suspension either obtained from tissue or ascites was enriched using the microbeads 
technology from Miltenyi Biotec (Tumour Cell Isolation kit, human) that eliminated contaminants 
such as fibroblasts or macrophages from the initial tumour cells suspension. A total up to 107 cells 
were resuspended in 80μl of MACS buffer (PBS, 0.5% BSA). Non tumour cell were labelled with a 
cocktail of antibodies conjugated to microbeads for 15min at RT (Tumour Cell Depletion Cocktail A) 
and trapped in the magnetic field of a LS MACS column, while the target cells of interest were 
eluted. The eluted tumour cells were then run through the column twice to increase the purity of 
the sample and the column was washed twice with MACS buffer.  The non-tumour cells fraction 
was collected by pushing the plunger into the MACS Separator Column. Cells were washed, counted 
and resuspended in growth media to seed them in T-25 flasks (Corning, UK) for cells culture.  
 
2.3.4. Purity evaluation using flow cytometry 
After a few days in culture, a sample of cells was stained using tumour-specific and fibroblast 
markers and run through a FACS machine to check the purity of the enriched tumour cells. Up to 
106 cells were placed in a 96 well plate U-bottom (Corning, UK), washed with PBS once and 
incubated with conjugated antibodies recognising human panCytokeratins-FITC and Vimentin-PE 
(for antibodies specification see below Table 2.5-1) for 15mins at RT. Cells were fixed in a buffer 
solution containing PBS, 5% BSA and 15% formaldehyde and analysed within 48hours. 
2.4. Drugs preparation 
HTL001, HXR9, CXR9 and P-HTL001 peptides were synthesised by Sigma UK, resuspended in PBS at 
a 100mM stock concentration and 25mM for P-HTL001 and stored at minus 80°C.  
The covalent bound carboxyfluorescein HTL001 (5/6 FAM-HTL001) was synthetized by 
AltaBioscience, UK, and a stock solution prepared at 25mM in PBS, aliquoted and stored at -20°C. 
All peptides showed a purity of at least 90%. Cisplatin (Accord Healthcare) 1mg/ml physiological 
solution for injection was stored at room temperature and diluted in media to the desired 
concentration.  BCI (NSC 150117) was purchased from AxonMedchem, prepared at 100mM 
concentration in dimethyl sulfoxide DMSO (Sigma UK), aliquoted and stored at -20°C. 
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2.5. Antibodies panel 
The below table summarises the primary and secondary antibodies reactive against human 
proteins used and working concentrations for each application: 
 
 
Host Antigen Company Catalogue Application and 
working dilution 
Mouse mAb Ki67 Dako M7240 1:100 IHC 
Rabbit pAb cleaved caspase 3 CTS 9661 1:50 IHC 
Rabbit pAb γH2A.X (P-Ser139) Abcam 2893 1:800 IHC 
Rabbit pAb poly-arginine (9R) Cell Application CY1114 1:1000 WB 
Goat pAb GFP Abcam 6673 1:1000 WB 
Rabbit mAb Phospho-DUSP1/MKP1 (Ser359) CST 2857 1:1000 WB 
Rabbit mAb c-Fos (9F6) CST 2250 1:1000 WB 
Rabbit mAb ATF-3 (D2Y5W) CST 33593 1:1000 WB 
Rabbit mAb Phospho-SAPK/JNK (Thr183/Tyr185) 
(81E11) 
CST 4668 1:1000 WB 
Rabbit mAb Phospho-p44/42 MAPK (Erk1/2) 
(Thr202/Tyr204) (D13.14.4E) XP® 
CST 4370 1:2000 WB 
Rabbit mAb Phospho-p38 MAPK (Thr180/Tyr182) 
(D3F9) XP® 
CST 4511 1:1000 WB 
Mouse mAb GAPDH Origene TA802519 1:2000 WB 
Goat pAb Mouse IgG - HRP Origene TA130003 1:2000 WB 
Donkey pAb goat IgG - HRP Fitzgerald 43R-1048 1:5000/1:10000 
WB 
Donkey pAb rabbit IgG - HRP Fitzgerald 43C-CB1134 1:5000/1:10000 
WB 
mouse IgG1κ Cytokeratin (CK3-6H5)-FITC Miltenyi Biotec 130-080-101 1:200 FACS 
recombinant 
human IgG1 
CD326 (EpCAM)-PE Miltenyi Biotec 130-110-999 1:200 FACS 
recombinant 
human IgG1 
Vimentin (REA409) Miltenyi Biotec 130-106-296 1:200 FACS 
Table 2.5-1: List of antibodies and their specification details used for this project . 
mAb, monoclonal antibody; pAb, polyclonal antibody; CST, Cell Signalling Technology; IHC, 
immunohistochemistry; WB, western blot; FACS, fluorescence activated cell sorting.  
2.6. Organotypic culture 
Specimens were collected after surgery from Royal Surrey County Hospital and transported on ice 
to the lab for immediate processing. The tumour tissue was chopped and a piece of a 9mm punch 
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biopsy was immediately fixed in 10% neutral buffered formalin (Thermo Fisher) as a control (original 
biopsy), the rest was embedded in a 6 well plate in 4% agarose gel and then mounted with super-
glue on a magnetic metal holder that was used as a support during the cutting. 
A Leica VT 1200S Vibratome (vibrating microtome) allowed the preparation of precision cut tumour 
slices: the machine was calibrated using a Vibro-Check, speed was adjusted to 0.4, oscillation to 
3.00 and thickness of the slices to 300μm.  The support block, media tray, ice tray were sprayed 
with 70% alcohol to sterilise and sterile plastic and flat forceps were used. The tray was filled up 
with ice, cold culture media (DMEM plus antibiotics) and the support magnetic block positioned in 
the media tray next to the blade. Rear and front cutting points were set with vibratome controls 
(Figure 2.6-1). 
 
 
The Vibratome controls  were used to define the cutting area (start and end poin t of the 
piece of t issue), the speed and the oscillation of the blade and thickness of the slices . A 
calibration step prior slicing occurred using a Vibro -Check to confirm the correct alignment 
of the blade with the blade holder. After calibration, the Vib ro-Check was removed, the 
blade left in position and the ice tray and media tray set up as shown on the image on the 
right. In the middle of the media tray a magnetic holder is positioned to block the tissue 
mounted with super -glue on a matching magnetic metal holder. Image on the left adapted 
from: https://www.leicabiosystems.com . Image on the r ight adapted from: 
https://med.nyu.edu/research/scientific -cores-shared-resources/experimental -
pathology-research-laboratory/instruments . 
 
 
Once a good slice was obtained, flat forceps were used to pick it up and transfer it to one well of a 
24 well plate previously containing a 1ml of culture media. Tumour slices were left half an hour to 
acclimatise in tumour growth medium, which was DMEM supplemented with 10% FBS, antibiotics 
Figure 2.6-1: Vibratome controls and Vibro -Check (left) and close up on the set up for 
tissue slicing (r ight).  
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penicillin/streptomycin and glutamine as set up with cell lines (Section 2.2) and then treated with 
anti-cancer compounds of interest. Plates were incubated at 37°C in a 5% CO2 atmosphere under 
<100 rpm shaking. Slices were cultivated for the duration of the experiment and fixed in 10% 
neutral buffered formalin at different time points. Duplicate slices were immediately fixed in 
formalin after slicing (time zero= t0) to act as a control for any potential artefactual effects of the 
blade on the tissues. 
 
 
 
Figure 2.6-2: Organotypic culture workflow from core biopsy collection to preparation of 
precision cut tumour slices and their applications . 
Tissue was collected at the hospital theatre in a sterile pot and immediately placed on ice 
and transported within few minutes to the  laboratory. The tissue was cut with a 9mm 
punch biopsy and embedded in 4% agarose in a 6 well plate before being cut in a square 
shape and attached with glue to a metal holder. The magnetic metal holder was then 
placed in the media tray in the Vibratome p recision cut machine. The obtained thin tissue 
slices were laid on Millipore cell insert in a 6 or 24 well plate and incubate d with tumour 
growth medium (Figure 2.6-3) and cultured for up to one week or challenged wi th cytotoxic 
compounds. Tumour slices were finally fixed in formalin for IHC or processed for molecular 
biology experiments.  
 
 
The protocol was then changed to optimise the viability of the slices in line with the guidelines 
published by Davies et al. [98]. Tumour slices were cultivated in a 6 well plate on plate inserts (EMD 
Millipore Millicell 0.4μm) and rotated on a tissue slice incubation unit (Alabama Research & 
Development). Tumour growth media with or without cytotoxic agents was replaced every 24hrs, 
maintaining a final volume of 1ml, 600μl in the lower chamber and 400μl in the upper chamber 
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(Figure 2.6-3). Facilities at the Pathology Laboratories at the University of Surrey Veterinary 
School were utilised for processing specimens. Samples were run overnight in an automatic tissue 
processor (Sakura Tissue-Tek VIP6) for a dehydration step in a series of alcohols and embedded in 
cassettes the following day at a paraffin embedding station (Sakura Tissue-Tek TEC). Paraffin blocks 
were cut using 4μm thickness at a microtome (Leica Biosystem) and sections were placed on glass 
slides (FLEX IHC Microscope Slides, Dako). 
 
 
 
Figure 2.6-3: Schematic view of the tumour slices in the wells ( left) and the tis sue 
incubation unit (r ight) . 
Tumour slices were cut at the Vibratome, left to acclimatise half an hour in growth medium 
and placed in 24 or 6 wells plates on the top of permeable Millipore inserts. 1ml of growth 
medium was used to fill up the well, adding 600μl in the lower chamber and 400μl in the 
upper chamber. Slices were then positioned on the rotating tissue incubation unit. The 
relatively low amount of medium in the upper chamber and the rotation on the incubation 
unit allowed the creation of a media -atmospheric oxygen gradient for a proper tissue 
oxygenation.  
 
2.7. Immunohistochemistry 
Sections of tissue were deparaffinised 3x times in 100% xylene (Fisher Scientific, UK), incubated in 
0.3% Methanol/H2O2 (Sigma, UK) in order to block endogenous peroxidases and then rehydrated 
in an series of 100%, 70% and 50% ethanol (Fisher Scientific, UK). The slide was then subjected to 
heat-mediated antigen retrieval in boiling citrate buffer (10mM, pH6), left to cool down and 
incubated with blocking 4% horse serum in PBS (R.T.U. Vectastain Universal Elite ABC kit, 
VectorLabs) and with an avidin/biotin block reagent (Avidin/Biotin blocking kit, VectorLabs). Three 
washes in PBS were done between each step.  Cleaved Caspase 3, Ki67, γH2A.X primary antibodies 
(for specifications refer to Table 2.5-1) were incubated on the tissues and left overnight at room 
temperature. The tissue was then incubated with biotinylated universal secondary antibody, RTU 
Vectastain Reagent and peroxidases substrate solution. (R.T.U. Vectastain Universal Elite ABC kit, 
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VectorLabs). Peroxidase activity was detected using a DAB kit (Vectorlabs). Three washes in PBS 
were done between each step. Finally, the slide was counterstained with haematoxylin, dehydrated 
in a series of alcohol (50%, 70%, 100%) and mounted with VectaMount mounting medium 
(Vectorlabs). Tonsil tissue was used as a positive control and negative controls without the addition 
of secondary antibody from the same cancer tissue were included as well. An automatic tissue 
stainer (Sakura Tissue-Tek VIP6) was used to perform H&E staining of the tissues at the Pathology 
Laboratories of the Royal Surrey Hospital (Guildford). 
2.8. Immunofluorescence 
Cell lines were plated in 8 well culture chamber slides at 1.5x104 in 500μl (Falcon®™ 8-well 
CultureSlide, Corning) and incubated at 37C overnight. Cells were then treated with different 
concentrations of 5/6-fam-HTL001 (see section 2.3) for 2hrs, washed twice with cold PBS and fixed 
with 4% paraformaldehyde (Sigma, UK) or just washed with cold PBX if performing a live cell 
staining. Cells were then permeabilised with PBS + 0.2%Triton X-100 (Sigma, UK) for 10 min and 
TOPRO-3 nuclear stain (Thermo Scientific) was added for 30 mins diluted 1:400 in PBS before 
removing the culture chamber. The slide was finally mounted with Vectashield mounting medium 
(VectorLabs). Washes with cold PBS were performed between each step to remove excess 
reagents. 
2.9. Image acquisition 
Images from immunohistochemistry slides were acquired using an optical microscope (Primo Star, 
Zeiss) with an integrated software for image capture and analysis (Cytocam, Micropix). Images from 
immunofluorescence staining were obtained with a Nikon Eclipse TE2000-5 inverted microscope 
and data analysis was performed using the Cytocam software. A Nikon A1M Confocal Microscope 
and DS-Qi1 Widefield Camera (on an Eclipse Ti-E Microscope) was used to collect images from 
immunofluorescence staining.  
2.10. Image quantification 
Images for slide scoring were acquired through the AperioScanScope slide scanner (Leica 
Biosystem) at 20X and processed with the ImageScope software. Three different regions within a 
tissue slice were highlighted (Area analysed 0.7mm2), positive cells counted and averaged with 
ImageScope Positive Pixel Count Algorithm. The data represent the average percentage of positive 
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staining of three different areas in the tissue slice and expressed as a fold increase in staining 
intensity as compared to the original biopsy. 
2.11. Cell Proliferation Assay (MTS) 
 The CellTiter 96® AQueous One Solution Cell Proliferation Assay (Promega, UK) is a colorimetric 
assay to measure the respiratory ability of cells in culture as the end point in cytotoxicity or 
proliferation assays. The amount of substrate, a tetrazolium compound [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt MTS], is converted 
into soluble coloured formazan product in tissue culture medium by the NAD(P)H-dependent 
dehydrogenase enzymes of metabolically active cells. The absorbance measurement occurs at 
490nm. Cells were seeded in a 96 well clear bottom plate in at least quadruplicate at a 104 per well 
concentration (5000 and 2500 cells for COV318 and patients’ derived cell respectively) and 
incubated overnight at 37°C. The following day growth media was replaced with relevant 
concentrations of cytotoxic agents. Untreated cells and blank wells were included in the 
experiment as controls. After two hours treatment, supernatant was substituted with freshly 
prepared MTS reagent diluted 1:10 in a reduced serum 2%FBS RPMI-1640 and incubated for 1-3 
hours before reading at 490nm with a Varioskan Flash (Thermo Scientific). The average OD of the 
background control was subtracted for each individual sample. The percentage of surviving cells 
was then calculated by dividing the average OD of treated cells versus untreated ones and 
multiplied by a factor of 100. 
2.11. Annexin V 
The Annexin V-PE assay kit (BD Biosciences) was chosen to confirm that the mode of death after 
treatment with cytotoxics was apoptosis/necrosis using flow cytometry. Annexin V is a probe 
labelled with a fluorescent dye (in our case PE) that has high affinity to phospholipid 
phosphatidylserines (PS) in a Ca2+ dependent manner. The membrane PS are translocated to the 
outer membrane in the event of membrane blebbing during early apoptosis, therefore becoming a 
target of the annexin V protein. A combination of annexin V and 7-AAD dye, that binds DNA, are 
used to discriminate the stages of apoptosis; for example early apoptotic cells will be Annexin 
positive and 7-AAD negative, while late apoptotic/necrotic cells with a damaged membrane and 
fragmented DNA will be double positive stained. 2x105 cells/well in a 6 well plate in duplicate were 
treated with the compounds HTL001 or BCI for 2 hours and trypsinised using a StemPro™ 
Accutase™ (Thermo Scientific). Supernatant and cells were collected, washed once with cold PBS, 
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spun at 690g for 5mins and resuspended in 200μl Binding Buffer provided by the kit. 5μl of Annexin 
V-PE and 5μl 7-AAD were added up to 106 cells in each well, incubated for 15mins at RT in the dark 
and analysed by flow cytometry within 1 hour. Untreated controls were analysed in the same way. 
2.12. Immunoblotting 
2.12.1. Preparation of whole cell lysates 
Whole cell lysates were prepared from commercial cell lines seeded in a 6 well plate and treated in 
the same way as set up for Annexin V assay (see section 2.11), detached from plastic vessels using 
trypsin (Sigma, UK) and resuspended in 200μl of Pierce RIPA buffer (Thermo Scientific) containing 
a Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Scientific). The lysates were clarified 
spinning at 13000 rpm for 10min at 4°C and supernatant was transferred to a new Eppendorf for 
long term storage at -80°C. 
 
2.12.2. Protein quantification 
The protein concentration of cell lysates was measured using a Pierce BCA Protein Assay Kit 
(Thermo Scientific), which is a colorimetric assay to calculate the total protein concentration in an 
unknown sample compared to a protein standard. The two steps reaction involves a first protein-
copper chelation followed by a detection of the reduced copper. The purple colour given by the 
BCA/copper complex is proportional to the protein amount with an absorbance that can be read at 
562nm. Samples, standards and blank wells were prepared in duplicate in a 96 well plate at 
25μl/well and diluted 1:9 with a solution mix of Reagents A and B (1:50) as per the manufacturer’s 
instructions. The plate was shaken for few seconds on a shaker, incubated at 37°C for 30mins and 
subsequently read on a plate reader Varioskan Flash (Thermo Scientific). A standard curve was 
generated plotting concentration versus absorbance. R2 was kept above 0.96 at least for a good 
curve linearity. Samples concentration was calculated on the equation y=mx, where m was the 
slope of the curve, y the absorbance read and x the unknown concentration. 
 
2.12.3. Western blot 
35μl of samples (10-25ng/lane) were loaded on a NuPAGE 4-12% Bis-Tris Protein Gel in a mix of 
NuPAGE Sample Reducing Agent (10X) and NuPAGE LDS Sample Buffer (4X) (Invitrogen, Thermo 
Scientific) after denaturing them 5 min at 96°C on a heating block. 3-7μl of Novex™ Sharp Pre-
stained Protein Standard (Invitrogen, Thermo Scientific) was included on the SDS-PAGE run. 
Running buffer was chosen according to the molecular weight of the protein of interest and it was 
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either NuPAGE MOPS or MES SDS Running Buffer (Invitrogen, Thermo Scientific). The gel was run 
at a constant voltage of 60V for the stacking and 120V for the running part of the gel in a Novex® 
NuPAGE® SDS-PAGE Gel System (Invitrogen, Thermo Scientific) for almost the entire length of the 
gel to allow for optimal separation of proteins. The proteins were then blotted on an iBlot™ 
Transfer Stack PVDF 0.2μm membrane (Invitrogen, Thermo Scientific) which was previously pre-
activated in 100% ethanol (Fisher Scientific, UK) and washed in distilled water for a few minutes. 
An iBlot® Gel Transfer Device (Invitrogen, Thermo Scientific) was used to perform a dry transfer 
maintaining a constant voltage of 20V for 7minutes. The blotted membrane was immediately 
blocked in 5% dried skimmed milk (Marvel) in TBS-0.1% Tween-20 (TBST0.1) (Sigma, UK) or TBS 5% 
BSA (Sigma, UK) with gentle shaking for 1 hour at RT and incubated with appropriate primary 
antibody overnight at 4°C with gentle shaking. For primary and secondary antibodies refer to Table 
2.5-1. The membrane was then subsequently washed three times with TBST0.1 and the relevant 
secondary antibody conjugated with HRP was added for 1 hour at RT with gentle shaking before 
being washed. The SuperSignal West Pico PLUS Chemiluminescent Substrate (Thermo Scientific) 
was applied to the membrane mixing 1:1 solution A and B provided by the kit for 5minutes at RT 
and the signal was immediately read with a ChemiDoc-It 2 Imager (UVP, UK). The ladder and protein 
signals were merged and images analysed with the integrated software ChemiDoc-It2 Imaging 
System (UVP, UK). The membranes were stripped with Restore PLUS Western Blot Stripping Buffer 
(Thermo Scientific), washed for a few minutes with TBST 0.1 and blocked, probed and developed 
again with different primary antibodies. 
2.13. RNA extraction 
Commercial cell lines were trypsinised to detach them from T-25 flasks (Corning, UK), washed once 
with cold PBS and resuspended vigorously in 600μl RTL Buffer Plus (Qiagen) with 1% 2-
mercoptoethanol (Sigma) to disintegrate membranes and release nucleic acids. The lysates were 
also homogenised using a QIAshredder column (Qiagen) before being spun at maximum speed for 
3mins in an Eppendorf centrifuge. The supernatant was applied then to a gDNA eliminator column 
of an RNeasy PLUS Mini kit (Qiagen) to remove contaminant genomic DNA. One volume of 70% 
ethanol 0.2μm filtered (Fisher Scientific) was added to the preparation, loaded on an RNeasy spin 
column and centrifuged for 30sec at maximum speed (~13200 rpm). The silica columns with the 
retained RNA were washed with 700μl of RW1 buffer and twice with 500μl RPE buffer for 30sec at 
maximum speed. The flow-through was discarded for each step. 30μl of RNA free water was then 
added directly to the column, incubated for 3mins and spun for 1min to elute the RNA. Purity and 
RNA amount were quantified using a NanoDrop ND-1000 Spectrophotometer (Thermo Scientific). 
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A good sample purity was indicated by an A260:A280 ratio between 1.9 and 2.1. More stringent 
conditions were kept for RNA to use with the RT2 profiler assay (Qiagen) (see section 2.15.4), where 
samples with A260:A230 ratio lower than 1.7 and concentration below 40 µg/ml were excluded 
from further applications. RNA samples were stored at -80°C. 
2.14. cDNA synthesis 
The cDNA production was performed using a First Strand cDNA Synthesis Kit (Thermo Scientific). 
The reaction exploits the ability of an AMVRT (Avian Myeloblastosis Virus Reverse Transcriptase) 
to convert total RNA into cDNA. The RNA samples were first heated at 65°C for 5 min to remove 
the presence of possible secondary structures that could impede the reaction in a Veriti Thermal 
Cycler (Applied Biosystems, Thermo Scientific) in a volume of at least 10μl to avoid evaporation. 
Each cDNA reaction was prepared according to Table 2.14-1 in a final volume of 20μl: 
 
 
Components Per reaction 
RNA 1 μg 
DEPC-treated water Adjust volume to 10 μl 
5x cDNA Synthesis buffer 4 μl 
0.1 M DTT 1 μl 
10 mM dNTPs mix 2 μl 
Oligo (dT) 1 μl 
RNase OUT (40U/ml) 1 μl 
Cloned AMV RT (15U/ml) 1 μl 
Table 2.14-1: Working volumes of a typical cDNA synthesis reaction mi x. 
cDNA, coding DNA; DTT dithiothreitol; dNTPs desossi nucleoside triphosphate; AMVRT 
Avian Myeloblastosis Virus Reverse Transcriptase.  
 
 
As the aim was to obtain total cDNA from coding RNA (mRNA), the oligo (dT) 18 were chosen based 
on their ability to synthesize cDNA binding poly (A) tailed mRNA. The reaction was performed in a 
Veriti Thermocycler for 40min at 50°C, followed by 5 min at 85°C for the inactivation of the enzyme. 
cDNAs were stored at -20°C or kept on ice and immediately used for qPCR reactions. 
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2.14.1. cDNA synthesis using RT2 First Strand Kit 
The RT2 First Strand Kit (Qiagen) was used to prepare the template cDNA for the RT2 array profiler 
PCR array. Samples were first heated up at 65°C as done for general cDNA synthesis followed by a 
genomic DNA elimination step with a 2μl of proprietary buffer GE that was added to 500ng of RNA 
and incubated for 5 min at 42°C in a Veriti Thermal Cycler, then placed immediately on ice for at 
least 1 min. 10μl of reverse-transcription mix containing 4μl 5x Buffer BC3, 1μl Control P2, 2μl RE3 
Reverse Transcriptase Mix and 3μl RNase-free water were added to each tube with the 10μl 
genomic DNA elimination mix. The reaction was incubated at 42°C for exactly 15 min and then 
immediately stopped at 95°C for 5 min before adding RNase-free water to a final concentration of 
5ng/μl. 
2.15. Quantitative PCR (qPCR) 
2.15.1. Primers design 
Housekeeping genes GAPDH and β-actin, c-FOS and a complete set of HOX primers were designed 
by Prof Richard Morgan using the Primer3 and Primers-BLAST tools 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/). All primers were purchased from Sigma (UK) 
at a concentration of 100μM and were stored at -20°C. 
Table 2.15-1 shows forward and reverse primer sequence for each target gene: 
 
 
Gene name Accession number Forward 5’-3’ Reverse 3’- 5’ 
Β-ACT NM_001101.4 5’- ATGTACCCTGGCATTGCCG - 3’ 5’ - GACTCGTCATACTCCTGCTTG - 3’ 
c-FOS NM_005252.3 5′ -  CCAACCTGCTGAAGGAGAAG - 3′ 5′ - GCTGCTGATGCTCTTGACAG - 3′ 
HOXA1 NM_005522.4 5’ - CTGGCCCTGGCTACGTATAA - 3’ 5’ - TCCAACTTTCCCTGTTTTGG - 3’ 
HOXA2 NM_006735.3 5’ - TTCAGCAAAATGCCCTCTCT - 3’ 5’- TAGGCCAGCTCCACAGTTCT - 3’ 
HOXA3 NM_030661.4 5’ - ACCTGTGATAGTGGGCTTGG - 3’ 5’- ATACAGCCATTCCAGCAACC - 3’ 
HOXA4 NM_002141.4 5’ - CCCTGGATGAAGAAGATCCA - 3’ 5’- AATTGGAGGATCGCATCTTG - 3’ 
HOXA5 NM_019102.3 5’ - CCGGAGAATGAAGTGGAAAA - 3’ 5’ - ACGAGAACAGGGCTTCTTCA - 3’ 
HOXA6 NM_024014.3 5’ - AAAGCACTCCATGACGAAGG - 3’ 5’ - TCCTTCTCCAGCTCCAGTGT - 3’ 
HOXA7 NM_006896.3 5’ - TGGTGTAAATCTGGGGGTGT - 3’ 5’ - TCTGATAAAGGGGGCTGTTG - 3’ 
HOXA9 NM_152739.3 5’ -  AATAACCCAGCAGCCAACTG - 3’ 5’ - ATTTTCATCCTGCGGTTCTG - 3’ 
HOXA10 NM_018951.3 5’ - ACACTGGAGCTGGAGAAGGA - 3’ 5’ - GATCCGGTTTTCTCGATTCA - 3’ 
HOXA11 NM_005523.5 5’ - CGCTGCCCCTATACCAAGTA - 3’ 5’ - GTCAAGGGCAAAATCTGCAT - 3’ 
HOXA13 NM_000522.4 5’ - GGATATCAGCCACGACGAAT - 3’ 5’ - ATTATCTGGGCAAAGCAACG - 3’ 
HOXB1 NM_002144.3 5’ - TTCAGCAGAACTCCGGCTAT - 3’ 5’ - CCTCCGTCTCCTTCTGATTG - 3’ 
HOXB2 NM_002145.3 5’ - CTCCCAAAATCGCTCCATTA - 3’ 5’ - GAAAGGAGGAGGAGGAGGAA - 3’ 
HOXB3 NM_002146.4 5’ - TATGGCCTCAACCACCTTTC - 3’ 5’ - AAGCCTGGGTACCACCTTCT - 3’ 
HOXB4 NM-024015.4 5’ - TCTTGGAGCTGGAGAAGGAA - 3’ 5’ - GTTGGGCAACTTGTGGTCTT - 3’ 
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HOXB5 NM_002147.3 5’ - AAGGCCTGGTCTGGGAGTAT - 3’ 5’ - GCATCCACTCGCTCACTACA - 3’ 
HOXB6 NM_018952.4 5’ - ATTTCCTTCTGGCCCTCACT - 3’ 5’ - GGAAGGTGGAGTTCACGAAA - 3’ 
HOXB7 NM_004502.3 5’ - CAGCCTCAAGTTCGGTTTTC - 3’ 5’ - CGGAGAGGTTCTGCTCAAAG - 3’ 
HOXB8 NM_024016.3 5’ - GTAGGCTTCAGCTGGGACTG - 3’ 5’ - GGGAGCCTTTGCTTAAATCC - 3’ 
HOXB9 NM_024017.4 5’ - TAATCAAAGACCCGGCTACG - 3’ 5’ - CTACGGTCCCTGGTGAGGTA - 3’ 
HOXB13 NM_006361.5 5’ -  CTTGGATGGAGCCAAGGATA - 3’ 5’ - CCGCCTCCAAAGTAACCATA - 3’ 
HOXC4 NM_014620.5 5’ - CGCTCGAGGACAGCCTATAC - 3’ 5’ - GCTCTGGGAGTGGTCTTCAG - 3’ 
HOXC5 NM_018953.3 5’ - CAGTTACACGCGCTACCAGA - 3’ 5’ - AGAGAGGAAAGGCGAAAAGG - 3’ 
HOXC6 NM_004503.3 5’ - AAGAGGAAAAGCGGGAAGAG - 3’ 5’ - GGTCCACGTTTGACTCCCTA - 3’ 
HOXC8 NM_022658.3 5’ - CTCAGGCTACCAGCAGAACC - 3’ 5’ - TTGGCGGAGGATTTACAGTC - 3’ 
HOXC9 NM_006897.2 5’ - AGACGCTGGAACTGGAGAAG - 3’ 5’ - AGGCTGGGTAGGGTTTAGGA - 3’ 
HOXC10 NM_017409.3 5’ - CGCCTGGAGATTAGCAAGAC - 3’ 5’ - GGTCCCTTGGAAGGAGAGTC - 3’ 
HOXC11 NM_014212.3 5’ - CGGAACAGCTACTCCTCCTG - 3’ 5’ - CAGGACGCTGTTCTTGTTGA - 3’ 
HOXC12 NM_173860.2 5’ - CAAGCCCTATTCGAAGTTGC - 3’ 5’ - GCTTGCTCCCTCAACAGAAG 3’ 
HOXC13 NM_017410.2 5’ - GTGGAAATCCAAGGAGGACA - 3’ 5’ - TTGTTGAGGGACCCACTCTC 3’ 
HOXD1 NM_024501.2 5’ - TTCAGCACCAAGCAACTGAC - 3’ 5’ - TAGTGGGGGTTGTTCCAGAG - 3’ 
HOXD3 NM_006898.4 5’ - CAGCCTCCTGGTCTGAACTC - 3’ 5’ - ATCCAGGGGAAGATCTGCTT - 3’ 
HOXD4 NM_014621.2 5’ - TCAAATGTGCCATAGCAAGC - 3’ 5’ - TCCATAGGGCCCTCCTACTT - 3’ 
HOXD8 NM_019558.3 5’ - TCAAATGTTTCCGTGGATGA - 3’ 5’ - GCTCTTGGGCTTCCTTTTTC - 3’ 
HOXD9 NM_014213.3 5’ - TCCCCCATGTTTCTGAAAAG - 3’ 5’ - GGGCTCCTCTAAGCCTCACT - 3’ 
HOXD10 NM_002148.3 5’ - GCTCCTTCACCACCAACATT - 3’ 5’ - AAATATCCAGGGACGGGAAC - 3’ 
HOXD11 NM_021192.2 5’ - GGGGCTACGCTCCCTACTAC - 3’ 5’ - GCTGCCTCGTAGAACTGGTC - 3’ 
HOXD12 NM_021193.3 5’ - CGCTTCCCCCTATCTCCTAC - 3’ 5’ - CTTCGGGCGCATAGAACTTA - 3’ 
HOXD13 NM_000523.3 5’ - GGGGATGTGGCTCTAAATCA - 3’ 5’ - AACCTGGACCACATCAGGAG - 3’ 
Table 2.15-1: Forward and reverse primer sequences for each target gene . 
Each primers set was synthesised at Sigma with a desalting purification method and 
supplied as a stock concentration of 100μM.  
 
 
I personally designed the human DUSP1 sets of primers (accession number NM_004417.3) using 
Primers-BLAST tool and analysed the sequence with OligoEvaluator (Sigma) to predict the potential 
presence of primers dimers, secondary structure, content of GC and annealing temperature (Ta). 
The Ta was calculated according to the general rule: (numb of C*4 + numb of G*4 + numb of A*2 + 
numb of T*2) ± 5°C. Figure 2.15-1 and Figure 2.15-2 show a screenshot of the graphical view of 
primer pair “DUSP1” and “DUSP1 bis”. The primers were spanning intron-exon boundary in two 
different sites of the gene. 
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Figure 2.15-1: Screenshot of the graphical view of “DUSP1” primers using the Primer -Blast 
tool.  Primer 9 corresponds to “DUSP1”.  
“DUSP1” primer sequences: 
F 5’- GGCCATTGACTTCATAGACTC - 3’ 
R 5’-TGGGAGAGATGATGCTTCGC - 3’ 
 
“DUSP1 bis” primer sequences:  
F 5’- GAGCTGTGCAGCAAACAGTC - 3’ 
R 5’- GGGCCACCCTGATCGTAGA - 3’ 
 
Primers were synthesized by Sigma and supplied at 100μM concentration and stored at -20°C. 
 
 
Figure 2.15-2 : Screenshot of the graphical view of “DUSP1 bis” primers using the Primer -
Blast tool. Primer 2 corresponds to “DUSP1 bis”.  
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2.15.2. Standard qPCR 
Multiple copies of target genes were created using a Stratagene Mx3005P qPCR machine and a 
SYBR system with a hot start Taq polymerase. 2μl of cDNA template (4ng) was mixed with 12.5μl 
SYBRGreen JumpStart Taq ReadyMix (Thermo Scientific), 0.25μl Reference Dye (ROX), 5.25μl RNase 
Free Water and 5μl primers for a total volume of 25μl for each reaction and added to a clear 96 
well plate. The thermal profile was set up as follows: 
 
Segment 1: (1 cycle) 95°C for 10 min  
Segment 2: (40 cycles) 95°C for 30 sec, 62°C for 1 min, 72°C for 1 min 
Segment 3: (1 cycle) 95°C for 1 min, 55°C for 1 min, 95°C for 30 sec, 
where segment 1 represents the hot start for the Taq polymerase, segment 2 the amplification step 
with a Ta set at 62°C and segment 3 the thermal profile to generate a dissociation curve to check 
eventual primer dimers. Gene expression relative to internal control β-actin was calculated with 
the 2-ΔCt method increased by a 10,000 factor. 
 
2.15.3. Reference gene selection for qPCR normalisation 
For best qPCR results free from large variables and errors, a normalisation to a fixed reference is 
strictly necessary: “fixed” means that the housekeeping gene selected as a reference should not 
vary with the experimental conditions and have a relatively low Ct value. For the purpose prior RT2 
array experiment, a selection of the most stable housekeeping genes across extracted RNA from 
PEA1 and PEA2 cell lines untreated or exposed with HTL001 in two independent biological 
repetitions was determined using a GeNorm Kit (Primer Design).  A panel of primers from 12 
different human genes (TOP1, SDHA, UBC, GAPDH, ATP5B, ACTB (β-Act), YWHAZ, 18S, RPL13A, 
B2M, CYC1, EIF4A2) were included and a qPCR run with the thermal profile and number of cycles 
same setting as for the RT2 array profiler. B2M (β 2-Microglobulin) and EIF4A2 (Eukaryotic initiation 
factor 4A-II) were chosen as the most stable reference genes across treated or untreated cells with 
HTL001 (less standard deviation and a ΔCt between 18-20 cycles) and used for normalisation in the 
RT2 array profiler only. However, B-act was used as internal control in the HOX profiling from 
ovarian cancer cell lines. 
 
72 
 
2.15.4. RT2 array profiler PCR array 
Cell lines from the PEA and PEO series (PEA1, PEA2, PEO1 and PEO4) and COV318 were screened 
for potential candidate upregulated or downregulated genes after HTL001 incubation. Cells were 
exposed to HTL001 for 2 hours at a concentration around their IC50, their RNA extracted, converted 
into cDNA and probed on the primers array of the RT2 profiler. 5ng/w of cDNA synthesis reaction 
from 2.14.1 were mixed with the RT2 SYBR Green Mastermix and RNA free water to each well of a 
96 well RT2 Profiler PCR Array containing customised primers for a total volume of 25μl. A positive 
control and a genomic contamination controls were included in the assay. The plate was briefly 
centrifuged at 1000g for 3min to mix reagents and the thermal profile was set up as follows: 
 
 1 cycle at 95°C for 10min (hot start) 
 40 cycles at 95°C for 15sec and 1min at 60°C 
 1 cycle as done in segment 3 of standard qPCR for the dissociation curve profile. 
Data analysis was performed using the web based software Qiagen Data Analysis Centre. Results 
were expressed as fold change (2(- ΔΔCT)) which is the normalized gene expression (2(- ΔCT)) in the 
treated group divided the normalized gene expression (2(- ΔCT)) in the untreated sample.  
2.16. Plasmid DNA preparation 
2.16.1. Bacteria transformation and glycerol stock 
LB broth with or without agar (Sigma) was autoclaved and left to cool down at RT under a safety 
cabinet for sterility. Ampicillin diluted 1:1000 from a 1000X stock (Sigma) was added to the LB broth 
with agar and roughly 20ml of mix was poured on a petri-dish and left to solidify. One Shot TOP10 
Chemically Competent E. coli (Invitrogen, Thermo Scientific) were used to produce the plasmid DNA 
[pcDNA3.1 (-)] of interest according to the manufacturer’s instructions (constructs details in 
Chapter 5). After thawing one vial, 2μl of DNA were added to the vial, inverted and incubated on 
ice for 30mins before heat-shocking the E.coli in a 42°C water bath for 30 seconds and then placing 
them on ice for 2 minutes. 250µL of S.O.C medium was added aseptically to the vial and incubated 
on an orbital shaker at 37°C for 1 hour at 225rpm. 5µL, 20µL or 100µL of each transformation was 
spread on pre-warmed petri dishes for 24 hours at 37°C to obtain single colonies. A negative control 
dish with non-transformed bacteria was included as well. A single colony was picked and inoculated 
in a T-75 flask with 120ml of LB media and ampicillin and further incubated for 24hrs at 37°C on an 
orbital shaker. 500µL of this liquid culture was mixed 1:1 with pure glycerol (Sigma) to make several 
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vials of stock and stored at -80°C for long term storage in cryotubes. The rest of the liquid culture 
was harvested by centrifugation at 3000g for 30mins at 4°C. 
 
2.16.2. Midi prep 
DNA plasmid was purified using a Plasmid Midi kit (Qiagen) according the manufacturer’s 
instructions. Briefly the bacteria pellet was first lysed with buffer P1, P2 and P3 and the resulting 
clear supernatant was applied to a Qiagen-tip 100 resin column and let to move through by gravity. 
Bound DNA was washed with buffer QC and eluted with buffer QF. DNA was further concentrated 
with isopropanol (Fisher Scientific) and washed with 70% ethanol. The air-dried pellet was finally 
resuspended in 100ul of buffer TE (10mM Tris pH 8.0, 1mM EDTA). 
 
2.16.3. DNA quality check 
DNA quality and quantity was checked using a NanoDrop ND-1000 Spectrophotometer. An 
enzymatic digestion was performed to verify the correct length of the target gene. 1µg of DNA was 
digested for 4 hours at 37°C in a Veriti Thermocycler with 1% BSA, buffer 3 and XhoI and BamHI 
enzymes (NEB, UK). Digestion products were then loaded with a 6X DNA loading buffer (30% 
glycerol, 0.25% bromophenol blue, dH2O) and run on a 2% E-Gel Agarose SYBR Gels with 1 Kb Plus 
DNA Ladder (Invitrogen, Thermo Scientific) and E-Gel 96 High Range DNA Marker (Invitrogen, 
Thermo Scientific). 
2.17. Transfection 
ViaFect (Promega) is a lipid-based method for transfection of cell lines that requires an initial 
optimisation of cell number per well, amount of DNA and Transfer Reagent: DNA ratio. 
Cells were seeded in a 96 well plate at 104 cells/well in 100μl in normal growth medium and 
incubated overnight at 37°C. 75ng – 100ng per well of DNA were then diluted in a reduced serum 
medium (Opti-MEM, Gibco, Thermo Scientific) in an Eppendorf tube. Transfection Reagent was 
diluted in Opti-MEM as well and added to the plasmid DNA to have a final Transfection Reagent: 
DNA mixture of 2:1, 3:1, 4:1 and 6:1. Complexes were allowed to form for 15minutes at RT and 10μl 
of reaction was added to each well with 90μl of fresh normal growth media. Cells were incubated 
for 24 – 48hrs and positive cells were identified by the GFP expression using the fluorescence 
microscope (see section 2.9). Controls with Opti-MEM only, excluding DNA or Transfection Reagent 
were included in the experiment. 
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CHAPTER 3 
 
3. Evaluation of the performance of HTL001 in 
panel of immortalised cancer cell lines and cancer 
cells derived from patients 
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3.1  Introduction 
The HOX genes are a family of 39 homeobox transcription factors normally expressed during 
embryonic development. In the context of cancer their re-activation and overexpression has been 
associated with cancer initiation, progression and metastasis in a large  group of solid cancer and 
blood malignancies [44]. 
A good example is colorectal cancer where a significant upregulation of genes from cluster A and B 
mainly (HOXA9, B3, B8 and B9) was observed in carcinoma tissue as compared to normal colon 
mucosa, whereas cluster D was downregulated (HOXB2, B13, D1, D3, D4, D8 and D12) [99]. The link 
between aberrant expression and prognosis was demonstrated in a study published by Liao et al. 
[100]. The overexpression of HOXB7 correlated with poor prognosis, with in vitro and in vivo 
experiments demonstrating how the homeobox factor was promoting proliferation. The 
mechanism was clearly seen in the in vitro experiments, where the HOXB7 upregulation was 
favouring the progression into the cell cycle from GS1 through increased levels of cyclin D1 and 
the activation of the MAPK and PI3K-Akt signalling pathways. 
In breast cancer, data from Hur et al. [101], showed that cluster A and B were differently 
upregulated in normal and cancer breast cell lines, while cluster C was overexpressed and cluster 
D downregulated in whole panel of cell lines. HOXA13, B2, B4, B5, B6, B7, B9, C9, C13, D1, and D8 
were significantly overexpressed in malignant tissues compared to healthy tissue.  
Chen et al. [102] demonstrated how the induced overexpression of HOXA5, a candidate gene 
previously found upregulated in breast carcinoma, was activated by the retinoic acid (RA) in vitro 
in breast cancer cell lines due to the presence of  a retinoic-acid responsive element (RARE) at the 
3’ end of the HOXA5 gene. 
The binding and activation of RA on HOXA5 was mediating apoptosis in a mechanism mostly 
unknown, suggesting the protective role of HOXA5. HOXA5 might also play a protective role as a 
consensus sequence on the p53 promoter was found in breast cancer cells and its mRNA and 
protein levels appeared to fluctuate with the expression of P53 [97]. The protective role of HOXA5 
comes from an additional evidence that the loss of Hoxa5-/- in female mice impaired the regulation 
of the oestrogens and the formation of ovarian epithelial cysts through the reactivation of the EGFR 
signalling pathway [103]. HOXA5 was overexpressed also in the extensive analysis of data from the 
Cancer Genome Atlas on 630 ovarian cases as well as HOXB9, whose overexpression was seen in 
patients that received suboptimal debulking surgery. HOXB3 and HOXA10 overexpression 
negatively correlated with overall survival [63]. In another study HOXB3 was identified as a 
response biomarker to platinum relapse and suboptimal debulking surgery [64]. Importantly 
HOXA9 and HOXA10 re-activation in ovarian carcinoma seemed to follow the principle of 
77 
 
collinearity observed during the embryonic development of the Mullerian tract and HOXA9 was 
found to be particularly highly expressed in the HGS subtype [49]. HOXA9 is one of the most 
upregulated genes in solid tumours [44] and altered in other cancer types as, to cite some, 
colorectal, glioblastoma and prostate cancer [69]. In colorectal cancer, Freschi et al. [104] 
demonstrated that HOXA9 was present in normal cells of the mucosa at the crypt base, which is 
the germination centre of the villi, using IHC analysis. Colorectal cancer generally arise due to an 
uncontrolled proliferation of the cells of the crypts. In glioblastoma, HOXA9 expression was 
associated to the PI3K pathway and AKT phosphorylation of EZH2, a protein involved in the 
Polycomb Repressive Complex 2 (PRC2). PRC2 operates gene silencing during development through 
histones methylation and HOX genes are a target of this complex [105]. The HOXs expression 
pattern in prostate cancer exhibited generally an upregulation of HOX genes from cluster C in 
primary tissue, lymph node metastases and commercial prostate cancer cell lines, in particular 
LNCaP cell line whose origin is from a metastatic lymph node [106]. The authors also found that an 
increased expression of HOXC8 was impairing the AR signalling, one of the key signalling pathways 
altered in prostate cancer providing additional basis to consider HOX genes for target therapies.  
For a detailed literature review of HOX genes in cancer and their functions refer to the Paragraph 
1.7.2. 
 
The homeobox transcription factors work in partnerships with other transcription factors member 
of the TALE family, PBX and MEIS. The cooperation between either HOX-PBX, HOX-MEIS or HOX-
PBX-MEIS enhances the binding affinity to the double helix and modulate the transcriptional 
activation of target genes, partly unknown [84]. In ovarian cancer, PBX1 and MEIS1 were the mostly 
upregulated proteins out of the four PBX and two MEIS protein isoforms respectively in patients 
cancer tissue, both with a nuclear or cytoplasmic expression suggesting the ability of these co-
factors to move across the nuclear membrane [107]. 
 
Our group has focused on the HOX-PBX interaction which can be targeted with a peptide inhibitor 
called HXR9. The HXR9 design has been described in Section 1.7.3.1.  The mechanism of HXR9 
peptide entry to the cell is based on a polyarginine repetition (9x). Polyarginine belongs to the 
superfamily of cell penetrating peptides, that cross the cell membrane  in a passive diffusion fashion 
at concentrations above 10μM, likely interacting with the proteoglycans on the cell membrane [88]. 
In addition, HXR9 contains an YPMW motif that mimics the hexapeptide (HX) of HOXs proteins for 
the binding to their co-factor PBX. The inhibition of this interaction leads to apoptosis and this has 
been extensively shown in vitro and in vivo [52, 67-72, 95, 108] in several solid malignancies 
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including melanoma, prostate, breast and ovarian cancer. Ovarian cancer cell lines SKOV3 and OV-
90, for example, showed different degrees of sensitivity to HXR9 mediated cellular killing via 
metabolic and cytotoxic assays. Immunoblotting of SKOV3 also revealed the presence of cleaved 
PARP, a biomarker for apoptosis. In the same study, flank tumours with SKOV3 cells in mice were 
significant reduced in HXR9-treated arms [70] (in details in Paragraph 1.7.3.2). 
 
 
Figure 3-1: Molecular mechanism of action of HXR9 or HTL001.  
HXR9 enters the cell membrane due to its polyarginine  tail and then binds PBX as it 
contains a hexapeptide -like motif. The inhibition of the cooperative binding between HOX 
and PBX stops the activation of their downstream target genes. Image from 
https://www.surrey.ac.uk/microbial/Research/cancer/cancer_research.htm  © University 
of Surrey. 
 
HXR9 is a 17 a.a. long peptide with a molecular weight of 2.7 kDa. The control peptide CXR9 has 
been designed exactly the same way with the substitution of Tryptophan  Alanine (WA) that 
makes the peptide still capable of cell penetration, but ineffective in triggering apoptosis. Moreover 
the C-term and the D-term have been constructed in the L-isoform to make them resistant to 
proteases [67]. The L- isomers do not exist in biological molecules, therefore proteases are not able 
to bind and cut molecules with atoms that are differently spatially arranged. 
Since the original experiments with HXR9, Prof. Richard Morgan developed a new version of HXR9, 
HTL001, that preserves the structure of HXR9, but contains some changes in the a.a. composition: 
    
  HXR9:  WYPWM KKHH RRRRRRRRR 
 HTL001:      WYKWM KKAA RRRRRRRRR 
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The resulting peptide is a 2.6 kDa with similar isoelectric point (PI) around 12 (so high positively 
charged at cell pH at 7), but the histidine alanine (HHAA) aminoacidic substitution should 
enhance the peptide flexibility and therefore it should facilitate the cell membrane entry. The 
modification of a large and rigid aminoacid as the proline (P) in favour of a lysine (K) should also 
reduce its sterical interference on the other a.a. implicated in the PBX interaction which translates 
probably in an increased peptide binding efficacy as well. The modifications should simplify the 
chemical synthesis of the peptide and its stability (personal communication Prof R. Morgan, 
University of Bradford). 
A linear interpolation between HOX genes expression and sensitivity to HXR9 has been shown in 
some of the breast cancer or squamous carcinoma cell lines and in primary breast tumours, in 
particular when analysing mean of expression of cluster B (breast) and A (squamous) and plotting 
versus the IC50 of HXR9 [68, 94] (detailed in Paragraph 1.7.3.2). This correlation opens the 
possibility of identifying predictive biomarkers of response to the treatment with HXR9/HTL001 
and may allow for a better patient selection for clinical studies. In particular, this should be valid 
for HOX paralogues 1 - 9 which are the ones exhibiting the HX domain, hence susceptible to the 
drug inhibition. 
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3.2 Hypothesis and objectives 
The scope of the present chapter was to evaluate the efficacy of the upgraded version of HXR9, 
HTL001 in a panel of immortalised cell lines and primary cultures from ovarian cancer tissue and 
ascites. The scientific question was whether HTL001 had a more potent anti-tumour activity 
compared to its counterpart HXR9 in vitro and if the mechanism of cell killing was 
apoptosis/necrosis. 
To test the hypothesis, the ability of HTL001 to inhibit cell metabolism was evaluated by an MTS 
assay followed by an Annexin V assay to validate the MTS results in some cell lines. 
We also wanted to assess whether there was a correlation between HOX gene expression and 
HTL001 sensitivity in commercial cell lines. This was evaluated with qPCR to measure HOX genes 
expression and correlated with the IC50 obtained in the MTS experiments. 
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3.3 Results 
3.3.1 HTL001 inhibited cell metabolism in immortalised cell lines 
HTL001 ability to inhibit cell metabolism and proliferation was tested in a panel of ovarian cancer 
cell lines (PEA1, PEA2, PEO1, PEO4 and COV318). A detailed description of their features can be 
found in Table 2.2-1. Whole set of ovarian cancer cell lines resemble the characteristics of HGS-
EOC, with mutations generating a non-functional P53 protein [109, 110]. Moreover PEA1 has a 
BRCA wild type, while PEO1 and PEO4 have a BRCA2 germline mutation. The latter do not exhibit 
any mutation at KRAS, BRAF, CTNNB1 or PI3KCA again suggesting the cell lines belong to the highly 
aggressive HGS type [109]. 
In order to screen the responses to HTL001 at different concentrations in a simple, convenient and 
fast way, a MTS colorimetric assay was used, which measured cell viability following drug exposure. 
The effects of HTL001 and HXR9 were compared and CXR9 was included as a control. Results were 
illustrated as normalised response of DMSO vehicle and plotted as a percentage of cell survival 
versus μM concentrations of drugs (Figure 3.3-1 and Figure 3.3-2). The IC50 was calculated with 
the GraphPad Prism 7.04 software interpolating the points with a non-linear regression curve fit, 
red line for HTL001 and blue one for HXR9 (Table 3.3-1). As expected CXR9 failed to induce any 
cytotoxicity to the cells (Figure 3.3-1). The paired cell lines from the PEA or PEO series 
demonstrated a high sensitivity to the drug around an IC50 of 25 - 35 μM. COV318, an 
adenocarcinoma metastatic cell line derived from peritoneal fluid, appeared to be one of the less 
sensitive cells to either HTL001 or HXR9 (Figure 3.3-2). There was no statistical difference in the 
inhibition efficacy of the two drugs. The statistical method of choice was a two-way ANOVA, with 
Sidak’s corrections for multiple comparisons calculated with Graph Prism software 7.04 (Figure 
3.3-1 and Figure 3.3-2). 
 
CELL HTL001 IC50 HXR9 IC50 
COV318 81.39 95.70 
PEA1 24.48 27.79 
PEA2 35.67 41.87 
PEO1 26.58 29.23 
PEO4 28.02 25.59 
Table 3.3-1: IC5 0  of HTL001 and HXR9 tested on commercial cell lines calculated with 
GraphPad Prism version 7.04.  
Data set for curve fit  and calculations are the results from  MTS assays and expressed in 
μM.
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Figure 3.3-1: MTS assay of paired cell lines PEA 1/PEA2 and PEO1/PEO4.  
Cells were seeded at 10000 cells/well in a 96 well plate and incubated O.N. Appropriate μM concentrations of drugs were then diluted in fresh 
growth media and applied to cells for 2 hours before the end point MTS assay. MTS reagent wa s diluted 1:10 in reduced serum RPMI (2%FBS) 
and incubated with cells for 2 - 3hrs before reading at 490nm on a plate reader Varioskan Flash (Thermo Scientific) . Blue and red lines are the 
curve fit  of the data sets interpolated with GraphPad software. Err or bars represent SD calculated on two biological repetitions.  
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Cells were seeded at 5000 cells/well in a 96 well plate and incubated O.N. Appropriate μM 
concentrations of drugs were then diluted in fresh growth media and applied to cells for 2 
hours before the end point MTS assay. MTS reagent was diluted 1:10 in reduc ed serum 
RPMI (2% FBS) and incubated with cells for 2 - 3hrs before reading at 490nm on a plate 
reader Varioskan Flash (Thermo Scientific). Blue and red lines are the curve fit of the data 
sets interpolated with GraphPad software. Error bars represent SD c alculated on two 
biological repetitions  
 
 
3.3.2. HTL001 induced apoptosis/necrosis in immortalised cell lines 
HXR9 triggers apoptosis in cancer cell lines [67, 95, 108, 111]. Most of the previous published 
articles tested the mode of death of HXR9 primarily with an Annexin V assay, therefore experiments 
were performed to confirm whether apoptosis was the mode of death of the new peptide version 
HTL001 as well and to validate the finding of the MTS assays with another assay measuring the 
cells’ susceptibility to cytotoxic compounds. 
A pair of representative cell lines, a HTL001/HXR9 very sensitive (PEA1) cell line and a more 
resistant cell line (COV318) were treated around the IC50 as shown in Table 3.3-1 for 2 hours with 
both HXR9 and HTL001 and analysed within 24 hours by flow cytometry for the expression of 
Annexin V. Annexin V is a protein able to detect the phosphatidylserine components of the 
membrane exposed on the surface since the early event of apoptosis, in particular membrane 
blebbing; 7AAD is a vital dye with strong affinity to DNA and an indication of the nuclear membrane 
status. Healthy cells with intact membranes (cytoplasmic and nuclear) exclude both staining. 30μM 
Figure 3.3-2: MTS assay of COV318 cell l ine.  
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of HTL001 or HXR9 was the concentration used to treat the PEA1 cell line and 100μM for the 
COV318 cell line (Figure 3.3-3). PEA1 and COV318 cells were positively stained for Annexin V and 
showed low and high 7AAD staining, suggesting cells were in early apoptosis (bottom right corner, 
Annexin V+/7AAD-) and late apoptosis/necrosis with a highly damaged cell membrane (top right 
corner, Annexin V+/7AAD+). The percentage of cells in early and late apoptosis was around 52% for 
both PEA1 and COV318 after treatment with HTL001. Notably, HXR9 treatment performed better 
than its newer counterpart inducing more than 60% of cell death.   
The flow data lacks appropriate statistics, but the experiments were repeated only twice and only 
one representative example is reported here.
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Cells were seeded in a 6 well plate and incubated O.N. Appropriate μM concentrations of drugs were diluted in fresh growth me dia and applied 
to cells for 2 hours before Annexin V/7AAD staining was performed. 30μM of either HTL001 or HXR9 was used for PEA1, while COV318 were 
treated with 100μM of each drug. Analysis by flow cytometry was carried out immediately. Each FACS plot shows 10000 events fr om one 
representative test.  
Figure 3.3-3: Annexin V/7AAD staining of OC cell lines after treatment with HTL001 or HXR9.  
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3.3.3. HTL001 inhibited cell metabolism in patient derived cells 
Primary cultures from patient derived tissue or ascites represent a precious model to test cytotoxics 
or understand cells behaviour to stress and cell to cell interactions in a way that is patient specific 
and close to reality. Their limitation is the availability of clinical samples and the short life in culture, 
up to 10 passages only, as cells undergo senescence. One of the major obstacles is the purity of the 
population of these cell cultures. Fibroblasts, endothelial cells and macrophages for tissue and 
monocytes and red blood cells for the peritoneal liquids are the main contaminants of the tumour 
cells isolated and their removal is necessary to obtain accurate responses to drugs. 
The method of choice to isolate tumour cells from patient tissue was a Human Tumour Cells 
Isolation kit from Miltenyi Biotec. The tumour tissue was first dissociated to a single cells 
suspension using a standardized approach of combining an enzymatic (Human Tumour Dissociation 
kit) and mechanical tissue disruption using a GentleMACS. The cell separation strategy utilised 
MACS® MicroBead Technology to enrich the sample on a MACS column depleting contaminants 
and leaving the tumour cells free to elute. The handling of body fluid was easier and the passage 
through a cell strainer and the use of a red blood cells lysis solution (refer to Section 2.3) should 
have been enough to remove monocytes and red cells, the most prevalent source of contaminants. 
Moreover, they do not adhere to flasks and they can be easily removed with the first media change. 
Generally, fibroblast contamination is rarely observed in primary cultures from ascites. For each 
experiment, prior to seeding cells for the endpoint MTS assay, the population purity was evaluated 
by flow cytometry using a panel of 3 markers. CD45 to quantify the percentage of leucocytes, 
vimentin as a biomarker for fibroblasts and a pan-cytokeratin (pan-CK) marker for epithelial cells; 
epithelial cells normally express high level of cytokeratins. 
 
It was quite challenging to judge the purity of the primary samples from the flow cytometry results 
(Figure 3.3-4). AS01 showed the existence of two populations of epithelial cells expressing a panel 
of cytokeratins at different degrees (low and high). The good purity of the sample was confirmed 
by the low expression of the lymphocyte common antigen (CD45) that remained around 5-6% and 
the more than 90% of vimentin negative cells. The data regarding the other primary culture derived 
from peritoneal liquid, AS03, was not included here due to the low number of cells analysed by 
flow cytometry. However, its analysis in a different biological repetition showed a population of 
cells expressing a 98% of pan-CK and only 2% of EpCAM positivity, another marker of cell to cell 
adhesion often found on cells of epithelial origin (data not shown). 
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Obtaining a pure population of epithelial cells from primary tissue was harder; EOC01 displayed 
10% of cells with low pan-CK expression, but at the same time a low expression of CD45, again 
around 5%. The remaining 90% of cells were expressing pan-CK, but 70% of this population stained 
positively for vimentin too. The EOC02 sample contained a mix population of cells with a largely 
low expression of the markers around 25% (CD45-, pan-CK -, vimentin-), half of the population with 
an epithelial origin expressing pan-CK +/vimentin- and another 25% subpopulation double positive 
for the epithelial and fibroblast biomarkers (pan-CK +/vimentin+). 
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The purity of the primary cultures was evaluated by flow cytometry with a 3 colour marker panel. A photo at the optical micro scope of each 
culture was taken prior to trypsinising the cells from a T-75 culture flask. Cells were stained with a pan -cytokeratin (pan-KRT) antibody 
(recognising KRT7, KRT8, KRT18 and KRT19), CD45 and vimentin. The image shows a representative example of each primary culture with less 
than 10000 events. AS= ascites; EOC= epithelial ovarian carcinoma.  
Figure 3.3-4: Primary cultures purity.  
89 
 
After having assessed their purity, primary cells metabolism in response to HXR9, HTL001 and CXR9 
was evaluated in the same way as described for commercial cell lines. Table 3.3-2 shows the IC50 
obtained for each drug. The control peptide CXR9 did not affect cell viability.  
 
CELL HTL001 IC50 HXR9 IC50 
AS01 70.58 79.73 
AS03 65.04 81.23 
EOC01 47.74 64.46 
EOC02 62.46 76.13 
Table 3.3-2: IC5 0 of HTL001 and HXR9 obtained from the patient derived cell l ines calculated 
with GraphPad. 
Prism version 7.03. Data set for curve fit and calculations are the results from MTS assays 
and expressed in μM.  
 
The overall trend revealed that primary cultures were far less sensitive to HTL001 or HXR9 than the 
immortalised cell lines and HTL001 performed slightly better than the old version of the peptide. 
The high variability (SD) of the experiment seen in the graphs (Figure 3.3-5) could be explained 
by the repetition of the initial removal of contaminants twice in two independent cell passage 
numbers or the event of an epithelial mesenchymal transition (EMT) that occurred during cell 
passaging (discussed in Paragraph 3.4). 
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Cells were seeded at 3000 cells/well in a 96 well plate and incubated O.N. Appropriate μM concentrations of drugs were dilute d in fresh growth 
media and applied to the cells for 2 hours before the end point MTS assay. MTS reagent was diluted 1:10 in reduced serum RPMI (2%FBS) and 
incubated with cells for 2-3hrs before reading at 490nm on a plate reader Varioskan Flash (Thermo Scientific). Blue and red lines are the curve 
fit of the data sets interp olated with GraphPad software. Error  bars represent SD calculated on two biological repetitions after two independent 
steps of purification using the MACS tumour cell isolation columns . 
Figure 3.3-5: MTS assay of patient derived cells exposed to HTL001 or HXR9.  
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3.3.4. HOX genes expression and HTL001 sensitivity 
HOX genes expression was quantified in the panel of ovarian carcinoma cell lines (PEA1, PEA2, 
PEO1, PEO4 and COV318) and expressed as relative expression of the housekeeping gene β-act 
(x10000). The calculation used a ΔCt method:  
 
Relative expression = 2(- ΔCt) x 10000 where ΔCt= (β-act - target gene).  
 
A further description could be found in Section 2.15. 
 
All ovarian cell lines demonstrated different degrees of HOXs expression in the 4 clusters. Normal 
ovary (commercial RNA) showed very little expression of HOXs from clusters C and D in particular, 
however the ovarian cell lines seemed to re-activate genes preferentially from clusters A and B to 
a variable extent. Paired cell lines PEA1 and its cisplatin resistant counterpart PEA2 showed a similar 
pattern of HOXs expression, with an additional upregulation of genes already overexpressed in the 
cisplatin sensitive cell lines (HOX A5, A9, A 10 and B9). Similarly, PEO4 further expressed HOX B3 
and B4 as compared to PEO1. COV318 did not display such overexpression of HOX genes despite 
its metastatic origin with the exception of HOXA5, A9 and A10 which were overexpressed, but to a 
lesser extent than the PEA series (Figure 3.3-6). 
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The relative expression to β-act was calculated with the ΔCt method  (refer to text) and multiplied by a factor of 10000. Results are shown as 
mean of two independent biological repetition and error bars represent SD.  
Figure 3.3-6: HOX  genes relative expression in the panel of ovarian cell l ines studied.  
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A Pearson correlation was calculated to establish whether the mean of expression of HOX 
paralogues from 1 - 9 from the entire four clusters was following a linear regression with the IC50 
of each cell line in response to the treatment with HTL001. The mean of expression was calculated 
as the average of the relative expression of each single HOX gene from each cluster (A, B, C and D) 
from paralogues 1-9 calculated in Figure 3.3-6. 
Figure 3.3-7 demonstrates how ovarian cell lines with a resistant/metastatic origin (PEA2, PEO4 
and COV318) had a sensitivity to HTL001 proportional to their HOXs expression. A poor HOX 
expression corresponded to less sensitivity to the drug. PEA1 and PEO1 were particularly sensitive 
to the drug despite the lower HOXs expression. 
The theoretical IC50 of the normal ovary calculated from the equation of the linear regression was 
86.32μM. 
Only excluding PEA1 and PEA2, a linear interpolation was possible. A possible explanation would 
be proposed in the discussion. 
 
 
 
Figure 3.3-7: Ovarian cancer cell l ines sensitivity to HTL001 (IC 5 0)  plotted against their 
mean of expression of HOX genes paralogues 1 -9 from all clusters.  
A Pearson correlation was calculated excluding cell l ines PEA1 and PE01 and resulted in a  
statistically significant negative linear correlation (Pearson score= -1 and P value = 0.02). 
Normal ovary mean of expression was acquired experimentally and its theoretical IC 5 0 
value calculated from the equation y = mx + c of the linear regression.
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3.4  Discussion 
The results described in this chapter form an introduction to further work presented in this thesis 
in relation to HXR9 and HTL001. The aminoacid changes in the revised version of HXR9, HTL001, we 
assumed were not altering the mechanism of cell entry (9R), but they aimed to improve the 
flexibility of cell entry and therefore cellular uptake, the chemical synthesis and the binding ability 
of the drug. These aminoacids changes in the new peptide needed to be tested in parallel with the 
original peptide HXR9, again in the context of ovarian cancer to assess whether there was an 
improvement of the cytotoxic efficacy of HTL001 and to confirm if the mode of death induced was 
still via apoptosis.  
In the first part of this chapter the killing efficacy of HTL001 was compared to its counterpart HXR9 
in a panel of immortalised cell lines. The MTS assay results showed there was no statistical 
significant difference in the IC50 obtained by HTL001 or HXR9. However, one of the limitation of this 
evaluation is that mechanism of action of the two peptide as HOX target binding and disruption of 
HOX/PBX interaction were not really tested, so it is difficult to compare whether the peptides are 
really acting differently. MTS assays were used, but the results are rather difficult to interpret 
relying only on a cytotoxicity assay. A further molecular analysis to link the genotype to the 
phenotype is needed, as for example repeating a band-shift assay that Morgan et al. [67] used 
before or introducing immunoprecipitation assays of PBX or HOXs from paralogues 1-9. A lack of 
difference in IC50 may suggest the modified peptide does not really act any differently from the 
original peptide. 
 
Annexin V data could indicate that the mode of death induced by HTL001 could still be considered 
as apoptosis/necrosis (Figure 3.3-3). This assay did not distinguish enough to judge whether 
apoptosis or necrosis was the cell killing mechanism as most of the cells highly expressed both the 
markers Annexin V and 7-AAD, an indication of an extremely damaged cell membrane. The flow 
data also lacks appropriate statistics, but the experiments were repeated only twice. More 
biological repeats and decreasing the HTL001 concentration would be advisable to be included in 
further experiments to have more robust data and to be able to distinguish between early and late 
apoptotic cells. However, previously published articles demonstrated that apoptosis was the mode 
of death using a fluorescence-based cleaved caspase 3 assay in melanoma cells and identifying the 
presence of cleaved PARP in the ovarian SKOV3 cells after HXR9 exposure [70, 95]. 
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Similarly, the primary cell lines established from ascites and tissue biopsies exhibited different 
degrees of sensitivity to the drugs, but overall the primary cultures displayed less sensitivity to 
HTL001 or HXR9 than the immortalised cell lines and close to the value obtained for the HGS 
COV318, derived from peritoneal ascites. Again there was no statistical significant difference in 
terms of cell killing efficacy between the two versions of the peptide (Figure 3.3-5). A loss of 
HTL001 sensitivity in the primary cultures could partly be explained by the absence of a 100% pure 
population of tumour cells (Figure 3.3-4) or the possibility of epithelial-mesenchymal transitions 
within the in vitro culture. The primary cultures from ascites reached overall a good purity with 
AS01 showing more that 90% of cells negative for vimentin and CD45, confirming the absence of 
fibroblast or macrophage contamination. Similarly, AS03 obtained 98% of cells expressing a panel 
of cytokeratins (CK 8, 9, 18 and 19) indicating the epithelial origin of these cells. The absence of 
EpCAM expression, another adhesion molecule generally expressed on the epithelial cells, has been 
seen before in the literature [112] and could be an indication of the transition to an aggressive and 
mesenchymal phenotype that can be expected from this sample collected from pleural effusion 
from an HGS stage IV patient (data not shown) (further details in Appendix A - Patients’ details). 
The mixed populations seen also in the primary cultures obtained from dissociated tissue, in 
particular 70% for EOC01 purity and only 25% purity for EOC02 cells expressing both vimentin and 
cytokeratins, suggest that the cells in the flasks might have undergone an epithelial – mesenchymal 
transition (EMT), thus the elongated cell morphology observed under the microscope. In AS01, the 
presence of a population with low expression of pan-CK (75%) could be the indication of the 
beginning of this change in phenotype (Figure 3.3-4). EMT is a well-documented process in cancer 
progression where cells progressively lose their cell- to-cell contact, for example adhesion proteins 
as EpCAM or E-cadherin, and acquire a “mobile” and elongated shape typical of a mesenchymal 
phenotype with expression of biomarkers as N-cadherin or vimentin [112-114]. 
HTL001 targets cells that selectively overexpress HOX genes, therefore normal cells such as 
fibroblasts or macrophages show a null to low expression of these genes and minimum signs of 
cytotoxicity should be seen in this type of non-malignant cell. The presence of contaminants in the 
primary cultures explains the low sensitivity to HXR9/HTL001, but it does not explain the double 
positive staining of cells to vimentin and a panel of cytokeratins that could characterise instead 
cells that started an EMT. “Mesenchymal-like” cells might express low levels of HOX genes, hence 
explain the less susceptibility. Future work to quantify HOXs expression in cells with high self-
renewal capacity as either mesenchymal cells or cancer stem-like cells in the context of ovarian 
cancer is required. Another limitation of the interpretation of the present work was that a HOX 
profiling was not performed in patient derived cells due to the technical limitation of a high number 
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of cells required for the MTS assay experiment and the necessity to passage the cells to a low ratio 
(1:2) to maintain the culture. Future work should include an HOX profiling in these cultures to link 
a genotype profile with an observed phenotype. 
 
One would expect that cells highly expressing HOX genes that translates into high levels of HOX 
proteins should be more responsive to the effect of HTL001; vice versa a low sensitivity would 
foresee for the cells with a HOX expression that resembles the normal tissue. If this is the case, a 
proper patients’ stratification and prediction of drug response using HOX as prognostic markers can 
be made impacting clinical decisions. To test the above statement, which is also the second 
hypothesis of the chapter, the HOX expression was quantified by RT-qPCR in commercial cell lines 
and correlated to the drug sensitivity. PEA1, PEA2, PEO1, PEO4 and COV318 seemed to re-activate 
HOX genes from cluster A and B preferentially, in particular HOXA5, A9 and A10 for PEA paired cell 
lines and HOX B3 and B4 for the PEO series (Figure 3.3-6). 
To assess the correlation of the diverse HOXs expression in commercial cell lines, a Pearson 
correlation was calculated between cells IC50 in response to HTL001 and mean expression of HOXs 
from whole clusters, but from paralogues 1 - 9 only. Paralogues 1 - 9 contains the conserved 
sequence mimicked by HTL001 to bind the PBX co-factor, therefore is the group of HOXs susceptible 
to the drug inhibition.  When all cell lines were analysed together there was no linear correlation, 
but interestingly a very strong linear regression was found when analysing only PEA2, PE04 and 
COV318 and when excluding from the analysis PEA1 and PEO1 (Figure 3.3-7).  It is very hard to 
speculate and propose a mechanism behind this differential sensitivity to HTL001 and why PEA1 
and PEO1 do not follow the regression. Looking for explanation from the anatomical origin of these 
cell lines, PEA2, PEO1, PEO4 and COV318 cells are isolated from ascites, while PEA1 is of pleural 
effusion origin. PEA1 is also the only cell line obtained from a chemo-naïve patient in primary 
disease, while PEA2, PEO1, PEO4 come from a platinum resistant relapse setting. I looked up from 
the literature at the work of Beaufort et al. [115] where they profiled 39 ovarian cancer cell lines 
for the most common altered genes to gain some insights from a mutational status analysis 
perspective. Excluding a non-functional P53, which has a missense mutation for all cell lines, 
remarkably PEO1 has a germline missense mutation in BRCA2, while its paired cell line PEO4 has a 
silent mutation and a functional BRCA2. The absence of a proficient DNA repair in PEO1 might let 
us to speculate the better sensitivity to the cytotoxic action of HTL001 due to the lethal 
accumulation of unsolved DNA damage. The molecular link is HOX-BRCA- (PARP?) is however 
completely unknown. PEA1 has CREBBP missense mutation as compared to PEA2. Perhaps a 
mutation in CREBBP, an epigenetic regulator (acetyl transferase), could alter the transcriptome and 
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create therapeutic vulnerabilities also to HTL001 as reported in the literature, where CREBBP 
alterations sensitized cells to DNA-damage drugs [116]. These alterations might not be linked to 
the HOX-PBX inhibition and even suggest off targets of HTL001. 
COV318 has CNNE1 amplifications which are generally linked to mechanisms of resistance through 
CDK2, so the low efficacy of HTL001 could be explained by a compensatory mechanism of resistance 
and not related at all to the level of HOX genes. 
The data are very limited to draw any general conclusions; probably more mechanisms of HOX 
genes regulation occur in ovarian cells, such as epigenetic modifications or lncRNAs (discussed in 
Section 1.6.1) and HOX gene expression might not be indicative of the HOX protein levels in the 
cells. In addition, the overexpression of MEIS1 in ovarian carcinoma and omentum, as shown in the 
human Affymetrix data set XPO1026, can also contribute to resistance bypassing the HOX-PBX 
inhibition through a HOX-MEIS interaction of paralogues 10-13, which could restores the HOX 
related functions of proliferation and survival [107]. 
Finally, platinum resistant cell lines such as PEA2, PEO4 and COV318 might have re-activated 
molecular pathways and oncogenes that protect from apoptosis and confers intrinsic resistance to 
cytotoxics, lacking in PEA1 and PEO1, which demonstrated quite a high sensitivity to HTL001 despite 
the expression of HOXs at a lower extent. The signalling cascade resulting in apoptosis initiated by 
HTL001 is still mostly unknown and further insights and possible explanations to the different 
sensitivity to the drug will be given in Chapter 6. 
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CHAPTER 4 
 
4.  An ex vivo organotypic culture: the precision cut 
tumour slices model to test new therapeutics 
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4.1. Introduction 
HXR9 or HTL001 cytotoxic effects on cancer cells have been shown extensively in vitro and in vivo 
in a variety of cancer types including melanoma, prostate, breast and ovarian cancer to name a few 
[67-70, 72, 111]. In Chapter 3, the successful ability to selectively inhibit cell proliferation and to 
induce apoptosis was also reconfirmed for HTL001, the upgraded version of HXR9, in immortalised 
ovarian cancer cell lines and primary cultures derived from patient tissue or ascites. A slightly better 
anti-neoplastic efficacy of HTL001 in 2D experimental models, i.e. monolayers of a unique 
population of cells adhering on flasks, prompted us to challenge the peptide in a scenario closer to 
what can be observed in a clinical context, moving to test the drug in tri-dimensional (3D) ex vivo 
platforms and in a patient personalised manner. 
An effective way to test new anti-cancer agents in a pre-clinical setting remains a challenging task. 
Ovarian cancer models are particularly difficult to establish, as tumours are very heterogeneous 
demonstrating a complex architecture and morphology. Although progress has been made in the 
last decade with testing cell lines derived from patients’ material (ascites or primary cultures), new 
platforms are needed due to the limited availability and lifespan in cell culture of these precious 
samples. 
 
4.1.1.  Experimental systems to study ovarian carcinomas 
Researchers are in desperate need of optimal experimental models to further explore the dynamics 
and biology of ovarian cancer and in particular the commonest subtype - high-grade serous 
epithelial ovarian cancer (HG-EOC) which accounts for 90% of the cases. 2D and 3D systems for in 
vitro studies are constantly expanding and improving: one of the main reasons is the fact that 
cancer is a multi-factorial disease with a very complex architecture and heterogeneity. It is also 
now well established that not only cancer cells themselves, but the microenvironment plays a role 
in progression, invasion and spreading of the disease and a remodelling of vascularisation, a 
process called angiogenesis, is re-activated as well. All these marked features have been described 
as hallmarks of cancer [117]. Mice with conditional expression or deletion of particular target genes 
and patient derived or EOC cell xenografts are still the preferred pre-clinical methods to resemble 
responses similar to reality, but clearly there are advantages and disadvantages for all of them that 
will be briefly addressed here, together with the current available experimental systems (2D and 
3D) for drug discovery in ovarian cancer. 
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4.1.1.1. Cell lines 
Immortalised cell lines are the most broadly used system, as they are economical, easy to 
manipulate and to grow, but it is not always straightforward to decide which cell line shows a 
genetic and physiological pattern closest to real responses. The main issue is the tumour 
heterogeneity is impossible to represent in tumour derived cell lines, exhibiting a population of a 
single cell type only. Attempts to comprehensively profile ovarian carcinoma cell lines come from 
recent work from Domcke et al. [118] that scanned a panel of 47 ovarian cell lines for mutations 
and mRNA level of expression of genes to identify similar patterns of gene expression to HG-EOC. 
The study revealed that the most commonly used cell lines SKOV3, A2780, IGROV1 and TOV21D 
are actually poor models of ovarian cancer far from containing the BRCA1 and BRCA2 and p53 
mutations typically seen in an HG-EOC patient. SK-OV-3 and A2780 are poorly suited as models for 
HG-EOC and together account for 60% of publications within the panel analysed. Both cell lines do 
not exhibit P53 mutations, however common mutations frequently found in other histological 
subtypes such as ARID1A, BRAF,PIK3CA and PTEN have been noticed. IGROV1 and TOV21D were 
found to be hyper-mutated probably due to mutations in the mismatch repair and in particular, the 
co-occurrence of PIK3CA and PTEN mutations is suggestive of an endometrial or endometrioid 
origin, rather than fallopian. 
 
4.1.1.2. Ascites 
Peritoneal liquid drained from patients offers the possibility to isolate metastatic cancer cells 
present in body fluids. Techniques have improved over time with the protocol well described by 
the pioneer Langdon et al. [119] in the optimisation of ascites derived cell lines. Ascitic fluid is easily 
centrifuged and once re-suspended in a tissue culture flask in simple growth media, it can result in 
a cell line with limitations such as the finite passage numbers of the culture and the presence of 
red blood cells and mesothelial cell contaminants that require subsequent selective steps to be 
removed. 
 
4.1.1.3. In vivo models 
Animal models and xenografts are the platforms for in vivo studies. Mice can be genetically 
engineered for conditional expression of certain genes (lentivector or RNAi technologies) in a stable 
or transient manner. In EOC models, the aim is the depletion of p53 whose mutation occurs in 95% 
cases of ovarian carcinomas and BRCA1 and BRCA2 genes, with a 10-15% frequency of mutation. A 
subcutaneous, intraperitoneal or orthotopic injection of commercial ovarian cell lines or primary 
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cell lines obtained from patient’s tissue in NOD/SCID mice is the ultimate technique for xenografts 
[120]. Advantages and disadvantages of patient derived xenografts, which are so far one of the best 
models, are summarised in Table 4.1-1. 
 
 
Advantages Disadvantages 
PDXs do not undergo selective pressure 
from in vitro  culture 
Immunocompromised mice cannot capture 
the cross talk between cancer cells, tumour 
microenvironment and immune system.  
PDXs maintain original tumour 
heterogeneity and characteristics  
Microenvironment influenc e can be 
partially studied as human stroma is 
replaced by murine stroma 
Molecular similarity is preserved  Orthotopic implantation requires expertise 
Microvasculature and tissue environment 
is maintained, although it is not known 
how long 
Costs of animal manipulation and 
maintenance 
Metastasis process can be evaluated  Coordination between departments  
Correlation PDX models and clinical 
responses 
Regulatory issues  
Table 4.1-1: Summary of principal advantages and disadvantages of PDX models . 
PDX= patient derived xerographs. Adapted from [120]. 
 
 
4.1.1.4. 3D models 
Three dimensions models (3D) represent the next generation of ex vivo systems to study EOC and 
the great advantage is the possibility to explore interactions of different cell types within the 
tumour microenvironment. However, as an artificial system all the variety of cells that an original 
cancer tissue display, such as infiltrating macrophages, ECM, fibroblasts, mesothelial cells and 
eventual adipocytes cannot be included and original tissue architecture can be only partially 
resembled. Common methods to generate ex vivo platforms are: 1) isolated epithelial fallopian 
tube cells assembled with collagen IV on a Transwell membrane or 2) plated on poly-2-hydroxyethyl 
methacrylate (poly-HEMA) tissue culture dishes to form spheroids; 3) spheroid plus components of 
the extracellular matrix or 4) primary cancer cells with omentum isolated from a mouse as a model 
for metastasis (reviewed by White et al. [121]). 
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4.2. Hypothesis and objectives 
The anti-cancer effect of HTL001 on ovarian cancer cell lines and primary cultures was shown in 
Chapter 3 using monolayers of cells from a single cell population adhering on flasks. There is also 
an extensive literature demonstrating the efficacy of HXR9 in 2D settings and in vivo. The data on 
analysis of HTL001 (and HXR9) properties on a three dimensional setting was missing, therefore we 
decided to challenge the cell-penetrating peptides in a new context. In practise, very few drugs pre-
clinically tested reach clinical trials and a lot of effort, money and time is invested in this direction. 
The aim of the chapter was to identify and characterise an experimental platform for ovarian cancer 
capable of recreating human tumour tissue environment and to assess response to drugs in a 
convenient and reproducible experiment. We seek to evaluate whether HTL001 was able to induce 
a selective apoptosis as target therapy in this model. 
  
104 
 
4.2.1. Organotypic culture: an ex vivo 3D model 
In recent years, the ex vivo organotypic model using precision cut tissue slices re-gained the well-
deserved attention from the scientific community. First efforts in setting up a protocol for this 
system date back to almost a decade ago with work from Hood et al. in 1998 using a Krumdieck 
tissue chopper [122]. Ever since the interest has been increasing due to the potential of the 
organotypic model and the improvement of the current techniques. The introduction on the 
market of new and more precise cutting machines such as the Leica Vibratome, have contributed 
to enhancing the quality of tissue slices [123]. For a detailed description of the methodology, refer 
to Section 2.6. The organotypic culture has several advantages that make it one of the most 
complete platforms to study EOC: cellular heterogeneity and complexity are maintained and within 
the slices, it is possible to appreciate the presence of infiltrating macrophages, an intact ECM, a 
thick stroma with interspersed fibroblasts, adipocytes and cancer cells. Moreover, the morphology 
and architecture are original, there is no “artificial” alteration introduced for example by a 3D 
spheroid model. Cytotoxic compounds or targeted therapies can be investigated in a patient 
specific manner moving to a better personalised medicine and avoiding some of the unnecessary 
toxicity due to side effects and costs of care and manipulation on animal models [124-126]. The ex 
vivo model described also offers a valid tool to study cytokines and growth factors released in the 
culture media in response to modifying agents [127]. Nevertheless, a 3D model forces the 
investigators to change the experimental design process taking into account that perhaps elevated 
concentrations of a particular drug are required, problems of penetration in a thicker and densely 
packed tissue could occur and that most of the conventional assays such as MTS or MTT or ATP 
measurement for viability and proliferation cannot be 100%, reliable again due to the fact that an 
homogeneous diffusion might be missed. Limitations of the platform are more derived from 
technical or logistic problems, but some of them can be overcome with a proper organisation of 
the workflow: the proximity of a hospital and a good collaboration with clinicians is essential to 
collect routine tumour’ core biopsies immediately from surgery and to work as fast as possible to 
preserve tissue integrity and viability. The ability of the operator to prepare tumour tissue slices is 
required as they are delicate and minimal manipulation has to be done, despite the differences in 
quality are more correlated to an optimal culture system [98]. The only limitation that cannot be 
solved is that the platform can be used to cut solid tissue only and it has been previously reported 
and confirmed in our lab that not all types of tissues can produce slices for downstream 
applications, in particular when they are too soft [124]. 
The application of the precision cut tissue slices model are multiple and potentially any tissue can 
be successfully cut at the cutting machine with the exclusion of too soft tissues. It could be cancer 
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and non-cancer tissue challenged with anti-neoplastic compounds or targeted therapy. The ex vivo 
experimental platform can be used for example to explore cell population interactions, in particular 
immunomodulation of tissue resident macrophages and T-cells [128], physiologic mechanisms, 
such as fibrosis in renal tissue [129] or the effects of oncolytic viral therapy in 3D settings [126]. 
As representative examples, precision cut tumour slices from ductal pancreatic cancer were 
preserved in good quality without important changes in surface area and morphology for up to 9 
days. Successive staining with a proliferation marker, Ki67 and a biomarker for apoptosis (cleaved 
caspase 3), demonstrated similar percentages of positive staining in the control slices (time 0) and 
the ones cultured for 6 days [128]. Proteomic alterations were minimal too, as confirmed by 
comparing the proteome (>2000 proteins) of control slices and cultured ones. Only 10% of proteins 
were in fact differentially expressed, suggesting the model can efficiently re-create the in vivo state. 
Upon optimisation of the platform, the authors moved on to track the interactions of immune cells, 
specifically T-cells (cytotoxic CD8 cells) and activated macrophages with cancer cells in the 3D 
setting through immunofluorescence labelling of specific antigens; their number was also not 
altered with culturing conditions. The ability of isolated and labelled autologous splenocytes to 
migrate across the entire section of tissue slices after one week in culture was demonstrated, as 
confirmed by evaluation using confocal Z-stacking. This provided a strong evidence of the feasibility 
of the model as a pre-clinical tool to assess immunomodulation in cancer.  
The organotypic model from breast tumour biopsies was a valuable system to screen the efficacy 
of conventional chemotherapeutics such as paclitaxel, as well as new anti-cancer compounds 
namely caffeic acid, ursolin acid and rosmarinic acid [124]. Tumour slice viability was assessed via 
an Alamar blue assay and slices cultured up to 4 days were showing a viability half of the initial 
control, re-confirmed also with immunohistochemical staining with Ki67. Despite the ability of the 
new compounds to induce visible apoptosis or necrosis in tissue slices, their combination with 
paclitaxel showed a more than 40% reduction of counted neoplastic nuclei per slice. Similarly 
Gerlach et al. [125] demonstrated that precision cut tumour slices from head and neck squamous 
cell cancer maintained original morphology for up to one week in culture as confirmed by selective 
immunostaining for proliferation, apoptosis and tissue-specific biomarkers. Following exposure to 
conventional chemotherapeutics such as cisplatin, docetaxel and cetuximab, tissue slices exhibited 
clear signs of nuclear fragmentation, a distinct feature of apoptosis and the activation of CC3.  
The organotypic culture proved to be a valuable tool for assessing the efficacy of viral distribution 
in oncolytic viral therapy as well. Hartkopf et al. [126] engineered an oncolytic measles vaccine virus 
containing an enzyme derived from yeast capable of converting a pro-drug (5-FC) into an active and 
cytotoxic compound (5-FU). Ovarian cancer tissue slices from patients were successfully infected 
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with measles virus as visualised by GFP tag expression and by the presence of the converting 
enzyme at immunoblotting after 72 hours post-infection. Z-stack analysis at confocal microscopy 
confirmed the capability of the oncolytic virus to penetrate into the deep layers of the slice too. 
Overall the organotypic precision cut tissue slices model proved to be a valuable tool for drug 
testing in a patient personalised and in a tri-dimensional setting. 
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4.3. Results  
4.3.1.  Optimisation of culturing conditions of precision cut ovarian cancer 
tissue slices 
In order to optimise the organotypic culture model a number of assays were run to improve viability 
and morphology of ovarian cancer tissue slices and to obtain a reliable platform that could be used 
for downstream applications. It was important to achieve a good quality tissue slices to avoid mis-
interpretation of the results, especially when a drug was applied to the experimental system. 
Table 4.3-1  is an overview of the patient samples presented in the present chapter and highlights 
clinical details as type, stage, grade and if the tissue previously received any platinum therapy. It 
also includes the summary of the type of cultivation methods adopted (that will be discussed in the 
next section) and which types of staining where used to present results regarding viability and 
response to cisplatin or HTL001. 
 
 
Sample: Type: Stage: Chemotherapy: 
Cultivation 
method: 
Data presented for: 
Staining 
presented: 
Patient 1 
High grade 
serous (HGS) 
IIIc 
No 
chemotherapy 
old Viability only Ki67, CC3 
Patient 2 HGS Iva Pre-surgery old Viability only H&E, Ki67, CC3 
Patient 3 Endometrioid Ic 
No 
chemotherapy 
old 
Viability, 
cisplatin 
CC3, γH2A.X 
Patient 4 HGS IVb Pre-surgery new Viability only CC3 
Patient 5 HGS IIIc Post-surgery new 
Viability, 
cisplatin, 
HTL001 
Ki67,CC3 
Patient 6 
HGS and clear 
cells 
IIIc Pre-surgery new 
Viability, 
cisplatin, 
HTL001 
Ki67,CC3, γH2A.X 
Patient 7 HGS IVb Pre-surgery new Cisplatin only CC3, γH2A.X 
Patient 8 HGS IIIc Pre-surgery new Cisplatin only 
H&E, Ki67, CC3, 
γH2A.X 
Patient 9 HGS IIIc Pre-surgery new Z-stack analysis 5/6-FAM-HTL001 
Patient 10 HGS IVa Pre-surgery new Z-stack analysis 5/6-FAM-HTL001 
Table 4.3-1: Patient samples outline.  
108 
 
This table summarises the patient samples that will be presented in the present chapter. 
Clinical details such as type of OC, stage and grade are included, as well as an overview of 
the results obtained regarding viability of slices over time and response  to platinum or 
peptide treatment.  
 
 
Two methods were tested to cultivate the precision cut tissue slices. The first method, called here 
for clarity “old method”, involved the use of the Vibratome machine to obtain the precision cut 
tissue slices. Slices were cultured on a 24 well plate, floating in media plus antibiotics (penicillin and 
streptomycin), placed on a shaker at <100rpm and incubated at 37C°, 5% CO2.  
The publication of the guidelines for the cultivation of precision cut tissue slices by Davies et al. [98] 
and reported in details in Section 2.6, led us to compare the “new method” of cultivation with the 
old one to assess which one was the most accurate to preserve slices viability and quality for a 
longer period of time.  Following the “new method”, tumour slices were cultured supported on 
permeable plate inserts in six well plates and rotated on a tissue slice incubation unit creating an 
air-liquid interface to allow a maximal oxygenation and at the same time preventing the drying of 
the tissue. Growth media was changed every day with or without treatments to maximise the 
availability of nutrients to the slice and the effects of drugs. The graphical abstract below Figure 
4.3-1  shows in details the workflow to prepare the immunohistochemistry images that will be 
presented in the chapter using either the “old” or “new method” and their relative staining 
quantification analysis. 
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Figure 4.3-1: Graphical abstract summarising the workflow to prepare precision cut tissue 
slices with the “old” or “new” method.  
Slices were cultured on a 24 well plate, floating in media plus antibiotics  (penicill in and 
streptomycin), placed on a shaker at <100rpm and incubated at 37C°, 5% CO2 in the “old” 
method.  
Following the “new method”, tumour slices were cultured supported on permeable plate 
inserts in six well plates and rotated on a tissue slice incubation unit creating an air -liquid 
interface to allow a maximal oxygenation and at the same time preventing the drying of 
the tissue. Growth media was changed every day with or without treatments to maximise 
the availability of nutrients to the slice a nd the effects of drugs. Slices were then fixed at 
different time points and immunohistochemistry images analysed and staining levels  
quantified.  
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With the “old method”, the slices were tried to be cultured at different time points for up to one 
week. Previous publications showed variability in deciding the time point with optimal viability, but 
all of them agreed that an acceptable quality could not have been achieved for more than 7 days 
[122, 124, 130]. Figure 4.3-4  depicts images of precision cut slices of a HGS, stage IIIc case (Patient 
1) at different time points up to 6 days in culture and stained for the cellular proliferation marker 
Ki67. Maintaining these culturing conditions, we found that the integrity of the slices decreased 
over time, especially after 3 days: “holes” and tissue stretches started to be noticeable probably 
due to the shaking conditions, however the viability of the slices was good (Day 3). This was 
confirmed by staining the slices for Ki67, a widely used nuclear marker for proliferation that was 
chosen to evaluate the viability of cancer cells. The time zero (t0), a slice cut at the Vibratome and 
immediately fixed in formalin, was included as a control to prove that the blade of the cutting 
machine did not affect at all the quality of slices. Tumour cells in fact, maintained a similar rate of 
proliferation to that of the original biopsy and morphology was intact. However, the same could 
not be said after 6 days in culture (Day 6). The original biopsy was conserved and processed with 
IHC techniques together with a control tissue to ensure that the overall quality was preserved 
(Original biopsy). Moreover, the comparison of the original biopsy and the t0 slice was the proof 
that the tissue transportation to the lab site and the process of slicing was not having a negative 
effect on tissue quality. 
Figure 4.3-2  shows a quantification of the staining intensity of the proliferation marker Ki67 over 
time. The data represent the average percentage of positive staining of three different areas in the 
tissue slice and expressed as a fold increase in staining intensity as compared to the original biopsy. 
After 3 days in culture, less than 15% of nuclei are stained as compared to the original biopsy, 
suggesting that an improvement of the cultivation method was necessary. 
 
 
Figure 4.3-2: Quantification of staining intensity of Ki67 in Patient 1. 
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The data represent the average percentage of positive staining of three different areas in 
the tissue slice and expressed as  a fold increase in staining intensity as  compared to the 
original biopsy. Patient 1 tissue slices were cultivated w ith the “old” method.  Area 
analysed 757436.52μm 2  (0.7mm2)  x3 with ImageScope Positive Pixel Count Algorithm.  Error 
bars refer to the SD calculated on the normalisation of the three individual measurements.  
 
 
In another example at higher magnification (x40) of precision cut tissue slices derived from a high 
grade serous carcinoma in stage IVa (Figure 4.3-5), a reduced viability of cancer cells after 4 days 
in culture was observed as confirmed by the declined percentage of brown staining for Ki67 as well 
as the “holes” and tissue stretches previously mentioned that can be appreciated with H&E 
staining. The statement is particularly evident for slices at Day 2 and Day 4. The Original biopsy 
included as a control was an indication of the ideal initial viability of the clinical sample. 
A quantification of the results is displayed in Figure 4.3-3. After 3 days in culture the slices 
demonstrated a 40% reduction in viability as compared to the original biopsy and a 20-30 fold 
increase in the staining intensity of cleaved caspase 3 for the quantification of apoptosis. 
 
 
 
Figure 4.3-3: Quantification of  staining intensity of  Ki67 and cleaved caspase 3  in Patient 
2. 
The data represent the average percentage of positive staining of three different areas in 
the tissue slice and expressed as  a fold increase in staining intensity as  compared to the 
original biopsy. Patient 2 tissue slices were cultivated with the “old”  method. Area 
analysed 757436.52μm 2  (0.7mm2)  x3 with ImageScope Positive Pixel Count Algorithm. Error 
bars refer to the SD calculated on the normalisation of the three individual measurements.  
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Slices were cultured in a 24 well plate, floating in DMEM 10% FBS me dia plus antibiotics (penicill in and streptomycin), placed on a shaker at <100rpm and 
incubated at 37C°, 5% CO2. Fixation in formalin occurred at the different time points indicated and slices subsequently stain ed for proliferation for Ki67 using 
immunohistochemistry (brown staining). Images captured at 20X magnification .
Figure 4.3-4: Precision cut tissue slices derived from a HGS, stage IIIc case  (Patient 1) at different time points in culture assessed for proliferation .  
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The analysis of tissue quality is a combination of the presence of brown staining in the tumour slice stained with Ki67 and a n evaluation of a 
maintained tissue architecture with H&E sta ining. Images captured at 40X magnification.  
Figure 4.3-5: Precision cut tissue slices derived from a HGS, stage IVa case (Patient 2) cultured for 4 days and assessed for morphology and proliferation rate . 
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The cases demonstrated a variable adaptation to the organotypic model as for example the tissue 
slices derived from an endometrioid case (Patient 3) that was more “resistant” and it could grow 
in for an extended period without resulting in poor viability. In fact, slices cultured for 5 days 
(Figure 4.3-6- Day 5) retained a morphology and integrity similar to the original biopsy (Figure 
4.3-6- Original Biopsy). Viability of tumour slices was confirmed by the low presence of the 
cytoplasmic marker cleaved caspase 3 (CC3), the active version of protein caspase 3, which is the 
converging point of both the intrinsic and extrinsic apoptotic pathways, hence a general indicator 
of a cell undergoing programmed cell death in response to different stimuli. The low level of CC3 
and the well-preserved architecture that can be appreciated with H&E staining were maintained 
up to 5 days, as well as after slicing at the Vibratome (Figure 4.3-7- Time zero). 
 
 
and relative original biopsy assessed for morphology and apoptosis rate.  Slices were 
cultured in a 24 well plate, floating in DMEM 10% FBS media plus antibi otics (penicill in 
and streptomycin), placed on a shaker at <100rpm and incubated at 37C°, 5% CO2. Fixation 
in formalin occurred at the time p oint indicated (Day5) and for the original biopsy and 
tissue was subsequently stained for evidence of apoptosis with cleaved caspase 3 (CC3) 
using immunohistochemistry (brown staining). Images captured at 20x magnification.  
Figure 4.3-6: Precision cut tissue slices of Patient 3 (endometrioid, Ic) cultured fo r 5 days  
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at time zero (immediately after slicing at the Vibratome cutting machine) and evaluated 
for morphology, proliferation and apoptosis rate . The analysis of t issue quality is a 
combination of the presence of brown staining in the tumour slice stained with Ki67, an 
absent or low staining of cleaved caspase 3 and an intact architecture with H&E staining. 
Images captured at 20X magnification.  
 
 
The quantification in Figure 4.3-8  reflects the ability of certain type of tissue to strongly adapt to 
the stress of the culturing conditions and it demonstrated a good viability of slices cultivated after 
5 days. In fact, at Day 5 the tissue slice had an apoptotic rate comparable to the original biopsy or 
even lower. 
 
 
 
Figure 4.3-8: Quantification of cleaved caspase 3  staining intensity in Patient 3.  
Figure 4.3-7: Precision cut tissue slices derived from an endometrioid, Ic case (Patient 3)  
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The data represent the average percentage of positive staining of three different areas in 
the tissue slice and expressed as  a fold increase in staining intensity as  compared to the 
original biopsy. Patient 3 tissue slices were cultivated with the “old” method.  Area 
analysed 757436.52μm2  (0.7mm2)  x3 with ImageScope Positive Pixel Count Algorithm.  Error 
bars refer to the SD calculated on the normalisation of the three individual measurements.  
 
 
An increased quality of the slices generated from precision cutting was obtained when we decided 
to follow the guidelines suggested by Davies et al. [98] and reported in details in Section 2.6. Briefly, 
tumour slices were cultured supported on plate inserts in six well plates and rotated on a tissue 
slice incubation unit creating an air-liquid interface to allow a maximal oxygenation and at the same 
time preventing the drying of the tissue. Growth media was changed every day with or without 
treatments to maximise the availability of nutrients to the slice and the effects of drugs. 
Representative results of tissue slice viability can be observed from tissue slices of Patient 4, an 
HG-EOC (stage IVb) sample: optimal morphology was retained for almost one week and assessed 
by H&E staining (Figure 4.3-10). Signs of loss of tissue integrity started to appear only at a later 
stage compared to previous results (Figure 4.3-4) and they were minimal. It is important to note 
that apoptosis seemed confined to stroma, while cancer cells looked intact and with an intense 
dark nucleus, typical features of an intact cell as observed by H&E staining (all across Figure 
4.3-10). 
The quantification analysis also showed how the precision cut tissue slices could preserve similar 
levels of cleaved caspase 3 after six days (Day 6) as compared to the slice fixed immediately after 
Vibratome cutting (t0), suggesting an increase in the viability with the new cultivation method 
(Figure 4.3-9). 
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Figure 4.3-9: Quantification of cleaved caspase 3 staining intensity  in Patient 4.  
The data represent the average percentage of positive staining of three different areas in 
the tissue slice and expressed as  a fold increase in staining intensity as  compared to the 
original biopsy. Patient 4 tissue slices were cultivated with the “new” method, which  
involves the use of well insert and an incubation on a tissue rotating incubation unit (see 
Figure 4.3-1).
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Tumour slices were cultured  in a six wells plate on plate inserts and rotated on a tissue slice incubatio n unit creating an air -liquid interface to allow 
a maximal oxygenation and preventing the drying of the tissue. Growth media was changed every day to maximise the availabilit y of nutrients. Fixation 
in formalin occurred at the different time points indicat ed and slices very subsequently stained apoptosis with cleaved caspase 3 (CC3) using 
immunohistochemistry (brown staining)  and H&E. Images captured at 10x magnification.  
Figure 4.3-10: Precision cut tissue slices from a HGS, I Vb case (Patient 4) at different time points in culture assessed f or morphology and apoptosis .  
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Another representative example of the improved protocol is reported in Figure 4.3-12 (next page). 
A high proliferation rate was maintained up to 3 days in culture. Notably, apoptosis started to 
appear at Day 3, but was confined to the stroma, while tumour cells remained intact and actively 
proliferating. 
The quantification in figure below is a graphical summary of the previous statement obtained 
averaging the percentage of positive staining of three different areas within the tissue slices and 
presenting the data as a fold increase in staining intensity as compared to the original biopsy. 
(Figure 4.3-11). 
 
 
 
The data represent the average percentage of positive staining of three different areas in 
the tissue slice and expressed as  a fold increase in staining intensity as compared to the 
original biopsy. Patient 5 tissue slices were cultivated with the “new” method.  Area 
analysed 757436.52μm 2  (0.7mm2)  x3 with ImageScope Positive Pixel Count Algorithm. Error 
bars refer to the SD calculated on the normalisation o f the three individual measurements.
Figure 4.3-11: Quantification of k i67 and cleaved caspase 3 staining intensity  in Patient 5.  
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Tissue was cultured with the improved protocol: tumour slices were cultured supported on plate inserts in six well plates and  rotated on a tissue 
slice incubation unit creating an air -liquid interface to allow a maxim al oxygenation and at the same time preventing the drying of the tissue. 
Growth media was changed every day with or without treatments to maximise the availability of nutrients to the slice and the effects of drugs. 
Fixation in formalin occurred at the dif ferent time points indicated and slices subsequently stained for evidence of apoptosis with cleaved 
caspase 3 (CC3) and Ki67 for proliferation using immunohistochemistry (brown staining). Images captured at 20x magnification.  
Figure 4.3-12: Precision cut tissue slices from a HGS, IIIc case (Patient 5) at different time points in culture assessed for proliferation and apoptosis rate.  
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Furthermore, a well preserved tissue quality of precision cut tumour slices derived from a case of 
HGS and clear cell IIIc was mainteined up to 3/4 days. The brown staining for proliferation was 
observed until Day 4 and it was very low at Day 7. This inversily correlated with a negative or low 
cleaved capsase 3 staining until Day 3 that however increased at Day 4 and Day 7 (Figure 4.3-14). 
The quantification analysis of Patient 6 demonstrated a good viability until Day 3, given the staining 
intensity of proliferation and apoptosis with a fold rate similar to the original biospy (Figure 
4.3-13). 
 
 
 
The data represent the average percentage of positive staining of three different areas in 
the tissue slice and expressed as a fold increase in staining intensity as  compared to the 
original biopsy. Patient 6 tissue slices were cultivated with the “new” method . Area 
analysed 757436.52μm 2  (0.7mm2)  x3 with ImageScope Positive Pixel Count Algorithm. Error 
bars refer to the SD calculated on the normalisation of the three individual measurements.
Figure 4.3-13: Quantification of k i67 and cleaved caspase 3 staining intensity  in Patient 6.  
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Note: Capture of the Figure in the next page.  
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Tissue was cultured with the improved protocol : tumour slices were cultured supported on plate inserts in six well plates a nd rotated on a tissue slice 
incubation unit creating an air -liquid interface to allow a maximal oxygenation and at the same time  preventing the drying of the tissue. Growth media 
was changed every day with or without treatments to maximise the availability of nutrients to the slice and the effects of drugs. Fixation in formalin  
occurred at the different time points indicated and slices  subsequently stained for evidence of apoptosis with Ki67 for proliferation and cleaved 
caspase 3 (CC3) using immunohistochemistry (brown staining). A decreased in tissue viability was observed after 7 days in culture as confirmed by a 
negative Ki67 and the presence of cleaved caspase 3 staining. Images captured at 20x magnification .
Figure 4.3-14: Precision cut tissue slices from a HGS and clear cells, II Ic case (Patient 6) at different time points in culture as sessed for proliferation 
and apoptosis rate.  
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A final comparison was performed between the two cultivation methods, old and new, to identify 
the best cultivation method. The summary bar chart of the staining intensity for both proliferation 
(Ki67) and apoptosis (CC3) indicated the use of the “new method” up to three days to recapitulate 
a tissue slice viability similar to the original biopsy with viability data slightly better than the “old 
method”. However tissue variabily between each individual case was observed as well. The viability 
in the tissue slices was compromised after 3 days both in Patient 1 and 2, but in Patient 2 only a 
less than 50% reduction in proliferation was observed against the 75% of Patient 1. Both cases were 
cultivated with the “old method”. With the “new method”, the staining intensity of Ki67  at Day 3 
was similar to the original biopsy for both Patient 5 and 6, suggesting an overall better performance 
of the “new method” (Figure 4.3-15). 
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Figure 4.3-15: Summary of quantification analysis of staining intensity of Ki67 comparing 
old versus new cultivation method.  
Patient 1 and 2 were cultivated with the old method, while Patient 5 and 6 with the 
improved method.  
 
 
Similarly the increase of apoptosis intensity was limited at Day 3 to 15, 3 and only 2 fold change as 
compared to the original biopsy respectively in Patient 4, 5 and 6. Those cases have been cultivated 
with the new improved method. However, an intensification in the apoptotic rate could be seen up 
to 30 fold for the case cultivated with the old method (Patient 1). Patient 2 instead demonstrated 
to be strongly adaptable even in the presence of the old cultivation method, as the apoptosis rate 
after five days was still comparable to the original biopsy. This would indicate variability in the 
adaptation to the cultivation conditions (Figure 4.3-16). 
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Figure 4.3-16: Summary of quantification analysis of staining intensity of CC3 comparing 
old versus new cultivation method.  
Patient 2 and 3 were cultivated with the old method, while Patient 4, 5 and 6 with the 
improved method.  
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4.3.2.  Assessment of the effects of cisplatin on tumour cells using the 
organotypic model 
After having optimised the viability of the precision cut tumour slices and established the use of 
the new cultivation method for a viability until three days capable of recapitulating proliferation 
and apoptotic rate similar to the original biopsy, the platform was used to test cytotoxics. 
First the precision cut tissue slices were exposed to the effects of cisplatin, the conventional 
chemotherapeutic compound for treatment of EOC, and used as a positive control for the tissue 
slices exposed to HTL001 (results in the next paragraph). Cisplatin creates cross-links with DNA that 
cannot be solved by DNA double strand break repair systems and thus it triggers a programmed 
cell death. ATM, which is the main response protein involved  in the DNA double strand breaks 
repair system, phosphorylates γH2A.X at Ser139, the sensor of damage, hence γH2A.X is a good 
biomarker to assess the efficacy of DNA stress response caused by an alkylating agent. As the 
literature reported that the IC50 of ovarian cancer cell lines to cisplatin exposure fluctuated 
between 3μM and 50μM or above [131-133], we tested cisplatin at different concentrations. An 
initial concentration of 3.3μM and 6.6μM was used as guided by the results published by Gerlach 
et al. [125].  
A representative dose-response was achieved in the precision cut tumour slice from a case of 
endometrioid carcinoma in Patient 3 (Figure 4.3-17). Increasing cisplatin concentrations 
correlated with increased intensity of nuclear staining of γH2A.X, confirming the induced damage 
in cancer cells. However, visible apoptotic or necrotic areas could not be observed judging purely 
from the intact tissue architecture and the undamaged nuclei of the slices, suggesting that an 
optimisation of platinum concentration was still necessary. 
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The original biopsy was added as a control. A correlation intesity of staining of the DNA 
double strands breaks marker and cisplating concentration can be appreciated. Images 
captured at x20 magnification. Error bars refer to the SD calculated on the normalisation 
of the three individual measurements.  
 
 
The data analysis in Figure 4.3-18  is a quantification of the intensity of the nuclear staining γH2A.X 
at different time points. The left graph indicates the total staining intensity expressed a fold 
increase in staining intensity as compared to the original biopsy, while the graph on the right 
displays the percentage of positive cells grouped by intensity. As expected the tissue slices treated 
with the highest dose of cisplatin demonstrated the highest score of staining (18 fold change) and 
strong intensity (30%). 
Figure 4.3-17: Precision cut tissue slices derived from an endometrioid tumour (Patient 3) 
stained for γH2A.X (brown staining) after 48 hours exposure to platinum  therapy.  
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Figure 4.3-18: Quantification of staining intensity of γH2A.X in Patient 3.  
The data on the left represent the average percentage of positive staining of three 
different areas in the tissue slice and expressed as  a fold increase in staining intensity as  
compared to the original biopsy. The bar chart on the right graph displays the percentage 
of positive cells  grouped by intensity weak, medium or strong. Patient 3 tissue slic es were 
cultivated with the “old” method. Area analysed 757436.52μm2 (0.7mm2) x3 with 
ImageScope Positive Pixel Count Algorithm. Error bars refer to the SD calculated on the 
normalisation of the three individual measurements.  
 
 
At the same concentration, cisplatin was effective on precision cut tissue slices derived from a case 
of HGS and clear cells, stage IIIc (Patient 6) after 48 hours treatment (Figure 4.3-19). The 
widespread presence of cleaved caspase 3 in the treated slice and the staining intensity of γH2A.X 
confirmed the successful cytotoxic activity of the drug. Tissue quality drastically decreased due to 
the action of the cytotoxic compound and a stress response was triggered in the resistant cells 
(indicated by red stars), while the core of the tumour slice already displayed apoptotic cells as 
confirmed by the CC3 staining.  
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Slices were cultured for 48 hours using the supportive cell culture inserts during culturing  and exposed to cisplatin. An untreated slice was included 
as a control as well the original biopsy. High intensity of cleaved caspase 3  staining was an indication of the cytotoxic effect of cisplatin together 
with the marked stress response seen in the cells highlighted with a red star. Images on the left were taken at 10X magnifica tion to have an overview 
of localisation of staining, on the r ight a 20X magnification was chosen to appreciate tissue quality after treatment.
Figure 4.3-19: Precision cut tumour slices from a case of HGS and clear cells, stage IIIc (Patient 6) stained for cleaved caspase 3 (CC3) and γH2A.X.  
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The quantification analysis from the same case confirmed the increase staining intensity of 
apoptosis in the cisplatin treated slices quantified to a double rate as compared to the the saline 
control at 48 hours. The results however indicate a stronger intensity of γH2A.X in the vehicle 
control (Figure 4.3-20). 
 
 
The data on the top graphs represent the percentage of positive staining of three different 
areas in the tissue slice and expressed as a fold increase in staining intensity as compared 
to the original biopsy. The bar charts on the bottom graphs displays the percentage of 
positive cells grouped by intensity weak, medium or strong.  Patient 6 tissue slices were 
cultivated with the “new” method. Area analysed 757436.52μm 2 (0.7mm2) x3 with 
ImageScope Positive Pixel Count Algorithm.  Error bars refer to the SD calculated on the 
normalisation of the three individual measurements.  
 
 
Not all the ovarian cancer tissue processed using the Vibratome displayed clear signs of tissue 
damage after treatment (data not shown), therefore the concentration of cisplatin was then 
significantly increased. Hypothesizing that a higher concentration was required by a 3D model, the 
amount of platinum therapy was increased to 25μM or doubled up to 50μM. There was a clear 
Figure 4.3-20 : Quantification of CC3 and γH2A.X staining intensity in Patient 6.  
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evidence that this concentration was effective and this was used as a proof of principle that the 
organotypic culture was suitable for the study of response to cytotoxic drug treatments.  
A representative example is reported in Figure 4.3-22  (next page) where precision cut tumour 
slices from a high grade serous case, HGS IVb (Patient 7) were exposed to the anti-cancer agent 
and stained for DNA damage and apoptosis. 
 
Below is reported the relative quantification analysis of the case demonstrating higher staining 
intensity for both apoptotic and DNA damage markers (Figure 4.3-21). The unexpected higher fold 
change of staining intensity of CC3 in the tissue slices exposed to 25μM cisplatin as compared to 
the 50μM cisplatin group could be explained by the presence of an abundant area of tumour tissue 
highly damaged within the slice as it could be seen in the relative image in Figure 4.3-22  (second 
from the top left). 
 
 
The data on the top graphs represent the percentage of positive staining of three different 
areas in the tissue slice and expressed as a fold increase in staining intensity as  compared 
to the original biopsy. The bar charts on the bottom graphs displays the percentage of 
positive cells grouped by intensity weak, medium or strong.  Patient 7 tissue slices were 
cultivated with the “new”  method. Area analysed 757436.52μm2 (0.7mm2) x3 with 
ImageScope Positive Pixel Count Algorithm.  Error bars refer to the SD calculated on the 
normalisation of the three individual measurement s.
Figure 4.3-21: Quantification of cleaved caspase 3 and γH2A.X staining intensity in Patient 7.  
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Slices were cultured for 72 hours using the supportive cell culture inserts and exposed to cisplatin. An untreated slice maintained for 3 days in 
the same conditions was included as a control.  High intensity of CC3 staining was an indication of the cytotoxic effect of ci splatin as well as the 
marked stress response induced. Images were taken at 10X magnification to h ave an overview of the localisation and extent of staining.
Figure 4.3-22: Precision cut tumour slices from a HGS, IVb case (Patient 7) stained for cleaved caspase 3 and γH2A.X.  
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It is important to underline that to prove the efficacy of the drug with a good level of certainty the 
four different IHC staining (H&E, CC3, Ki67 and γH2A.X) were evaluated each time as a combined 
panel of stains in the different cases. Figure 4.3-23 shows representative images from a high 
grade serous case, HGS IIIc (Patient 8); the necrotic/apoptotic areas indicated by the red stars 
visible by H&E stain after treatment for three days with 50μM cisplatin, as well as the low level of 
proliferation (Ki67) and the high level of apoptosis (cleaved caspase 3) and DNA damage (γH2A.X) 
showed the successful activity of the drug. Once again the untreated control for 72 hours in culture 
exhibited a good morphology of the tissue (H&E), a decent proliferation rate (Ki67) and low 
apoptosis (CC3) confirming that the effects seen in the treated slice are real perturbations induced 
by the cytotoxic compound and not due to the culturing conditions. 
 
 
The data analysis in Figure 4.3-24  (next page) quantifies the overall good viability of the vehicle 
control after 72 hours in culture with proliferation, apoptotic and DNA damage rate comparable to 
the original biopsy. The cisplatin treated slices showed an overall decline of proliferation of 1/3 as 
compared to the vehicle control Day 3 (0.75 vs 0.25 fold change), as well as a four fold change rise 
was observed in the cisplatin treated slices (0.5 cntl VS 2 50μM cisplatin). 
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Slices were cultured for 72 hours using the supportive cell culture inserts  and exposed to 
50μM cisplatin. An untreated slice maintained 3 days in the same conditions  was included 
as a control, as well as the original biopsy. The combination of the four different staining 
was an indication of the consistent responses observed. Images were taken at 10X 
magnification to have an overview of intensity and localisation of p ositive cells.  
Figure 4.3-23: Precision cut tumour slices from Patient 8 (HGS, IIIc ) stained for H&E, Ki67, 
CC3 and γH2A.X.  
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Figure 4.3-24: Quantification of Ki67, cle aved caspase 3 and γH2A.X staining intensity  in 
Patient 8.  
The data on the left  graphs represent the percentage of positive staining of three different 
areas in the tissue slice and expressed as a fold increase in staining intensity as  compared 
to the original biopsy. The bar charts on the r ight  graphs display the percentage of positive 
cells grouped by intensity weak, medium or strong. Patient 8 tissue slices were cultivated 
with the “new” method. Area analysed 757436.52μm2 (0.7mm2) x3 with ImageScope 
Positive Pixel Count Algorithm.  Error bars refer to the SD calculated on the normalisation 
of the three individual measurement s.  
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4.3.3. Assessment of the effects of HTL001 on tumour cells using the 
organotypic model 
Finally, the organotypic model was also used to test the effect of the small penetrating peptide 
HTL001 on ovarian cancer tissue. For each representative example reported in the following 
paragraph, precision cut tumour slices treated with cisplatin and untreated slices cultured in 
normal growth media were included as controls and manipulated as done for the tissue slices 
exposed to HTL001. To obtain reliable signs of cytotoxicity induced by the drugs applied to the 
platform and not due to suboptimal culturing conditions, slices were generally treated no longer 
than 72 hours and growth media plus treatment was changed every day. 
As the small penetrating peptide effects have not been evaluated on such a 3D system using ovarian 
cancer patient tissue, a range of working concentrations for the drug needed to be screened. The 
IC50 calculated in Chapter 3 for monolayers of commercial or primary ovarian cancer cell lines were 
around 15 to 90μM for up to 104 cells seeded per each well. We started by at least doubling the 
average HTL001 concentration for the precision cut tumour slices hypothesising that a higher 
number of cells packed in a thick connective tissue would require an increased concentration of 
drug to observe signs of cytotoxicity. In preliminary experiments, HTL001 was used in a range of 
100 - 800μM. However, at high concentrations, the peptide was less soluble in growth media, 
therefore a screening of the maximal concentration of peptide allowed without loss of solubility in 
growth media was run. At the same time growth media parameters were changed in order to 
identify a better growth solution: RPMI or DMEM supplemented with 2, 5 or 10% FBS and a reduced 
serum (OPTI-MEM) were tested for this purpose. None of the media appeared to be superior from 
the other and a maximum peptide concentration in media without loss of solubility was found to 
be 400μM. The standard DMEM at 10% FBS was used for further experiments. 
 
 
A representative example shown in Figure  4.3-25 demonstrated how either the positive control 
cisplatin or the HTL001 concentration were ineffective at inducing cell death in a case of high grade 
serous cancer, HGS IIIc (Patient 5); both the proliferation and apoptotic index (Ki67 and CC3 
respectively) were expressed at a rate comparable to the untreated slice left in culture for 3 days. 
Cell nucleus and tissue architecture was perfectly preserved too. 
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Slices were cultured for 72 hours using the supportive cell culture inserts and exposed to 400μM HTL001. An untreated slice maintained 3 days in 
the same conditions was included as a control (Cntl), as well as the cisplatin treated tumour slice exposed to a concentratio n of 6.6μM added as 
positive control. The intact tumour nuclei and the tissue integrity was an indication of the failure to induce cell death for  both drugs, as well as the 
proliferation and apoptotic index comparable to the untreated slice. Red arrows hig hlight mitotic cells. Images were taken at 20X magnification .
Figure 4.3-25: Precision cut tumour slices from a case of high grade serous carcinoma, HGS IIIc (Patient 5) were stained for Ki67 and CC3 .  
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The quantification analysis summarises what reported in the IHC images. There was no substantial 
difference in the staining intensity of both proliferation and apoptotic marker in the tissue slices 
treated with either cisplatin or HTL001 as compared to the vehicle control (Figure 4.3-26). Once 
again even high doses of HTL001 failed to show any cytotoxicity. 
 
 
The data on the top graphs represent the perc entage of positive staining of three different 
areas in the tissue slice and expressed as a fold increase in staining intensity as  compared 
to the original biopsy. The bar charts on the bottom graphs display the percentage of 
positive cells grouped by intensity weak, medium or strong.  Patient 5 tissue slices were 
cultivated with the “new” method. Area analysed 757436.52μm2 (0.7mm2) x3 with 
ImageScope Positive Pixel Count Algorithm.  Error bars refer to the SD calculated on the 
normalisation of the three individual measurement.  
 
 
Another representative example is reported in Figure 4.3-27. Tissue slices from a high grade 
serous and clear cell, IIIC (Patient 6) ovarian cancer proved to be “resistant” to a high concentration 
of HTL001 (400μM) as both proliferation and apoptotic markers again resembled the rate of the 
untreated counterpart. 
Figure  4.3-26 :  Quantification of Ki67 and cleaved casp ase 3 staining intensity  in Patient 5.  
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Slices were cultured for 48 hours using the supportive cell culture inserts  and exposed to 
400μM HTL001. An untreated slice was included as a control. The similar distributi on of 
proliferation marker (Ki67) and apoptotic marker (CC3)  (brown staining)  in the treated 
and untreated slices indicated a lack of cytotoxicity induced by the peptide. Images were 
taken at 20X magnification.  
 
 
The quantification analysis for the case indicates contradictive results. While cisplatin treated slices 
showed no decrease in Ki67 staining intensity, the apoptosis marker suggested instead an 
accumulation of CC3 staining intensity. However, there was no substantial difference in the level 
of proliferation or apoptosis between the vehicle and the HTL001 treated slices, suggesting the 
inefficacy of the peptide even at high doses (Figure 4.3-28). 
Figure 4.3-27: Precision cut tumour slices from a case of high grade serous and clear cell, 
IIIc (Patient 6) stained for Ki67 and cleaved caspase 3.  
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Figure 4.3-28: Quantification of Ki67 and CC3 staining intensity in Patient 6. 
The data on the top graphs represent the percentage of positive staining of three different 
areas in the tissue slice and expressed as a fold increase in staining intensity as  compared 
to the original biopsy. The bar charts on the bottom graphs displays the percentage of 
positive cells grouped by intensity weak, medium or strong. Patient 6 tissue slices were 
cultivated with the “new” method. Area analysed 757436.52μm2 (0.7mm2) x3 with 
ImageScope Positive Pixel Count Algorithm.  Error bars refer to the SD calculated on the 
normalisation of the three individual measurements.  
 
 
As the lack of any reduction in cell viability by HTL001 was thought to be due to the limited ability 
of HTL001 to penetrate the thick ovarian connective tissue subsequent experiments led us to 
explore methods to enhance peptide delivery to the target tissue. For this purpose ovarian cancer 
precision cut tumour slices were partly digested with the enzymes contained in the Tumour 
Dissociation Kit (Miltenyi Biotec). The protected formulation more likely contains enzymes able to 
digest connective tissue (collagenases and proteinase K). Enzymes were diluted according to the 
manufacturer’s instruction and added to tumour slices which were rotated on a MACSmix Tube 
Rotator at 37°C for only half an hour to avoid excessive tissue disaggregation (for further details 
refer to Section 2.3.1). Despite the pre-treatment with connective tissue dissociation agents, albeit 
limited to certain areas, HTL001 failed to show any anti-neoplastic potential on the tissue slices as 
confirmed by H&E, Ki67 and cleaved caspase 3 staining performed on the treated tissue slices with 
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200μM HTL001 compared to untreated slices (Figure 4.3-29). Again, the distribution of positive 
staining to apoptosis and proliferation markers were comparable in the two tissue slices. H&E 
staining demonstrated the preserved tissue morphology and architecture, with intact tumour cells 
in both cases. 
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Slices were cultured for 72 hours using the supportive cell culture inserts  and exposed to 
200μM HTL001. An untreated slice maintained 3 days in the same conditions was included 
as a control. Slices were then fixed in formalin and stained for H&E, Ki67 and CC3 . The 
analogous rate of apoptosis (CC3) and proliferation index (Ki67) as well the preserved 
tissue architecture (H&E) in treated and u ntreated slices were an indication of a limited 
efficacy of HTL001. Images were taken at 20X magnification.  
 
Figure 4.3-29: Precision cut tumour slices from a case of high grade serous carcinoma HGS, 
IIIc (Patient 8) pre-digested with enzymes A, H and R from the Tumour Dissociation Kit.  
(continu  next page  
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The quantification analysis for the case below is just another way to look at the results. Ki67 and 
CC3 staining rate were comparable to the original biopsy. The combination of the two biomarkers 
is indication a lack of response to the peptide in the tumour slices even in the presence of a partial 
pre- digestion with tissue dissociation enzymes (Figure 4.3-30). 
 
 
 
The data on the top graphs represent the percentage of positive staining of three different 
areas in the tissue slice and expressed as a fold increase in staining intensity as  compared 
to the original biopsy. The bar charts on the bottom graphs disp lays the percentage of 
positive cells grouped by intensity weak, medium or strong. Patient 8 tissue slices were 
cultivated with the “new” method. Area analysed 757436.52μm2 (0.7mm2) x3 with 
ImageScope Positive Pixel Count Algorithm.  Error bars refer to the SD calculated on the 
normalisation of the three individual measurements.  
 
 
In order to understand the limitation of HTL001 in inducing apoptosis on the precision cut ovarian 
cancer slices, HTL001 was tagged with a fluorescent dye (5/6- carboxyfluorescein) to track its tissue 
penetration within the slices (5/6 FAM – HTL001). Preliminary experiments were performed in PEA1 
and PEA2 cell lines to demonstrate the fluorescent dye was not affecting HTL001 ability to enter 
the double layer of the cell membrane and to navigate to the nucleus to fulfil its function of 
Figure 4.3-30: Quantification of Ki67 and cleaved caspase 3 staining intensity in Patient 8.  
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HOX/PBX inhibition. In a representative example, 5/6 FAM – HTL001 successfully entered the 
nucleus after two hours treatment in PEA1 cell line as shown in Figure 4.3-31. 
 
 
PEA1 was seeded in 8 wells cell  culture chamber and left in the incubator O.N.  Following 
day 60μM  of fluorescent tagged 5/6 FAM –  HTL001 (green) was added to the supernatant 
for two hours.  After incubation time, cells were washed with TBS 0.1% Tween 20, fixed 
with 4% paraformaldehyde and counterstained with TOPRO3 (blue). Images were  acquired 
with a Nikon A1 confocal microscope at 40X magnification. The green dots confined within 
the cell nuclei were an indication of the successful cell entry of the tagged peptide to the 
nuclear membrane to probably fulfil its HOX/PBX inhibition.  
 
 
Z-stack analysis at confocal microscope on precision cut tissue slices of a case of high grade serous 
carcinoma, suggested that HTL001 failed to enter the nucleus of any cells composing the tissue and 
the peptide appeared confined to the stroma. No signs of infiltration within the slice were visible 
and HTL001 seemed to remain on the surface of the slice (Figure 4.3-32- top). The untreated 
control slice was included to detect any tissue background auto-fluorescence (Figure 4.3-32– 
bottom). 
 
 
Figure 4.3-31: PEA1 cell l ine treated with 5/6 FAM –  HTL001 for two hours at 60μM.  
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The precision cut tissue slices was cultured for three days on a filter support and incubated 
at 37C° on the rotating incubation unit. 5/6 FAM –  HTL001 was added to the supernatant. 
After the incubation time, the tissue was washed with TBS 0.1% Tween 20 and fixed with 
4% paraformaldehyde and counterstained with TOPRO3 (blue). Images were acquired with 
a Nikon A1 confocal microscope at 20X magnification using z -stack analysis  
 
 
Moreover, images acquired with confocal microscopy revealed a very high signal, due probably to 
tissue auto-fluorescence and in particular to the high concentration of peptide used. The high 
concentration of 5/6 FAM – HTL001 was chosen to use the same concentration of the non-tagged 
peptide and to induce visible signs of cytotoxicity. However, tagged HTL001 failed to demonstrate 
any visible marks of tissue apoptosis (data not shown) and the high fluorescence signal made 
impossible to draw any certain conclusions despite the working concentration was lower to 60μM 
(Figure 4.3-33). 
 
Figure 4.3-32: z-stack confocal analysis of a precision cut tissue slices obtained from a 
HGS, stage IIIc case (Patient 9) and treated with  200μM of 5/6 FAM –  HTL001. 
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Figure 4.3-33: Confocal analysis of a precision cut tissue slices obtained from a HGS, stage 
IVa case and treated with 60μM of 5/6 FAM –  HTL001.  
The precision cut tissue slices was cultured for one or three days on a filter support and 
incubated at 37C° on the rotating incubation unit. 5/6 FAM –  HTL001 was added to the 
supernatant. After the incubation time,  the tissue was washed with TBS 0.1% Tween 20 
and fixed with 4% paraformaldehyde and counterstained with TOPRO3 (blue). Images were 
acquired with a Nikon A1 confocal microscope at 20X magnification.  
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4.4. Discussion 
Cancer is a multifactorial disease composed of a great heterogeneity of cells and characterised by 
continuously emerging various “hallmarks of cancer”. In addition to the traditional six hallmarks 
(sustaining proliferative signalling, evading growth suppressors, activating evasion and metastasis, 
enabling replicative immortality, inducing angiogenesis and resisting cell death) new characteristics 
have been added (avoiding immune destruction, tumour-promoting inflammation, genomic 
instability and mutation and deregulating cellular energetics) [117]. Such intricate pathology 
requires a complex experimental model to recapitulate its features. It was briefly illustrated in the 
introduction of this chapter the advantages and disadvantages of the existing 2D models to study 
ovarian carcinoma, as cell lines and ascites, or the limitations of 3D models, such as spheroids with 
an artificial and reconstructed morphology and cell composition. So far, xenografts in animal 
models are considered the best candidates as a platform to study OC, but ethical issues and high 
costs of manipulation remain an obstacle, as well as the restriction that the interactions between 
immune system and cancer cells cannot be monitored and studied in immune-compromised mice. 
The organotypic ex vivo culture model represents an attempt to move towards a personalised 
medicine, it avoids extra costs and preventable side effects as drugs can be tested directly on 
patients tissue routinely removed after surgery. The precision cut tumour slices conserve most of 
the variety of cells that can contribute to the capabilities described in the hallmarks of cancer, thus 
providing a complete platform to test anti-neoplastic agents. Given the described benefits of the 
organotypic model, our choice to further test HTL001 in a setting closer to a clinical scenario fell on 
this experimental system. Furthermore, only limited attempts reported from the literature had 
adopted the precision cut slices model as platform for drug testing in the context of ovarian 
carcinoma. 
 
Preliminary work set out to optimise the viability of the organotypic model. It was necessary to 
construct an efficient workflow capable of carrying minimal alterations to the quality of the original 
specimen for subsequent drug testing. Several parameters were tested to avoid the occurrence of 
suboptimal culturing conditions, including 1) method of culture, 2) experimental end-point, 3) type 
of growth media and 4) thickness of the slices. The initial method (“old” method) of precision cut 
tissue slices left floating in growth media and placed on a shaker in the CO2 incubator was later 
abandoned in favour of the improved standardisation of the workflow described by Davies et al. 
[98] (“new “method). Slices cultured with the “old” method had in fact a poor viability, confirmed 
by staining for the proliferation marker Ki67 for up to three days and quantifying for staining 
positivity (Figure 4.3-2 and Figure 4.3-3) and a loss of tissue architecture was already 
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noticeable (Figure 4.3-4 and Figure 4.3-5). However, data indicated a variable ability to adapt to 
the experimental model. Tissue slices from Patient 3 demonstrated a conservation of a superior 
morphology and maintenance of cell activity for a longer period despite the “old cultivation 
method” adopted (Figure 4.3-6, Figure 4.3-7 and Figure 4.3-8). The better viability might be 
attributed to the fact that the tumour tissue were the slices originated from was from an 
endometrioid case, low stage that did not received any previous chemotherapy, while most of the 
other cases were HGS carcinoma that received extensive chemotherapy pre-surgery that could 
have somehow decreased the initial viability. A similar trend was also observed in the work by 
Davies et al. [98] where experiments with two primary human ER positive (ER+) breast tumours 
showed that the importance of the cultivation method chosen was variable. 
The “new method” adopted was based on the finding of this systematic work across four 
independent laboratories [98], where different culturing conditions were compared and the 
expression of a panel of different genes involved in stress response to assess the molecular changes 
induced by the experimental model investigated. The same conclusion that the essential elements 
needed to ensure viability were the use of cell culture filter insert supports and atmospheric 
oxygen. This was evaluated by the analysis of tissue viability after fixation and combining IHC 
staining for markers of proliferation (Ki67), apoptosis (cleaved caspase 3) and hypoxia (HIFα). The 
authors described that the combination of these two components (cell culture inserts, Millipore 
and a rotating incubator, Alabama Technologies) created an “intermittent immersion” that had the 
potential to permit oxygenation on the surface of the slice, as well as to provide a physical support 
to preserve slices integrity and allow for nutrients/oxygen exchanges between upper and lower 
chambers in the well. 
 
Ovarian carcinoma precision cut slices cultivated with the “new” method proved to maintain a good 
tissue architecture and viability comparable to the original biopsy for up to three days and an 
overall decent viability for up to one week (Figure 4.3-10, Figure 4.3-12 and Figure 4.3-14). A 
comparison of the quantification data for “old” versus “new” method for the staining levels of Ki67 
and CC3 demonstrated a better quality of tissue slices cultivated with the improved method 
(Figure 4.3-15 and Figure 4.3-16). As a general guideline for further experiments involving 
novel drug testing, slices were cultured no more than three days to avoid losing the characteristics 
of the original tissue, to minimise the stress response induced by the culturing system and due to 
the fast working cytotoxic activity of HTL001 (2 hours on cells monolayers) (Figure 4.3-12).  The 
loss of viability of the stroma, rather than tumour cells after 5 days in culture was also reported by 
Roife et al. [134] as well (Figure 4.3-10, Figure 4.3-12 and Figure 4.3-14). To our knowledge, 
the ability of the operator in preparing the slices were helped to minimize perturbations, as well as 
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the timely transport of the tissue to the laboratory for subsequent processing as ensured the 
optimal quality of the original biopsies (Figure 4.3-4- Figure 4.3-14). The cutting itself did not 
have a negative impact on the tissue slices as “t0” control slices demonstrated a viability rate and 
tissue morphology identical to the original specimen (Figure 4.3-4, Figure 4.3-7 and Figure 
4.3-14).  
Other experiments with precision cut ovarian slices aimed at evaluating the effect of different 
growth media on tissue quality. For this purpose DMEM was used and compared to OPTI-MEM, a 
serum-reduced media without phenol red, chosen mainly to overcome a problem of solubility of 
HTL00-1 (discussed in the next section). Differences in viability according to the growth media used 
were not detectable (data not shown) and even in the literature, there was no standardisation of 
which media and supplements have to be used or a clear evidence of supremacy of one above the 
others. A rich media (glucose, aminoacids and vitamins) as DMEM is considered to be ideal for our 
purpose, supplemented with antibiotics to prevent infections. Thickness of the slices was another 
parameter that needed to be optimised. We decided to cut at 300μm to stay in a range indicated 
by one the most recent publications available at the beginning of the project: breast precision cut 
tissue slices were cut around 250 - 300μm [124]. It was pointed out that some samples could not 
be cut due to their texture (too soft), hence our major concern was not to manipulate too thin and 
fragile slices, but at the same time not to have too thick ones where a proper oxygenation, diffusion 
of nutrient from media and eventual treatments was probably hard to get. It was found out (2016) 
that it was not possible to cut below 175μm and more importantly that thickness of the slices was 
not affecting the oxygen distribution within tissue as confirmed by HIFα staining for hypoxia 
(supplementary data from Davies et al. [98]). However, experiments in our lab were not done to 
confirm the above and 300μm thickness was kept across all the experiments. In keeping with 
published data by Carranza et al. [124], a cutting at the Vibratome was impossible when 
manipulating too soft (fatty) or too hard (fibrous) tissue in our experience too. 
 
The understanding of the ovarian cancer precision cut slice behaviour in culture led us to then use 
the platform to test the effect of cisplatin, a broadly used chemotherapeutic for the management 
of ovarian cancer, on the tissue slices. The ability of cisplatin to induce apoptosis or necrosis in 
tissue slices was demonstrated even at low doses (Figure 4.3-19) as confirmed by the increased 
presence of cleaved caspase 3 staining (Figure 4.3-20). In other cases, the same low dosage 
(6.6μM) did not demonstrate clear signs of tissue damage and morphology alterations (Figure 
4.3-17 and Figure 4.3-25, Figure 4.3-18 and Figure 4.3-26). However, the staining with a 
sensor for the activation of the DNA repair system after double strand breaks (γH2A.X) suggested 
the activation of stress response in the tissue slices in a dose-dependent manner (Figure 4.3-18). 
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Ovarian carcinoma precision cut slices were then used to test the effects of an inhibitory and 
cytotoxic small penetrating peptide as HTL001, in this organotypic model system. In preliminary 
experiments tumour slices were exposed to at least a double amount of the IC50 calculated in the 
panel of immortalised ovarian cancer cell lines and primary cultures used in Chapter 3. It was clear 
that a higher concentration of agent would be required to appreciate signs of tissue damage due 
to the necessity to penetrate the three dimensional setting of the tissue where we were operating; 
a densely packed number of cells was present, certainly greater than the ten thousand cells seeded 
per well in a MTS assay (Chapter 3). Following a similar approach that Carranza and colleagues took 
where they doubled the IC50 of the natural compounds calculated via survival assays on cell 
monolayers when treating breast precision cut tissue slices [124], we also decided to at least double 
the dose of HTL001 on the ovarian cancer slices. The initial 200 – 800μM range of peptide 
concentration was then lowered to a range of 100 - 400μM after seeing loss of solubility of HTL001 
in media supplemented with serum above 400μM. Despite the high amount of HTL001 applied onto 
the slices, the novel compound did not show any clear signs of cytotoxicity on ovarian cancer tissue: 
treated slices were similar to untreated slices in terms of viability and tissue architecture (Figure 
4.3-25, Figure 4.3-27 and Figure 4.3-29). CXR9 was included in the experiments, but not 
presented here as also the control peptide failed to demonstrate signs of tissue damage as 
expected. 
The dosage of HTL001 was adjusted mainly to avoid the degradation of HXR9 observed in serum 
after 18 hours (Morgan et al. [67], supplementary figure) and to overcome the solubility issues 
described above. The peptide was then applied to the organotypic model with fresh media every 
24 hours, but no improvement of programmed cell death was achieved. HTL001 relies on an 
extremely positively charged poly-arginine repetition at the N-term (9R) interacting with the 
negatively charged double lipids layer for cell entry and a selective over-expression of HOX genes 
in cancer cells for its targeted cytotoxic action. The lack of HTL001 activity on ovarian cancer slices 
was most likely due to the poor tissue penetration and the indiscriminate cell entry in all cells 
(tumour and non-tumour). Perhaps the stroma with a thick connective tissue was acting as a “trap” 
to stop the peptide function on interspersed tumour cells. However, the attempt to “loosen” the 
stroma by pre-digesting tumour slices with tissue dissociation enzymes (formulation by Miltenyi 
Biotech), once again resulted in no evident signs of anti-tumour effect (Figure 4.3-29, Figure 
4.3-30).  
In an attempt to understand this negative effect, a carboxyfluorescein dye was tagged to the C-
term of HTL001 (5/6 fam-GG-HTL001, AltaBioscience) to monitor the peptide dispersal within the 
precision cut tumour slices and to obtain a better understating of the diffusion of HTL001 through 
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the entire deep of the slice. The fluorescent-tagged peptide successfully entered cytoplasm and 
nucleus in monolayers of ovarian cancer cells line PEA1 and PEA2 at 60μM (Figure 4.3-31), however 
the bright dye was giving an enormous auto-fluorescence background impossible to analyse by z-
stack confocal analysis within precision cut tissue slices (Figure 4.3-32 and Figure 4.3-33). 
 
The tumour slices were assessed by a histopathologist to ensure that they were representative and 
contained malignant cells. Certainly, a more systematic work, but time consuming for a single 
operator, would have been the immune-staining of the slices to confirm the presence of ovarian 
epithelial cells using for examples cytokeratins 7, 8 or 18 and 19 and to assess the “health status” 
of the slices quantifying level of hypoxia (HIFα) or integrity (E-cadherin). Immuno-staining was the 
preferred method to verify the viability of the tumour slices over time and later the activity of 
platinum therapy and HTL001, because the primary aim was to visualise the eventual changes in 
histology or tissue integrity within the precision cut slices when optimising viability, and secondly 
to localise apoptotic/necrotic areas when treating with anti-neoplastic agents. Besides, attention 
is required when utilising conventional assays such as MTS or ATP measurement or any colorimetric 
based assay for assessing the metabolic activity in an intact slice: those assays implicate an 
homogenous penetration of a substrate in the tissue that perhaps might be not totally achieved in 
a densely populated system as a 3D model, especially in the core of the slice and therefore giving 
variable results.  
A systematic scoring of the positive staining was also performed for all the cases presented here, 
accompanied by an evaluation of percentage of intensity for weak, medium and strong staining. 
Three identical areas within the slices were evaluated with the ImageScope Positive Pixel Count 
Algorithm, averaged and normalised against the staining positivity of the original biopsy. Only few 
articles included the testing of a new target therapy with a comprehensive scoring system and the 
present work represents a novelty for the assessment of efficacy of HTL001. The only limitation 
was the lack of identification of tumour area only, as the quantification did not take in account the 
exclusion of non-tumour areas that needed to be identified by additional tumour staining or by a 
comprehensive evaluation by a histopathologist. 
Other groups, (Gerlach et al.) [125], moving to an un-biased, standardised and less time consuming 
alternative methods for evaluating the efficacy of anti-neoplastic compounds on the tissue slices 
rather than using immunohistochemistry and staining measurement, support the view of the 
quantification of soluble markers such as cytokeratins (epithelial origin) and LDH or M30 
(apoptosis) in the supernatant of the slices or in the homogenates after lysis for a more practical 
readout. However, this approach does not allow for cell type localisation or studies to understand 
diffusion of a certain drug within the slice. 
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Cisplatin was used in “all or nothing” manner (positive control): high concentrations of 
chemotherapeutic were used to induce an evident cytotoxicity giving a clear and detectable 
staining (Figure 4.3-22 and Figure 4.3-23). Nevertheless, there is a necessity to screen for new 
potential biomarkers of responses for HTL001 in a similar way as done for cisplatin with γH2A.X 
(Figure 4.3-18) to perhaps be able to detect the efficacy of HTL001 even in the absence of evident 
apoptosis. Future work could include staining of the slices for the expression of c-FOS given its 
selective RNA and protein overexpression after exposure to HTL001 (see Section 1.7.3.2). On the 
other hand, c-FOS plays a pivotal and controversial role in several cellular functions, including cell 
proliferation, cell survival, stress response and apoptosis. Perhaps due to its multiple roles a unique 
response to HTL001 might be missing or be unclear, hence the necessity to explore for new markers 
of response and combination therapy in Chapter 6. 
 
 
In conclusion, we produced an optimised workflow for the preparation and use of precision cut 
ovarian carcinoma slices that opens a possibility to apply it to several downstream applications, 
with an emphasis on all individualised approach to cancer treatment and novel drug testing. 
General guidelines to future strategies and directions to improve the efficacy of drug penetration 
and in particular of HTL001 on the organotypic model will be considered in the conclusion in 
Chapter 7. Indeed, the organotypic model represents a first “valid barrier” to screen for potential 
successful targeted therapies, before moving to clinical trials and an alternative and valid tool for 
drug discovery to use in combination with animal models. 
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CHAPTER 5 
 
5. Strategies for HTL001 delivery via adeno-associated 
viruses: a pilot project 
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5.1. Introduction 
The targeted cytotoxic effects of HOX/PBX inhibition in cancer cells overexpressing HOX genes, 
including HGS-EOC immortalised and primary cells were illustrated in Chapter 3. The mode of 
cellular killing of HTL001 recapitulated previous finding for the prior version of the small 
penetrating peptide HXR9. A slightly superior anti-proliferative efficacy of HTL001 encouraged us 
to test the peptide in a scenario closer to a clinical context and operating in a tri-dimensional (3D) 
setting. The organotypic ex vivo model and the approach to move to a precise medicine drug 
discovery was described in Chapter 4. The lack of an evident induction of cytotoxic effects of 
HTL001 on precision cut slices derived from ovarian carcinoma was a suggestion of the limitations 
that a small penetrating peptide could have once acting on a tissue. The speculation was mainly 
the mechanism of cell entry of HTL001 relying on the poly-arginine tail indiscriminately entering 
normal and cancer cells, the half-life of the compounds observed in serum due probably by the 
presence of proteases and the high dosage necessary leading to solubility issues in the growth 
media used to cultivate the tumour slices. The results prompted to explore alternative approaches 
for HTL001 distribution within the tissue slices and explore HTL001 as gene therapy using a viral 
vector. Gene therapy is an attractive option of treatment and the advantages of using viral vectors 
such as adeno-associated viruses for HTL001 delivery will be briefly addressed in the next 
paragraphs. 
 
5.1.1. Gene therapy 
Gene therapy is a therapeutic technique to insert genetic information in a living organism, humans 
included, to cure a disease. Mainly used for the treatment of monogenic diseases as β-thalassemia 
or ADA-SCID, gene therapy aim at replacing a mutated or an absent gene with a long-term one, 
substituting the altered or missing original function. Gene therapy has been adopted for targeting 
cancer as well and several strategies are still currently being tested. Briefly summarising, 1) 
apoptotic genes as TRAIL or TNF were inserted into vectors to enhance cellular death or 2) suicidal 
genes under the form of pro-drugs. Ultimate examples are Ganciclovir to treat Cytomegalovirus 
(CMV) or 5-FU (Fluoracil) as a medication for several solid cancers. The internalisation of Ganciclovir 
lead to its phosphorylation by a thymidine kinase encoded by CMV. Its subsequent phosphorylation 
by cellular kinases converts Ganciclovir into a trisphosphate form that acts as competitive analogue 
of guanidine (dGTP), therefore blocking DNA polymerase and inhibiting viral replication [135]. 
Similarly, Hartkopf et al. inserted two enzymes of bacterial origin into an oncolytic measles virus to 
convert a non-toxic 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU). 5-FU operates as a 
thymidylate synthase (TS) inhibitor and interrupts cancer cells replication due to the absence of 
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thymidine available for DNA incorporation [126]. Other approaches of cancer gene therapy 3) insert 
key regulatory onco-suppressor genes mutated in cancer as p53 or PTEN to overcome their lost 
function or 4) introduce interfering RNA (RNAi) to block oncogenes activity (i.e. MYC or RAS) and 5) 
play with immune checkpoints for immune-modulation (i.e. PD1/PDL1 and CTLA4). 
Carriers to deliver genetic information in cells can be non-viral or viral vectors. Non-viral vectors 
methods inject naked DNA by electroporation or pack oligonucleotides into nanoparticles and lipo-
complex. Non-viral methods have a low immunogenicity, but the expression of the transgene is not 
long-term and the amplification of the transgene thanks to viral replication and infection in 
therapeutic cells is absent. Viral vectors that have been used for human gene therapy include 
herpex virus, vaccinia, retroviruses, adenoviruses and adeno-associated virus. The recombinant 
version of these viruses allow researchers to insert transgenes with a persistent expression and to 
exploit the natural ability of viruses to infect and propagate in host cells. However, main limitations 
of viral cargos are safety profiles due to insertional mutagenesis and the immune rejection of the 
host species [136]. 
On a side note, oncolytic virus would be more efficient as the virus lytic action would be combined 
with the cytotoxic action of the peptide once expressed, but the fast HTL001 cell death observed 
within two hours could inhibit viral replication and immunomodulation at target tissue. 
 
5.1.2. Adeno-associated viruses 
Adeno-associated virus were first isolated and characterised as contaminants of adenovirus 
preparations back in 1960. AAV belongs to the family of ssDNA Parvoviruses, to a subgroup called 
Dependovirus. The name indicates the necessity of adenovirus or herpes simplex virus to co-infect 
the host and start a lytic cycle. In the absence of a helper virus, wild type adeno-associated viruses 
enter a lysogenic cycle integrating their DNA information on human chromosome 19 and switching 
viral gene expression to a latent mode. The small 5 Kb AVV genome consists of two inverted 
terminal repeats (ITRs) flanking Rep and Cap that respectively translate for proteins involved in 
replication (Rep78, Rep68, Rep52, Rep40) and capsid formation (VP1, VP2, VP3). 
Recombinant AAVs (rAAV) for gene delivery replace the Rep and Cap region with a promoter as 
CMV, SV40 or EF1 for high mammalian expression levels of the gene of interest, the transgene and 
a poly A tail and a transcriptional terminator. Rep and Cap are supplied in trans to eliminate the 
possibility of chromosomal integration. In this way rAAV genome is transcribed and assembled into 
extra-chromosomal structures called episomes. A third plasmid containing helper genes isolated 
from adenoviruses E1A, E1B, E2A, E4ORF6 and VA RNA is co-transfected to provide genes for the 
lytic cycle and viral replication. 
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Figure 5.1-1: Schematic representation of wild type and recombinant AAV g enome. 
Wild type adeno-associated virus consist of two identical 145bp ITR that flank genes for 
production of replication and capsid formation (Rep/Cap). Wild type AAV lysogenic 
integration occurs at human chromosome 19. Recombinant AAV for gene delivery p urposes 
replaces in trans  Rep/Cap with the transgene and its promoter containing an enhancer 
(CMV, SV40 or EF1) for higher gene expression. A helper plasmid delivers proteins from 
adenovirus for viral lytic replication.  
 
 
Among the range of viral vectors available, adeno-associated virus (AAV) are the preferred carrier 
for gene therapy: prior exposure of humans to adeno associated viruses reduce their 
immunogenicity, while a DNA incorporation that occurs in the form of double strand episomal 
circular organisations promotes a long lasting expression in diving and non-dividing cells and a safe 
profile eliminating insertional mutagenesis. Limitations of the vector are its packaging capacity 
limited to short sequences (that can be cloned in tandem) up to 5Kb and a possible antibody 
neutralisation given by prior exposure to different AVV serotypes. AAV2 was the first adeno-
associated virus to be isolated and most of the genetic engineering has been developed around this 
serotype. The tropism observed for AAV (eleven so far) helps to construct mixed pseudo-serotypes 
to optimise transduction efficacy in a specific organ and to avoid immune neutralisation (reviewed 
from Luo et al. [137]). 
Some of the latest reports on the use of AAV as a strategy for the treatment of ovarian carcinoma 
come from the work of Xie and colleagues [138]. The study demonstrated that a single 
intraperitoneal dose of recombinant AVV10 expressing anti-VEGF Bevacinzumab provided a long 
term expression of the transgene even in metastatic districts of ovarian cancer, such as omentum 
and diaphragm up to 36 weeks. Angiogenesis was inhibited in Balb/c nude mice injected 
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intraperitoneally with A280 ovarian cancer cell line and tumour growth was reduced and overall 
survival extended in xenograft models of mice treated with a combination of chemotherapeutics 
and rAAV-Bevacinxumab. Mullerian inhibiting substance (MIS) have been previously found to 
retard the growth of a population of stem-like ovarian cancer cells. In another study, a single 
injection of MIS transiently expressed by an adeno-associated virus serotype 9 (rAAV9) vector 
successfully reduced tumour growth in a xenograft model with OVCAR5 cell lines and patients 
cancer cells isolated from ascites and cultivated under the form of spheroids or adhering cultures 
[139]. Besides, Nguyen et al. [140] demonstrated the significant reduction of residual tumour 
growth in mice treated with an AAV2 expressing Kringle 5. Kringle 5 exhibited potent anti-
angiogenesis properties in previous in vitro studies. Elevated quantities of transgene (Kringle 5) 
were detected in blood as well as an observed diminished tumour growth subcutaneously and 
intraperitoneally in an orthotopic model of a suspension of MA148 ovarian cancer cells. Anti-
angiogenic therapy was confirmed by reduction of blood vessels formation in the experimental 
model. 
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5.2. Hypothesis and objectives 
The purpose of the work presented in this chapter was to enhance the bio-availability of HTL001 at 
target tissue by using gene therapy. My previous work presented in Chapter 4 demonstrated that 
HTL01 has limitations in terms of delivery at target tissue. Delivering HTL001 as gene therapy would 
have supplied a persistent HTL001 expression and anti-neoplastic activity at target tissue avoiding 
unnecessary systemic cytotoxicity or peptide decay given by the action of cellular proteases. The 
objective was to express HTL001. 
To test the hypothesis, an adeno-associated virus AAV2 was the choice of vector thanks to its safety 
profile that can open up to the future use in clinical trials and the long-term expression in host cells 
of small molecules such as HTL001 (2.6kDa). HTL001 peptide sequence was converted into a 
nucleotide one and optimised for mammalian expression. Several constructs (cassettes for 
expression) were tested in a vector for mammalian expression in preliminary experiments, before 
aiming at sub-cloning into an AAVpro® Tet-One™ Inducible Expression System (Clontech). 
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5.3. Results 
5.3.1. 1st strategy to deliver the transgene (HTL001): expression Cassette 1 
The vector of choice for transfecting HTL001 into ovarian cancer cells was an adeno-associated 
virus serotype 2 (AAV2) due to the advantages outlined in the introduction of this chapter. The 
strategy adopted was to use the AAVpro Tet-One Inducible Expression System (Clontech). The 
system contains the canonical three plasmids for the production of recombinant adeno-associated 
virus AAV2 (rAAV2) in mammalian cells with the advantage of high expression of the gene of 
interest only after exposure to doxycycline (Dox) (Figure 5.3-1-a). The pAAV-TetOne plasmid 
translates for a Tet-On® 3G transactivator protein that tightly regulates the TRE3G promoter 
(TRE3GS) upstream the gene of interest (GOI) only in the presence of doxycycline, otherwise the 
basal transcription is very low (Figure 5.3-1-b). 
 
 
Figure 5.3-1: Schematic overview of the production of a rAVV2 using the AAVpro . 
Tet-One Inducible Expression System  (Clontech).  a)  The pAAV-TetOne plasmid containing 
the transgene is co-transfected with helper plasmids for viral ass embly (Rep/Cap) and 
replication exploiting adenovirus proteins for lytic cycle (pHelper) in packaging cells 
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HEK293. Viral particles produced are isolated from packaging cells, counted and used to 
infect target cells. b) The transgene is expressed at high l evels only after exposure of target 
cells to doxycycline. Image adapted from AAVpro Tet-One Inducible Expression System  
User Manual (Clontech Laboratories ).  
 
 
Following the described workflow for viral production and target cells infection, a conventional 
vector for mammalian expression was selected for a dual function: 1) first to subclone the GOI 
(HTL001) into the pAAV-TetOne plasmid and 2) importantly to perform a pilot study to check the 
ultimate function of the transgene to induce cytotoxicity in ovarian cancer cell lines. The vector for 
mammalian expression pcDNA3.1(-) was adopted because the restriction enzymes for subcloning 
were also present in the multiple cloning site (MCS) of the pAAV-TetOne plasmid. BamHI and EcoRI 
were designated for the purpose (Figure 5.3-2). 
 
 
pcDNA3.1(-) was chosen as a vector for mammalian expression as it was containing two 
restriction enzymes in common with the pAAV-TetOne plasmid in the MCS (BamHi and 
EcoRI). pcDNA3.1(-) was carrying the GOI (HTL001) to subclone into the Tet -One Inducible 
Expression System.  
 
 
Our group previously attempted to express a single copy of HXR9 inserted in a plasmid for 
mammalian expression (pCI neo) under CMV promoter in prostate cancer cell lines PC3 and LnCap, 
but no signs of decreased cell survival were observed when comparing transfected cells with HXR9 
and GFP (unpublished data, personal communication from Dr Guy Simpson). 
Figure 5.3-2: Schematic representation of the plasmids used for the study.  
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A first expression cassette was then designed (Cassette 1) comprising multiple copies of HTL001 
(pcDNA3.1- x3HT) to maximise its quantity at target cells, flanked by self-cleaving small peptides 
(called under the collective name of “2A peptides”) from Porcine Teschovirus (SCP-P) and Thosea 
asigna virus (SCP-T) respectively to separate portions of transcribed construct after ribosomal 
translation (Figure 5.3-3-a). The sequences built-in were as follows: 
 
GSGATFNFSLLKQAGDVEENPGP (SCP-P)  23 a.a.  
GSGEGRGSLLTCGDVEENPGP  (SCP-T)  21 a.a.  
 
CMV enhancer was previously contained in the pcDNA3.1(-) plasmid upstream the MCS, as well as 
a poly A tail for mRNA nuclear export under a SV40 promoter (SV40-pA). A canonical Kozak 
consensus sequence, the first methionine (Met) and a stop codon were added for initiation and 
termination of translation. A GFP tag was included as reporter for the successful mammalian cells 
transfection. Residual amino acids around HTL001 sequence were further eliminated via a Furin 
cleavage site (Fu) with input sequence Arg - X - Arg/Lys - Arg (RAKR). The cleavage sites are indicated 
by a black arrow (Figure 5.3-3-b), while resulting peptides after both cleavages (SCP + Fu) are 
indicated in Figure 5.3-3-c. A pcDNA3.1 plasmid expressing GFP only was added as a control for 
the experiment. 
 
a) Cassette 1 delivered multiple copies of HTL001 (3 x HT) separated during mRNA 
translation by small self -cleaving peptides of viral origin (SCP -P and SCP-T). Furin cleavage 
sites (Fu) further removed residual aminoacids surrounding HTL001, while a GFP tag was 
added to monitor cancer cells transfection with the construct. b) black arrows indicates 
cleavage sites around HTL001 sequence and c) the resulting peptides after cutting. In blue 
are indicated residual aminoacids that alter original HTL001 sequence. HT = HTL001, SCP = 
self-cleaving peptide, fu = furin cleavage site, GFP = green fluorescent protein, poly A = 
polyadenylation.  
 
Figure 5.3-3: Schematic representation of Cassette 1.  
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The expression Cassette 1 was designed with the help of Dr. Guy Simpson. The constructs were 
purchased by Genscript  and they generated a report to show how the nucleotide sequence was 
optimised for human expression with OptimumGene analysis tool to reach a GC content around 
55%, to have codons preferred for human translation and to remove unnecessary CIS-acting 
elements or undesired extra restriction enzymes sites. The resulting peptide sequences (Figure 
5.3-3-c) were personally examined with the ProtParam (Expasy portal) to forecast peptides half-
life in mammalian cells. It is noteworthy to underline that the new peptides were all in the L-
enantiomer form, therefore susceptible of proteases cut, while synthetic HTL001 was developed 
with N-term and C-term in D-enantiomer to prevent proteases cut [67]. Table 5.3-1 summaries 
properties of synthetic HTL001 (*considering all aminoacids being in the L-enantiomer) and new 
resulting peptides: 
 
 
Sequence WYKWMKKAAR(x9) MAWYKWMKKAAR(x9)RAK PWYKWMKKAAR(x9)RAK 
Number of a.a. 18 23 22 
Molecular weight (Da) 2617.18 3174.89 3069.73 
Theoretical pI 12.55 12.61 12.61 
Estimated half-life 2.8 hours* 30 hours >20 hours 
Table 5.3-1: Summary chart of peptides parameters.  
The table compared some properties of original HTL001 sequence and the new peptides 
resulting from the expression Cassette 1 after translation and cut. *HTL001 parameters 
were expressed as the whole aminoacid sequence was in the L -isomers. Estimated half -life 
was calculated in human reticulocytes. pI = isoelectric point, a.a. = aminoacids.  
 
 
5.3.2. Transfection of ovarian cancer and COS1 cell lines with pcDNA3.1-x3 HT 
Ovarian cancer cell lines PEA series (PEA1 and PEA2) and a control cell line COS1 were transiently 
transfected with the plasmid delivering multiple copies of HTL001 (Cassette 1) using a lipid-based 
reagent. Transfection was optimised for cells number per well in a 96 or 24 wells plate, initial DNA 
content, DNA:Reagent ratio, brand and monitored for 24, 48 and occasionally 72 hours. ViaFect 
(Promega) was chosen in favour of Lipofectamine 2000 (Thermo Fisher) due to the lower 
cytotoxicity observed and the slightly better transfection efficacy. However, ovarian cancer cell 
lines demonstrated a low-medium transfection efficacy as compared to COS1 cell line that was 
chosen for further experiments. COS1 is a fibroblast-like monkey cell line expressing the large T 
antigen for high expression of vectors carrying the SV40 promoter, such as pcDNA3.1(-) and it is a 
cell line generally used for high transfection efficiency, therefore maximal expression of the 
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transgene. Images below show how transfection was successful in all cell lines (PEA1, PEA2 and 
COS1) by the expression of the reporter gene GFP. However, ovarian cancer cell lines seemed to 
suffer the introduction of genetic information, while cell lines were healthy and proliferating when 
exposed to the experimental control of the reagent only (ViaFect), or either the plasmid only, or 
the growth medium used for transfection, a media free from antibiotics and serum to maximise the 
formation of the complexes DNA and lipids, such as Opti-Mem (Figure 5.3-4). Transfection 
efficacy was quite low for PEA1 and PEA2 for both the test plasmid pcDNA3.1-3xHT and the control 
plasmid with GFP only after 48 hours of exposure. GFP expression was extended to the entire cell 
in the cells transfected with the control plasmid, while it was confined to dots for the vector 
carrying multiple copies of HTL001. It was also challenging to judge the effective cytotoxicity of the 
transcribed HTL001, because cells in the control plasmid and in the test plasmid (Cassette 1) were 
undergoing apoptotic stress (bright field) that could have been induced by transfection itself and 
perhaps the peptide. 
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Figure 5.3-4: Representative examples of PEA1 and PEA2 cell l ines transiently transfe cted with pcDNA3.1-3XHT (Cassette 1).  
PEA series cell lines were transiently transfected with the test plasmid and the control plasmid and visualised for GFP expre ssion after 48 hours 
exposure to the complex DNA:lipids. The negative GFP expression in the c ontrols (medium only, DNA only and reagent ViaFect only) was an 
indication of the selective transfection and a suggestion of the health status of the cells, as can be appreciated in the bri ght field. GFP expression 
was broad in the control plasmid (GFP onl y) and confined to single dots in the test plasmid. X10 magnification on live cells. HT= HTL001 .
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COS1 was selected for further experiments for its easier manipulation in transfection experiments, 
in an attempt to try to maximise transfection efficacy, to monitor the behaviour of the construct in 
a simplified setting and for downstream analysis. It was important to bear in mind that COS1 was a 
cell line not derived from carcinoma, hence probably it was not overexpressing HOX genes and 
therefore it was not susceptible of HTL001 cytotoxicity (Figure 5.3-6-b, next paragraph). COS1 
transfection with test plasmid and control plasmid recapitulated results from the ovarian cancer 
cell lines in term of localisation of GFP expression, together an improved overall cell viability as 
expected (Figure 5.3-5). 
 
 
Figure 5.3-5: Representative example of monkey fibroblast COS1 cell l ine transiently 
transfected with pcDNA3.1-3XHT (Cassette 1).  
COS1 cell l ine was transiently transfected with the test plasmid and the control plasmid 
and visualised for GFP expression after 48 hours exposure to the complex DNA:lipids. GFP 
expression was broad in the contro l plasmid (GFP only) and confined to single dots in the 
test plasmid. Cell l ines did not suffer transfection and transfection efficacy was improved 
as compared to the ovarian cell l ines. X20 magnification  on live cells. HT= HTL001.  
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The absence of a clear anti-proliferative action in the ovarian cancer cell lines transfected with the 
test plasmid pcDNA3.1-3XHT led us to hypothesises of a failure of the small cleaving peptide (2A 
peptides) and/or the furin cleavage site (Fu) in operating a cut on the  mature construct.  
Immunoblotting of COS1 lysate and supernatant after transfection with test vector and a different 
ratio DNA:ViaFect Reagent using an anti-GFP antibody revealed the presence of two distinct bands 
around 40kDa and 30kDa (Figure 5.3-6-a). The sum of the molecular weights of the several 
components of the CASETTE 1 resulted in a final 36kDa (Figure 5.3-6-b), which can be associated 
with the upper band just below 40kDa band from the ladder. The lower band at 30kDa was an 
indication of a cut operated somewhere in between probably the SCP-T or the upstream furin 
cleavage site. 29.6kDa and 32.1kDa were in fact the sum of GFP+HTL001 and GFP+HTL001+SCP-T 
respectively. Unfortunately, definite conclusions could not be drawn due to the difficulty to set up 
an immunoblotting for small fragments such as HTL001 or the 2A cleaving site. 
 
 
 
Figure 5.3-6: Immunoblotting of COS1 cell l ine wi th an anti-GFP antibody.  
a) supernatant and lysate of COS1 cell line were collected 48 hours post -transfection with 
test plasmid and immunoblotted on a PVDF membrane. Two distinct bands were revealed 
in the lysates and supernatant (indicated with a red sta r).  The upper bands was believed 
to represent the entire construct, while the lower band at 30kDa one of the fragment 
resulting after a cut of the translated and mature construct. b) schematic representation 
of CASETTE 1 construct and the possible cuts (bl ack arrows) that develop the second band 
around 30kDa. Sup HTL001 refers to supernatant HTL001, while 1:1, 1:2, 1:4 are the lysates 
169 
 
of COS1 cells transfected with different ration of DNA:ViaFect reagent.  HT = HTL001, SCP = 
self-cleaving peptide, fu = furin  cleavage site, GFP = green fluorescent protein, poly A = 
polyadenylation. 
 
 
5.3.3. 2nd strategy to deliver the transgene (HTL001): expression Cassette 2 
A second expressing cassette (Cassette 2) was designed due to the open questions still unsolved 
with the first attempt of Cassette 1 transfection in ovarian cell lines and COS1. Cassette 2 construct 
was simplified: the number of HTL001 sequence repetitions was reduced to only one, the Furin 
cleavage site removed completely and only a small cleaving peptide from Porcine Teschovirus (SCP-
P) maintained. GFP tag was positioned upstream HTL001, flanking the first Met and the SCP-P. The 
expressing Cassette 2 was again inserted in a pcDNA3.1(-), cloning in between the restriction 
enzymes BamHi and EcoRI (pcDNA3.1 - HT). A control plasmid was prepared in the same way 
including GFP and the small cleaving peptide only (pcDNA3.1 - GFP).  
 
 
 
Figure 5.3-7: Schematic representation of Cassette 2  
a) Cassette 2 delivered a single co py of HTL001 (pcDNA3.1 - HT) separated during mRNA 
translation by a small self -cleaving peptides of viral origin (SCP -P). A GFP tag was added 
to monitor cancer cells transfection with the construct and was positioned bordering SCP -
P upstream of HTL001. b) the black arrow indicates the cleavage site around HTL001 
sequence and c) the resulting peptide after cutting. In blue it is pointed out the residual 
aminoacid that alters original HTL001 sequence. HT = HTL001, SCP = self -cleaving peptide, 
GFP = green fluorescent protein, poly A = polyadenylation.  
 
 
A codon optimisation for human expression was run again with the OptimumGene (Genscript) 
analysis tool and again the ProtParam (Expasy portal) estimated resulting pre-test peptide (Figure 
5.3-7-c) molecular parameters summarized in Table 5.3-2: 
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Sequence WYKWMKKAAR(x9) PWYKWMKKAAR(x9) 
Number of a.a. 18 19  
Molecular weight (Da) 2617.18 2714.29 
Theoretical pI 12.55 12.55 
Estimated half-life 2.8 hours* >20 hours 
Table 5.3-2: Summary table of peptides parameters.  
The table compared some properties of original HTL001 sequence and the new peptide 
resulting from the expression Cassette 2 a fter translation and cut. *HTL001 parameters 
were expressed as the whole aminoacid sequence was in the L -isomers. Estimated half -life 
was calculated in human reticulocytes.  
 
 
As done for pcDNA3.1- x3HT, pcDNA3.1 - HT and its control peptide pcDNA3.1 – GFP, the plasmid 
were used to transform TOP10 competent E.coli, select positive clones, antibiotic resistant 
(ampicillin), and to amplify DNA content with a MIDI preparation for downstream experiments. 
DNA quality was controlled using a Nanodrop and the correct length of the insert (expression 
cassette) analysed on agarose gel after a DNA digestion with cloning restriction enzymes EcoRI e 
BamHI. The three selected clones for pcDNA3.1 - HT and its control peptide pcDNA3.1 – GFP 
expressed a correct insert (Figure 5.3-8). 
 
 
 
Figure 5.3-8: DNA quality check.  
The products of the MIDI preparation were run on a 2% agarose gel to control the presence 
of the inserts and their correct molecular weight. DNA was digested 6 hours with 
restriction enzymes BamHI and EcoRI.  
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5.3.4. Transfection of ovarian cancer and COS1 cell lines with pcDNA3.1-HT 
Similarly to what previously done, ovarian carcinoma cell lines PEA1 and PEA2 were transfected 
with test plasmid carrying Cassette 2 and the control vector (GFP-SCP). Again representative images 
in Figure 5.3-9 showed a low transfection efficacy in PEA1 and PEA2 as confirmed by GFP 
expression monitored with fluorescence microscopy. Cells viability was acceptable in the negative 
controls (Opti-Mem, DNA and ViaFect only), however it was hard to discriminate any significant 
presence of HTL001 efficacy in the cells transfected with pcDNA3.1-HT, because there was a high 
background level of cellular stress already induced by the transfection. The bright field images 
demonstrated apoptotic cells in both the test and controls plasmid to a similar extent. Remarkably, 
when transfecting ovarian cancer cell lines PEA1 and PEA2 and COS1, reporter gene GFP expression 
was extended to the entire cell surface, suggesting a soluble GFP free to move within the cell. 
Transfection of COS1 cells resulted in similar conclusion, with a higher transfection efficacy and less 
cellular stress (Figure 5.3-10).  
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Figure 5.3-9: Representative examples of PEA1 and PEA2 cell l ines transiently transfected with pcDNA3.1 -HT (Cassette 2).  
PEA series cell l ines were transiently transfected with the test plasmid and the control plasmid and visualised for GFP expression after 48 hours exp osure 
to the complex DNA:lipids. The negative GFP expression in the controls (medium only, DNA only and reagent ViaFect only) was a n indication of the 
selective transfection and a suggestion of the health status of the cells, as can be appreciated in the bright field. Soluble  GFP was free to diffuse on the 
entire cell surface. X10 magnification on live cells.  
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Figure 5.3-10:  Representative example of monkey fibroblast COS1 cell line transiently 
transfected with pcDNA3.1-3XHT (Cassette 2).  
COS1 cell l ine was transiently transfected with the test plasmid and the control plasmid 
and visualised for GFP expression after 48 hours exposure to the complex DNA:lipids.  
Soluble GFP was free to diffuse on the entire cell  surface.  Cell l ines did not suffer 
transfection and transfection efficacy was improved as compared to  the ovarian cell l ines. 
X10 magnification on live cells.  
 
 
Again lysate of cell lines transfected with the plasmid pcDNA3.1-HT carrying a single copy of HTL001 
and its control plasmid were immunoblotted on a PVDF membrane and probed for anti-
polyarginine (9R) antibody recognising the polyarginine tail of HTL001. The anti-polyargine 
antibody failed to detect any peptide and it was impossible to discriminate whether the cause was 
technical (WB protocol) or due to the absence of HTL001 translation from the construct. Only one 
band appeared on the membrane when probing for the anti-GFP antibody previously used in both 
test and control plasmid, suggesting that perhaps the cut of the 2A peptide (SCP-P) was successful 
(Figure 5.3-11). If the cut was happening the two resulting constructs had exactly the same 
molecular weight that is the case of the data shown in the figure below. On the other hand, there 
is only a minimal difference of 2.6kDa between the two constructs (test VS control), which is the 
molecular weight of HTL001, that perhaps could be not appreciated with a not highly sensitive 
technique as immunoblotting.  
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Figure 5.3-11: Immunoblotting of ovarian cancer cell lines with an anti -GFP antibody.  
a) lysate of PEA1 and PEA2 cells line was collected 48 hours post -transfection with test 
plasmid and immunoblotted on a PVDF membrane.  Lanes 1 and 3 represent cells 
transfected with pcDNA3.1-HT, while 2 and 4 with the control plasmid. Only one distinct 
band was revealed suggesting that the cut at the 2A peptide (SCP -P) was positive.  b) 
schematic representation of Cassette 2 construct and the possible cut (black arrow ). HT = 
HTL001, SCP = self -cleaving peptide, GFP = green fluorescent protein, poly A = 
polyadenylation. 
 
 
A further pilot test was run to detect any signs of cytotoxicity on ovarian cancer cell lines exposed 
to the translated HTL001. COS1 cell line, despite highly expressing the construct, is resistant to 
HTL001 (Figure 5.3-12) as HOX genes are minimally expressed (non-cancer cells). Therefore COS1 
supernatant and clarified lysate was applied to cultured ovarian cancer cell lines in a 96 wells plate. 
Again there was no evident cytotoxic activity detected through a simple MTS assay (data not 
shown).  
 
As a proof of principle of the anti-proliferative effects on cancer cell lines, a synthetic version of the 
peptide after translation was generated. The biological properties after an aminoacid modification 
were in fact not tested before. The new peptide had a proline at the N-term resulting from the 2A 
cleavage, just before the Tryptophan of the PBX binding motif. P-WYKWMKKAARRRRRRRRR was 
then tested on COS1 and PEA series cell lines in a range 0 – 50μM and cell metabolic activity 
evaluated via an MTS assay and expressed as a percentage of surviving cells (Figure 5.3-12-b). 
The new P-HTL001 induced a high rate of apoptosis in both normal and cancer cells (Figure 
176 
 
5.3-12-a), however COS1 cells are resistant to standard HTL001 (Figure 5.3-12-b), demonstrating 
a plausible non-specific mechanism of action of the new version of peptide. 
 
 
A synthetic version of the resulting peptide after 2A peptide cut was created and cell l ines 
were exposed to increasing concentrations of the new peptide. a) non –cancer COS1 and 
ovarian cancer cell  l ines PEA1 and PEA2 were high ly susceptible to P-HTL001 and undergoing 
cell death. Images show cell treated with 50μM of P -HTL001. b) dose-response curve 
obtained after treatment with P-HTL001 and HTL001. COS1 was resistant to HTL001, but not 
to P-HTL001, an indication of a possible u nspecific  mechanism of action of the new peptide. 
PEA1 and PEA2 were more susceptible to P -HTL001, when comparing to the results obtained 
in 3.3.1. Graphs are expressed as % of cell  survival and error bars indicate SD from 2 
biological repetitions.  
  
Figure 5.3-12: COS1 and PEA series cell l ines exposed to 0 -50μM P-HTL001. 
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5.4. Discussion 
The scope of the present chapter was to explore a new approach to deliver HTL001 at target tissue 
using gene therapy. In Chapter 3 I demonstrated that HTL001 was superior, but there was not great 
difference in efficacy of HTL001 versus its earlier version HXR9 when evaluated in a panel of 
commercial ovarian cancer cell lines and primary culture derived from patient tissue or ascites from 
body fluids. The results prompted us to challenge HTL001 moving to a personalised medicine, using 
the new established and optimised model of precision cut ovarian cancer tissue slices. The absence 
of clear signs of anti-neoplastic action on the organotypic culture observed in Chapter 4 was 
thought to be related to tissue penetration and a limitation of the poly-arginine tail as a strategy 
for delivering the drug in 3D setting, closer to a clinical scenario. This encouraged us to adopt gene 
therapy as a potentially useful approach to enhance the bio-availability of HTL001 on tumour cells, 
avoiding off-target cytotoxicity and increasing overall peptide half-life. Among the available vectors 
for gene therapy outlined in the introduction of the present chapter, viral vectors were chosen for 
the purpose to exploit the natural ability of viruses to replicate, translate and then propagate to 
neighbour cells the genomic information they are carrying. In particular, adenoviruses had a proven 
track of successful delivery of therapeutic antibodies or pro-drugs in ovarian cancer tissue, in 
particular at their preferred metastatic sites, omentum and diaphragm, as described in the 
introduction [138-140]. Their safe profile, given by the low rate of insertional mutagenesis as 
integrated virus DNA remains episomal, the low immunogenicity and the limited genome that 
allows for insertion of short sequences up to 5kb in tandem, makes them ideal candidates for 
delivery of a small peptide such as HTL001. The AAVpro® Tet-One™ Inducible Expression System 
(Clontech) seemed a valid method to generate rAAV2, the most common and studied AAV serotype, 
with the important feature of being an inducible system, therefore having the possibility to activate 
the cytotoxic activity of HTL001 only at target cells. Our fear was a possible side cytotoxicity in the 
packaging cell lines for viral production. Generating and producing viral particles is a long workflow 
with lots of possible troubleshooting along the way. Prior inserting the HTL001 transgene in the 
AAVpro® Tet-One™ Inducible Expression System, a pilot project was run to assess the most 
performing delivery strategy (cassette for expression) and to check whether the targeted and 
cytotoxic activity of HTL001 was preserved after translation in cancer cells. Two different 
expression cassettes (Cassette 1 and Cassette 2) were inserted into pcDNA3.1(-), a vector for 
mammalian expression (Figure 5.3-3 and Figure 5.3-7). Published literature demonstrated a 
superior cleaving efficacy when adding different self-cleaving fragments in tandem to the construct 
[141], as well as obtaining a higher product expression upstream the 2A cleaving site [142]. The 
multiple copies of HTL001 were in fact placed upstream the reporter gene GFP (Figure 5.3-3). 
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However, GFP was placed upstream the 2A cleaving site in expression Cassette 2 given the necessity 
to minimise the addition of residual aminoacids around original HTL001 sequence that could have 
altered the biological function of the peptide (Figure 5.3-7). SCP-P was chosen for its superior 
cleaving efficacy over SCP-T and SCP-E (Small Cleaving Peptide from Equine Rhinitis A virus) [141, 
143]. Translated proteins, upon entering the endoreticulum (ER) for maturation, have cut 
unwanted residual sequences via Furin, one of the major cellular endoprotease localized in the 
trans-Golgi for the secretory pathway, if containing the preferred consensus sequence -RAKR- [142] 
(Figure 5.3-3). Protoparam is an analysis tool available at the Expasy database portal for the 
calculation of protein parameters including molecular weight, isoelelectric point (i.e. null charge on 
the aminoacidic sequence) and importantly it provides a calculation of the theoretical half-life of 
the peptide in human reticulocytes, precursors of lineage blood cells without nucleus. Reticulocytes 
represent a simplified model of a eukaryotic cell, eliminating interference of nuclear import/export 
of proteins and being widely adopted when studying protein translation. Noteworthy, an addition 
of just a proline (P) or a few aminoacids (MA, RAK) in front of HTL001 enormously increased its half-
life in cells as compared to the only 3 hours estimated for HTL001 (Table 5.3-1 and Table 5.3-2). 
Last, the poly-arginine tail for cell entry was left in both expression cassette to exploits a possible 
bystander effect of HTL001 on nearby cells; in this way apoptotic cells infected by the rAVV2 and 
killed by translated HTL001 were releasing in the surrounding tissue functional copies of HTL001. 
Maintaining HTL001 original strategy for cell entry, an amplification of cytotoxic effects on 
carcinoma cells would have been possible. 
 
Ovarian carcinoma cell lines PEA1 and PEA2 were then transiently transfected via a lipo-complex 
based transfection with the optimised expression Cassette 1 and 2 using a common plasmid for 
mammalian expression such as pcDNA3.1(-). The low transfection efficacy as reported by GFP 
expression and the poor cell viability made difficult to judge whether 1) HTL001 was actually 
expressed and 2) still maintaining a functional cytotoxic activity on cancer cells. The scarce viability 
observed in the ovarian carcinoma cell lines was more likely due to the transfection itself; cells 
transfected with control plasmids for both expression cassettes resembled test sample results. 
However, the transfection reagent alone or naked DNA and growth medium (Opti-Mem) did not 
affect at all cell viability (Figure 5.3-4  and Figure 5.3-9). Transfection efficacy and cell viability 
were much improved when using COS1 (Figure 5.3-5 and Figure 5.3-10). COS1 was utilised with 
the only final purpose of expressing high copies of the transgene and to analyse resulting cell lysate 
and supernatant in downstream experiments. COS1 is in fact a non-cancer cell line, probably not 
overexpressing HOX genes (not assessed), and therefore it was resistant to HTL001 targeted HOX-
PBX inhibition (Figure 5.3-12-b). Analysis of COS1 or PEA series cell lines lysate or supernatant 
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showed the presence of a truncated product or a partial cut when immunoblotting with an anti-
GFP antibody cell lines transfected with pcDNA3.1-3XHT (Figure 5.3-6). The hypothesis was 
strengthen by the confined GFP expression to single dots within cell cytoplasm (Figure 5.3-4 and 
Figure 5.3-5). Cells transfected with Cassette 2 demonstrated promising results, because 
translated soluble GFP was free to move across whole cell surface (Figure 5.3-9  and Figure 
5.3-10) and both test plasmid (pcDNA3.1-HT) and control plasmid (pcDNA3.1- GFP/SCP-P) aligned 
bands at 30kDa, an indication of a successful self-cleavage of SCP-P. Unfortunately, immunoblotting 
is not a highly sensitive assay to accurately detect small differences in the molecular weight of 
proteins and the failure to detect the tail of HTL001 was difficult to explain with certainty. The poly-
arginine antibody failed also to detect the original HTL001 included as a positive control on the 
Western Blot, suggesting that the immunodetection of small proteins such HTL001 was very 
arduous, despite changing protocols parameters as acrylamide percentage, running buffer MES or 
MOPS and transfer time (data not shown). The application of COS1 supernatant or clarified lysate, 
perhaps containing translated HTL001, failed to induce any signs of cytotoxicity when added to 
separate cultures ovarian cancer cell lines from PEA series (data not shown). 
 
Despite trying a number of different protocols there was no clear evidence of any tangible 
transfected HTL001 activity on cancer cells. This can be explained by a several factors: firstly, the 
absence of an effective cut either operated by the 2A peptides or the Furin site altering the original 
HTL001 peptide sequence; results were not sufficiently informative to exclude the option. 
Secondly, HTL001 production was not enough to activate noticeable anti-neoplastic effects on 
carcinoma cells. HTL001 works in fact in the range of μM on monolayers of ovarian cancer cell lines 
(Chapter 3) and the production achieved here was probably too low (picomolars?). We cannot 
definitely exclude the action of cellular proteases on the translated mature HTL001 in the 
cytoplasm, making the peptide inactive even before entering the nuclear compartment to bind PBX 
co-factor. The question of a preserved biological function was instead addressed artificially 
synthetizing the resulting peptides after translation and applying them in the range of μM to 
ovarian cancer cell lines. P-HTL001 demonstrated for example a strong cytotoxic function on 
ovarian cancer cell lines, as wells as COS1, suggesting how just a change in one aminoacid was 
altering the target mechanism of HTL001 (Figure 5.3-12). In a repeat experiment I would first 
check the biological function of the peptides formed after translation in pilot assays, before moving 
to transiently transfect cell lines and to downstream analysis. Single aminoacid changes in the 
aminoacids flanking the hexapeptide motif (YPWM), the conserved binding consensus sequence 
between HOX-PBX (refer to Section 1.7.3), have reported before and can drastically alter the 
stability of the HOX-PBX complex [79]. Future work here should include the testing of human non-
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neoplastic cell lines with P-HTL001 to assess whether P- HTL001 lose its specificity to prevent HOX-
PBX interaction (COS1 is a monkey derived cell lines) and further analyses on the function of the 
extra proline before the hexapeptide motifs that seems to enhance HTL001 killing efficacy. A 
speculation could be that the extra proline is one of the recurrent aminoacids for some HOX genes 
upstream the conserved motifs that increases binding affinity of P-HTL001 to PBX (indicated by red 
arrows in figure below).  
 
 
Figure 5.4-1: Alignment of P-HTL001 and the conserved HOX hexapeptide sequence 
highlighted in light grey.  
HOX proteins are characterised for a conserved hexapeptide motifs YPMW for their binding 
with co-factor PBX. HTL001 mimics this binding sequence with a very similar sequence 
YKWM, therefore activing as a competitive binding element to PBX. P -HTL001 contains a 
proline upstream the hexapeptide motifs that perhaps can contribute to increase its 
binding affinity to PBX and as a consequence to enhance HOX -PBX inhibition. This proline 
is in fact present in HOX paralogues HOXA2, B2 and B6 (indicated by red arrows). Image 
adapted from [79]. 
 
 
The work presented in this chapter leaves a number of unanswered questions and potential 
interpretations of the results displayed. Possible more sensitive methodologies to detect the 
translated peptide, alternatives in the expression construct design and future directions to 
overcome the problems encountered in the present chapter will be further discussed in the general 
conclusion (Chapter 7).  
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CHAPTER 6 
 
6. Exploring HTL001 molecular pathways leading to 
apoptosis and the role of DUSP1 in HTL001 induced 
apoptosis.  
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6.1. Introduction 
In Chapter 3 the ability of HTL001 to effectively kill malignant cells has been shown in commercial 
and patient derived ovarian cell lines with an efficacy comparable or slightly better than the original 
peptide version HXR9 assessed with viability assays. Experiments using Annexin V assays on ovarian 
cells treated with HTL001 and analysed by flow cytometry recapitulated previous experiments: for 
example mouse melanoma B16 cell treated for two hours with 60μM of HXR9 showed that nearly 
50% of cells with a highly damaged cell membrane expressed high 7AAD and Annexin V, suggesting 
that the mode of death was late apoptosis/necrosis [67]. Similar results were observed in the 
ovarian SKOV3 cell line where 60% cells died following exposure of cells to 120μM of HXR9, 
indicating ovarian cell lines were less sensitive than melanoma cells and required a double 
concentration of HXR9. In the same study, the presence of a cleaved PARP detected with 
immunoblotting in the treated ovarian cancer cell line SKOV3 was a further indication that cell 
death was through apoptosis rather than necrosis [70].  
There is currently no clear understanding what is the molecular cascade leading to apoptosis 
triggered by HXR9 and whether the programmed cell death follows an intrinsic or extrinsic 
pathway. Cell death through apoptosis would be favourable as it allows the cells’ 
microenvironment to avoid  chronic inflammation, which as shown in necrosis can be detrimental 
to the tissue affected [144]. Importantly, the process can be modulated targeting other proteins 
involved in the downstream or upstream route to cellular suicide with combination therapy. 
Nevertheless, identifying the molecular pathway started by a class of drugs could help to 
characterise a panel of biomarkers to predict responses to the treatment and to allow a more 
accurate patient stratification. 
 
6.1.1.  Overview of apoptosis regulation 
Apoptosis is a complex molecular mechanism of controlled “cellular suicide” highly regulated in 
response to several factors, such as cytotoxic compounds, cytokines and environmental insults. It 
is a “demolition procedure” organised by a cell to remove old or damaged cellular components 
without affecting nearby tissue, orchestrated by a family of effector Caspases and characterised by 
typical occurring events: 1) DNA fragmentation in 200 base pair pieces operated by cleaved PARP, 
2) a rearrangement of the cytoskeleton to produce membrane blebbing, 3) a flipping of the 
phosphatidylserine (PS) on the outer double membrane layer and 4) a Golgi and endoplasmic 
reticulum (ER) crumbling. There are two main routes that result in a final cleavage of pro-caspases 
into active and effector caspases with a core proteolytic activity (Figure 6.1-1): the intrinsic 
pathway is initiated by internal signals telling the cell that the damage is too advanced to be 
183 
 
repaired and the extrinsic pathway. The intrinsic pathway signal is captured and converted into a 
molecular cascade by proteins of the BH3 family such as BAD, BIM, NOXA, PUMA that promote the 
assembly of BAX-BAK channels on the mitochondrial membrane for the release of cytochrome c. In 
turn, cytochrome c starts the assembly of the caspase 9 and apoptotic protease-activating factor-
1 (APAF1) complex. The proteolytic activity of active caspase 9 promotes the cleavage of pro-
caspases 3 and 7. Members of the BCL-2 family can act as negative regulators of apoptosis inhibiting 
the assembly of the BAX-BAK channels. In the extrinsic route, ligands such as FasL, TRAIL or TNFα 
(TNF superfamily) bind to “death receptors” and the conformational change induced attracts Fas-
associated death domain protein (FADD) that triggers the proteolytic activity of caspase 8. Caspase 
8 cleaves caspase 3 and 7, which are the converging point of both routes. BID can instead operate 
an earlier cross-talk between intrinsic and extrinsic routes interacting with caspase 8 (reviewed in 
[145]). 
 
 
 
Figure 6.1-1: Apoptosis overview: intrinsic and extrinsic molecular pathways.  
Cells undergo a programmed cell death in response to a variety of external stimuli as UV 
radiations, inflammatory cytokines and cytotoxi c compounds and are able to convert the 
signal of damage into a molecular cascade of events orchestrated by effector Caspases. 
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Caspases are enzymes with a proteolytic ability to target proteins that once cleaved 
become active and drive the typical phenomen a occurring during apoptosis: 1) DNA 
fragmentation, 2) membrane blebbing, 3) flipping of the phosphatidylserine (PS)  on the 
outer double membrane layer and 4) Golgi and endoplasmic  reticulum (ER) disintegration. 
There are two main apoptotic pathways, the i ntrinsic activated in response to internal 
stimuli such as DNA damage, hypoxia and metabolic stress, while the extrinsic is tr iggered 
by death ligands (FasL, TNF -α, TRAIL) binding death receptors (FAS, TNFR). A detailed 
description of the molecular pathway s involved can be found in the paragraph. Image 
taken from [145] with permission of Springer Nature, License Number 4443560207569.  
 
 
6.1.2.  HXR9 mechanisms leading to apoptosis 
Understanding the molecular perturbations induced by HXR9 from its initial HOX/PBX inhibition to 
apoptosis was a line of research since the first publication about this small inhibitory peptide by 
Morgan and colleagues. In 2007, an exploratory pilot experiment was performed to identify 
potential transcriptional modifications induced by the treatment with HXR9 [67]. A Mouse Genome 
430A 2.0 Array (Affymetrix) was used to characterise RNA expression of 14,000 genes in murine 
melanoma B16 cells treated for 2h with 60μM of HXR9 or the control peptide CXR9.  Out of the 
14,000 genes on the array, only 22 showed a significant fold increase in the gene expression as 
compared to the control peptide CXR9. These candidate genes were further validated at qPCR and 
Dusp1, Atf3 followed by c-Jun and c-Fos demonstrated a differential high overexpression. Other 
highly regulated genes were Klf4 and Smad7, but to a lesser extent. Similarly A549, a non-small-cell 
lung cancer cell line was treated with 60μM HXR9 or CXR9 for 3 hours and its RNA probed on a 
Whole Human Genome Microarray slide (4x44K) containing more than 41,000 human genes. Again 
few genes demonstrated a significant high expression and among them were cFOS and FOSB and 
EGR1 with a 5 to 20 fold upregulation as compared to untreated cells [146]. 
Analysing the activated genes we decided to focus on DUSP1 and its role will be discussed in details 
in the next paragraph. EGR1 is an early response zinc fingers transcription factor involved in 
responses to growth stimuli, mitogens or apoptotic signals. It has been found to interact with JUN 
protein to inhibit Survivin and then activate downstream caspases in human multiple myeloma cell 
lines OCI-My5, OPM2, and U266 [147]. JUN, FOS belong to a family of transcription factors capable 
of DNA binding thanks to a conserved bZIP motif. The DNA binding occurs only as dimers forming 
the Activator Protein-1 (AP1) complex. Members of the JUN family (c-Jun, JunB and JunD) can 
homodimerize or bind members of the FOS family (c-Fos, FosB, Fra-1 and Fra-2) or ATF2. ATF2 is a 
member of the ATF family (ATF2, ATF3/LRF1, B-ATF, JDP1, and JDP2), which includes ATF3. In 
addition, ATF proteins can homodimerize themselves. Jun-Jun or Jun-Fos recognise prevalently 
TPA-responsive element (TRE) sequences at target genes containing 5′-TGA(C/G)TCA-3′, whereas 
Jun-ATF, ATF dimers, as ATF3 for example, prefer a different DNA consensus sequence containing 
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5′- TGACGTCA-3′ typical of cAMP-responsive element (CRE).  This variety of partnerships opens to 
the activation of multiple target genes according to the cellular context and type of insults received 
by the cell, therefore it implicates a diversity of functions where the AP1 complex and its close 
partners (ATF family) can be involved in the context of cancer, including proliferation, metastasis, 
inflammation and apoptosis (Figure 6.1-2) [148, 149].  
 
 
Figure 6.1-2: AP1 complex binding partners.  
The image illustrates the possible combinations of binding among AP1 complex members 
(Jun-Jun, Jun-Fos and Jun-Atf2) and satellites transcription factors. Jun family protei ns can 
homodimerize or heterodimerize with all the other families. Atf family has the ability to 
homodimerize or to interact occasionally with members of Fos family. Image adapted from 
[150]. 
 
 
The apparent opposite roles that the AP1 complex initiates can be explained by AP1 operating as a 
scale between death stimuli and survival: if the stress stimulus on the cell is too sustained, and 
perhaps this is the case with HXR9 cytotoxicity, the balance moves to a programmed cell death. c-
JUN and c-FOS transcription first and then their protein phosphorylation and activation later on, 
are a transient and rapid event within minutes following cellular stress operated respectively by 
Jun-N terminal-Kinases (JNK1 or JNK2) and Extracellular signal–Regulated Kinases (ERK1 or ERK2). 
These kinases, belonging to the Mitogen Activated Protein Kinases (MAPK) family together with 
p38, are in charge to respond to a variety of stimuli and act as mediators between the stress signal 
and the apoptotic cascade resulting in an intrinsic or extrinsic pathway according to the type of 
insult (Figure 6.1-3) [150, 151]. 
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Figure 6.1-3: MAPK signalling pathway. 
Schematic representation of Mitogen Activated Protein Kinases (MAPKs), their upstream 
adaptors MAPKKs (MAPK Kinases) in red and relative substrates transcriptionally activated 
in green. In a simplified description, EKRs are active in response to grow th stimuli and then 
switch on the transcription of targets, such as c-FOS or  ATF2. p38 and JNK are key 
mediators of a stress or inflammatory response activating c-Jun or ATF2  among other 
transcription factors according to cellular type and type of input.  Image adapted from 
[152]. 
 
 
It is not surprising that most of the work by Morgan and collaborators focused on the proto-
oncogene c-FOS, due its pivotal role in a variety of cellular processes, in particular its role as c-JUN 
partner in the formation of the pro-apoptotic AP1 complex, as mentioned before. c-FOS 
transcriptional upregulation in cancer cells after treatment with HXR9 was confirmed in vivo in 
xenograft mice models and in vitro in several immortalised cell lines including melanoma, ovarian, 
acute myeloid, prostate and breast cancer [67-70, 72]. 
To test whether the selective overexpression of c-FOS was partly responsible for a HXR9 related 
apoptosis, melanoma B16 cell were pre-treated with FOS anti-sense siRNA and then incubated for 
two additional hours with HXR9. The partial rescue in the percentage of cell survival was an 
indication of a c-FOS mediated apoptosis [67]. Similarly in prostate cancer cells DU145, c-FOS was 
partially responsible for the programmed cell death as cells pre-treated with an anti-sense c-FOS 
RNA were significantly less sensitive to the drug treatment alone as confirmed in a cell survival 
assay [69]. 
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The partial cell death rescue obtained in the experiments when silencing c-FOS is an indication that 
other transcription factors, for example c-JUN or other partners of the AP-1 complex and/or 
transcription factors (i.e. EGR1 in the case of non-small-cell lung cancer cell lines or ATF3) are 
probably involved in a complicated molecular machinery acting differently according to cellular 
context. 
 
6.1.3.  Role of DUSP1 in cancer 
Dual Specific Phosphatase -1 (DUSP1) is one of the 25 members of the family of tyrosine 
phosphatases. MKP-1 (MAPK phosphatase-1) is the alternative name given to the protein whose 
ATP-ase catalytic domain has the ability to de-phosphorylate the MAPKs proteins ERKs (1/2), JNKs 
(1/2), and p38. There is evidence of DUSP1 playing an important role in cancer progression, 
cytotoxic agents responses, inflammation and apoptosis, working as a negative regulator of the 
molecular pathways where the MAPKs are involved, therefore contributing to chemoresistance in 
cancer [153]. 
DUSP1 protein has been found to be generally strongly expressed in normal cells or in the early 
onset of disease and then progressively disappearing with higher tumour stage and metastasis in 
cohorts of primary tissue from prostate, colon, and bladder cancer. Breast carcinoma, however, 
showed an opposite trend with significant overexpression of MPK-1 even in poorly differentiated 
cancer [154]. Similar findings were observed by Denkert et al. [155], where a gradual loss of DUSP1 
expression was detected with higher tumour grade in ovarian carcinoma in primary tissue. Normal 
ovarian surface epithelium as well as benign adenomas expressed high protein content. In the same 
study, univariate survival analysis on selected patients with invasive ovarian carcinoma only 
revealed a significant association of shorter progression‐free survival and DUSP1 expression (only 
18.33 months for positive versus 40.57 months for patients with negative MKP‐1), indicating MKP-
1 as a poor prognostic factor. The decreased expression of DUSP1 in high grade ovarian carcinoma 
can be explained by a loss of DUSP1, which corresponds to a loss of uncontrolled negative feedback 
regulation resulting in a sustained signalling of the MAPKs, in particular of the ERKs, which is 
generally associated with cell proliferation [156]. 
The role of DUSP1 in the development of chemoresistance has been observed in different cancer 
types and in response to several cytotoxic agents. The ectopic expression of DUSP1 in 293T cells 
showed an inhibition on JNK and p38 transcriptional activity and protein content after treatment 
of the cells with cisplatin. The low transcription of c-JUN, a JNK transcriptional target and a 
transcription factor of the pro-apoptotic AP-1 complex was confirmed as well, suggesting the 
possible role of DUSP1 in protecting the cells versus apoptosis [157]. In another study the level of 
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MKP‐1 mRNA was highly induced after treatment with cisplatin in OVCAR‐3 cells, even in the case 
of a persistent and long platinum treatment for up to 24 hours as confirmed by western blot 
analysis [155]. 
Paclitaxel resistance was observed in ovarian HeyA8 cells with an ectopic expression of DUSP1 or 
with an induced multi-drug-resistance (HeyA8-MDR) through an increased p-glycoprotein protein 
expression, a drug efflux pump, and an augmented phosphorylation of DUSP1 target, p38. Silencing 
DUSP1 with a shRNA therefore resulted in an intensification of cell death [158]. 
DUSP1 transcriptional upregulation was found also in pancreatic cell lines BxPC-3 and COLO-357 in 
response to Gemcitabine concomitant to the amplified phosphorylation of stress response kinases 
(SAPK) p38 and JNK, and the downstream JNK target c-JUN up to 24 and 48 hours of exposure with 
Gemcitabine. The selective pharmacological inhibition of the MAPKs p38, ERK and JNK respectively 
was an indication of a DUSP1 induction mediated by p38 and JNK, rather than ERK. DUSP1 
knockdown in the same cell lines before gemcitabine treatment sensitised the cells to the inhibitory 
effects of the drug [159]. Besides, DUSP1 and c-FOS have been found to play an important role in 
mediating Tyrosine Kinase Inhibitors (TKI, Imatinib) resistance in Chronic Myelogenous 
Leukaemia (CML) in an experimental model where pre-B cells, BaF3, constitutively expressed the 
oncogene fusion gene BCR-ABL (BaF3-BA). DUSP1 and c-FOS were upregulated in those cells and 
similarly in primary CD34+ cells obtained from patient samples from chronic and blast-phase CML 
as compared to normal cells. The forced overexpression of DUSP1 and c-FOS impaired the effect of 
Imatinib on cell survival, however their shRNA inhibition restored the sensitivity of BaF3-BA cells to 
the drug to a level similar to the parental cell line BaF3. Genetic results were recapitulated when 
stopping c-FOS and DUSP1 related functions using pharmacological inhibition in vitro and in vivo in 
transplanted mice with bone marrow cells expressing BCR-ABL. As pharmacological inhibition with 
small molecules DCI and BCI, targeting respectively c-FOS and DUSP1, combined with the treatment 
with the TKI inhibitor Imatinib, resulted in a delayed BCR-ABL-induced tumour onset by one week 
and an eradication of the minimal residual disease and a disease latency up to two months [160]. 
Chronic adrenergic stimulation by catecholamines in ovarian cancer altered paclitaxel and cisplatin 
efficacy in vitro in two ovarian cell lines HeyA8 and SKOV3ip1 and increased DUSP1 transcription, 
as confirmed in genome wide studies of HeyA8 and SKOV3ip1 exposed to catecholamines. Silencing 
DUSP1 (siRNA) resulted in additional apoptosis observed through an increase in the level of JNK 
and c-JUN phosphorylation. Besides, they proposed an ADRB2/cAMP/PLC/PKC/CREB signalling 
cascade to activate DUSP1 transcription [161]. A study by Candas et al. [162], published in Cancer 
Research, a translocation and accumulation of DUSP1 into the mitochondria up to 8 hours post-
irradiation was found in breast carcinoma cell lines. The highest protein concentration was 
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observed after 4 hours and correlated with lower cleaved caspase 3 and cytochrome c release, an 
indication of a protection from apoptosis. Again MPK1 (DUSP1) inhibited the activation of JNKs to 
induce apoptosis and not ERKs, but the latter were found to act as upstream regulators of DUSP1. 
Interestingly, a strong correlation of HER2, commonly overexpressed in breast cancer, and MPK1 
was observed in breast cancer stem cells and primary tissues, prompting the authors to perform 
combination therapy using Lapatinib (a FDA approved HER2 inhibitor). Cells exposed to Lapatinib 
and DUSP1 siRNA or to HER2 siRNA and a MKP1 inhibitor, sanguinarine, both resulted in a 
decreased cell viability in breast cancer cells. However, ectopic expression of DUSP1 without 
irradiation failed to add any survival benefit, suggesting a specific role of DUSP1 only in response 
to cell stress. 
 
Given these features, DUSP1 can be an attractive target for combination therapy and it is essential 
to understand its role, functions and protein interactions in the context of ovarian cancer, HOX 
targeting and response to cytotoxic agents. 
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6.2. Hypothesis and objectives 
A lack of a complete understanding of molecular mechanisms leading to apoptosis after HTL001 
treatment encouraged us to identify potential biomarkers of response to HTL001 involved in the 
programmed cell death and possible targets for combination therapy to enhance cell killing in a 
panel of immortalised ovarian cancer cell lines. Analysing transcriptional alterations of key 
regulatory genes from the intrinsic and extrinsic molecular pathways of apoptosis after HTL001 
exposure, we identified few key genes/proteins involved in the molecular pathway triggered by 
HTL001 treatment. We focused on DUSP1, as its role in response to HXR9 (or HTL001) exposure has 
not been explored before. Previous studies focused on the function of c-FOS only. 
A pharmacological inhibition with BCI, a small molecule targeting DUSP1 activity [163], was used in 
combination with HTL001 to check the effects of the molecular modulation on the sensitivity of the 
ovarian cell lines to HTL001 and to obtain further insights of the molecular mechanism of cell killing 
of the cell-penetrating peptide.  
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6.3. Results 
6.3.1. HTL001 exposure induced alterations in the transcriptional and protein 
content in ovarian cancer cell lines 
A comprehensive overview of molecular modifications that drive programmed cell death after 
exposure with HTL001 was lacking, hence the decision to explore the transcriptional alterations 
leading to cell death in a panel of ovarian cancer cell lines (PEA1, PEA2, PEO1, PEO4 and COV318). 
A complete list of genes included in the array are listed in Table 6.3-1. The rationale behind the 
choice of the genes of the array was to monitor the alterations of the apoptotic process after 
HTL001 exposure, including the mRNA expression of the most important intrinsic and extrinsic 
pathway regulators, members of the AP1 complex and stress response genes. The hypothesis was 
that a sudden cytotoxic stress in a range of two hours would have strongly activated also the mRNA 
expression of the caspase and FAS ligand family, even if they constitute a pre-existing machinery in 
the cells and they undergo post-transcriptional modifications mainly. The strong cytotoxic input 
would change the balance of the cell on a death signal rather than survival, increasing the mRNA 
levels, which would correspond to more protein level and more post-transcriptional activation in a 
cascade leading to more apoptosis. 
The timing of the experiment was set to two hours to be able to link the molecular changes 
happening in the cell with the phenotype observed in the MTS assays showed in Chapter 3. 
 
Intrinsic Extrinsic 
CASP9 TNF 
BCL2L11 (BIM, pro-apopt) FASL 
BCL2 (anti-apopt) CASP8 
BCL2L1 (BCL-XL, anti-apopt) CFLAR (CFLIP anti-apopt) 
CASP3 CASP3 
AP1 complex Stress Response 
JUN ATF3 
FOS DUSP1 
ATF2 MAPK14 (P38) 
 
MAPK8 (JNK-1) 
 
MAPK9 (JNK-2) 
 
MAPK1 (ERK-2) 
 
MAPK3 (ERK-1) 
Table 6.3-1: List of genes included in the RT2 RNA  Profiler Array. 
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In order to screen the transcriptional changes induced by the treatment of cancer cell lines 
with HTL001, a panel of genes from the intrinsic or extrinsic apoptotic pathways were 
chosen. In addition, HTL001 is a cytotoxic cancer agent capable of probably tr iggering 
metabolic stress in cells, hence the inclusion of key regulators of the MAPKs signalling 
cascade. Members of the AP1 complex and DUSP1, ATF3 were added to the array due to 
their significant gene overexpression found in previous studies of mouse melanoma B16 
cells exposed to HXR9 [67]. FasL is highlighted in red as in all arrays repetitions across cell  
lines the Ct value was over 35 or no Ct suggesting a negative output probably due to primer 
dimers or other unknown technical issues with the Qiagen array in both control and treate d 
sample. 
 
 
In red were highlighted genes with at least a 2 fold change in upregulated expression (>2), while in 
blue genes with at least a half fold change in downregulation or more (<0.5) as compared to the 
reference gene (Figure 6.3-1). Overall, more genes appeared to be upregulated rather than 
downregulated in the whole set of cell lines, with the exception of the most sensitive cell line to 
HTL001, PEA1, where a borderline fold change in favour of downregulation was seen for MAPK1 
(ERK1), MAPK3 (ERK2), MAPK9 (JNK2) and  Caspase 3. An expected downregulation in the anti-
apoptotic genes BCL-2 and BCL2L1 (BCL-XL) and an upregulation in BIM (BCL2L11) was seen in line 
with the programmed cell death induced. BIM was upregulated in PEO1 and PEO4 as well. Notably, 
c-JUN, c-FOS, ATF3, TNF-α and DUSP1 were commonly overexpressed in all cell lines to a different 
extent, poorly upregulated in the least sensitive to HTL001 cell line COV318 and highly 
overexpressed in the most sensitive PEA1. Unfortunately, FAS ligand expression could not be 
assessed due to a technical problem showing high Ct value (above 35) in the vehicle control and 
test sample, or vice versa suggesting the possibility of a null expression of the gene in a range of 
two hours which cannot be excluded.
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Figure 6.3-1: Line chart and relative table expressing genes as fold change 2( -ΔΔCT) of the 
treated group (group 1) divided by the untreated control group in a panel of ovarian cancer 
cell lines.  
In red are genes with at least a 2 fold change in upregulation (>2), whi le in blue the ones 
with a downregulation of at least a half fold change (<0.5) as compared to the internal 
reference gene EIF4A2. B2M was slightly less stable as housekeeping gene, therefore the 
normalisation was performed with EIF4A2 only. A couple of te chnical repetitions were 
included in the array for each gene plus each array contained internal controls to: 1) detect 
the presence of possible genomic contaminations HGCC (High Genomic Content Control);  
2) check the efficiency of transcription of the Taq polymerase PPC (real-time PCR 
efficiency) and 3) check the efficacy of the reverse transcription RTC (Reverse Transcription 
Control). All these controls passed a quality test using a Data Analysis Tool Software from 
Qiagen. 
 
 
In parallel to the RT2 profiler array, a quantitative qPCR was performed following the Oncology Lab 
standard protocol using the DUSP1 set of primers that I designed and c-FOS primers in the PEA 
series of cell lines after treatment for 2 hours with a concentration of HTL001 around their IC50  
(Figure 6.3-2). Results were expressed as fold change 2^ (- ΔΔCT) which is the normalized gene 
expression 2^(- ΔCT) in the treated group divided the normalized gene expression 2^(- ΔCT) in the 
untreated sample.  The upregulation seen in PEA1 and PEA2 validated the overexpression observed 
in the RT2 profiler array where a different methodology was performed and a different set of 
primers against DUSP1 and c-FOS were probed on the array. Again, the transcriptional changes 
induced after HTL001 exposure appeared more prominent in the most sensitive cell line PEA1 for 
both DUSP1 and c-FOS. 
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In order to validate the findings at the transcriptional level, a quantification of the protein content 
after HTL001 exposure was conducted in a couple of ovarian cancer cell lines (Figure 6.3-5). PEA1 
and PEA2 were incubated with HTL001 in the same way as performed for the transcriptional 
profiling and their lysate extracted before immunoblotting. As expected an increased amount of c-
FOS, ATF3 and phospho-DUSP1 was observed in both cell lines, in particular for PEA2, despite their 
transcriptional changes were suggesting an inverted outcome. The fold changes of c-FOS, ATF3 and 
DUSP1 were in fact more evident for PEA1. A phosphorylated version of DUSP1 was chosen as 
DUSP1 is more stable and its ubiquitination prevented when the protein is phosphorylated by ERK 
family kinases [164]. The overload amount of protein content in PEA1 and PEA2 untreated controls 
(Figure 6.3-5, lane 1 and 5 in GAPDH) was not affecting the validity of the results as the target 
genes c-FOS, ATF3 and DUSP1 were expressed at very low level in the untreated cells. 
 
 
 
Figure 6.3-2: Quantitative qPCR of DUSP1  and c-FOS  in the PEA series of cell l ines  
expressed as fold change between control and treated group . 
Cells were treated for 2 hours with HTL001  at a concentration around their IC 5 0  and their  
RNA extracted. Results  were expressed as fold change 2^( - ΔΔCT)  which is the normalized 
gene expression 2^(- ΔCT)) in the treated group divided the normalized gene expression 
2^(- ΔCT)  in the untreated sample.  
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6.3.2. BCI, an allosteric small molecule inhibitor of DUSP1 effectively inhibited 
DUSP1 related functions 
Out of the three candidate upregulated genes (or proteins) c-FOS, ATF3 and DUSP1, we focused on 
DUSP1 as its role in modulating HTL001 response was never unravelled before and, in addition, we 
could obtain a pharmacological called BCI (NSC 150117, 2-benzylidene-3-(cyclohexylamino)-2, 3-
dihydro-1H-inden-1-one) in order to get some insights into its biological function. 
Preliminary experiments aimed at optimising a maximal working concentration and an exposure 
time of BCI that were modulating the downstream molecular pathways involved, but they were not 
affecting the cell viability in a panel of ovarian cancer cell lines PEA1, PEA2 and COV318. A metabolic 
MTS assay was used for the purpose. Cells were treated for 1, 2 or 4 hours and screened for a range 
of concentrations of BCI from 100nM to 100μM as shown in Figure 6.3-3. Pioneering assays were 
performed in a range from 10 - 100μM in PEA1 and PEA2 at different times points (data not shown), 
but as a complete viability was not achieved, the concentration was then further diluted to a range 
0.1 - 10μM. 2 hours was set as exposure time, hence the working concentration for COV318 was 
later screened for 2 hours only. Finally, a concentration of 10μM was used for COV318 and PEA1. 
PEA2 was demonstrated to be more susceptible to the BCI treatment, therefore half of its 
concentration was used for subsequent assays. 
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Cells were seeded in a 96 well plate and incubated O.N before adding different 
concentrations of BCI at various time  points to identify the optimal concentration and 
exposure that did not induced any signs of cytotoxicity, but modulating the molecular 
pathways only in ovarian cancer cell l ines. An MTS assay was used to monitor cell  viability. 
Error bars represents SD calculated from two independent experiments.  
 
 
To prove the ability of BCI to effectively target DUSP1 and modulate molecular pathways I 
conducted immunoblotting (Figure 6.3-4). Ovarian cancer cell lines PEA1 and PEA2 were treated 
for 2 hours with the working concentrations identified via the MTS assay. DUSP1 is a phosphatase 
that can de-phosphorylate ERK1/2, or p38, or JNK1/2 according to cellular type and stress status of 
the cells. In the presence of a DUSP1 allosteric molecule as BCI, that functionally inhibits the 
enzyme, a greater phosphorylation of its targets was expected. The results demonstrated a 
successful DUSP1 inhibition as confirmed by the increased phosphorylation via p38 and JNK1 and 
JNK2 in the BCI treated cells (lanes 2, 4, 6 and 8). However ERKs remained unchanged. Besides, 
DUSP1 inhibition was more prominent in the PEA2 cell line as shown with the higher phospho-p38 
and phospho-JNK1/2 (lanes 4 and 8), despite the fact that the concentration of BCI was half of the 
one used for PEA1. Phospho-JNK2 was not or slightly altered after BCI treatment in PEA1 (lanes 2 
Figure 6.3-3: BCI concentration and exposure time optimisation.  
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and 6).  DUSP1 quantity and phosphorylation status was unchanged as well (not shown) and 
confirmed the selectivity to targets of BCI and the reported role of inhibiting only DUSP1 function, 
but not its protein content. 
 
 
 
Figure 6.3-4: Immunoblotting of PEA series cells treated with DUSP1 inhibitor BCI.  
Cells were treated for 2 hours with BCI at worki ng concentrations identified via the 
metabolic MTS assay (10μM and 5μM for PEA1 and PEA2 respectively), their lysate 
prepared and loaded equally for immunoblotting. Membrane was probed and stripped for 
subsequent re-probing for phosphorylated protein conte nt of JNK1 and JNK2 (p54 and p46), 
p38, ERK1 and ERK2 (p44 and p42). GAPDH was included as loading control. Lanes 1, 3, 5 
and 7 untreated samples; lanes 2, 4, 6 and 8 BCI treated samples. Results show two 
biological repetitions blotted on the same membrane . 
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Figure 6.3-5: Protein content analysis after HTL001 treatment in the PEA series of cell lines.  
Cells were treated for 2 hours with HTL001 at a concentration around their IC 5 0  and their  
lysate obtained and loaded for immunoblotting. Membrane was probed and stripped for 
subsequent re-probing for ATF3, c -FOS and phospho-DUSP1. GAPDH was included as 
loading control. Lanes 1, 3, 5 and 7 untreated samples; lanes 2, 4, 6 and 8 HTL001 treated 
samples. Results show two biological repetitions blotted on the same membrane.  
 
 
6.3.3. Pharmacological inhibition of DUSP1 increased the sensitivity of ovarian 
cancer cell lines to HTL001 
Having established the dose of BCI in ovarian cancer cell lines and its efficacy in inhibiting DUSP1 
(as demonstrated by increased phosphorylation and activity of MAPKs, p38 and JNKs), the DUSP1 
pharmacological inhibition was used in combination with HTL001. The rationale behind it was first 
to confirm whether DUSP1 and related targets MAPKs were responsible for contributing to the 
molecular signalling pathway leading to apoptosis induced by HTL001 and secondly to demonstrate 
the negative feedback regulation of DUSP1 on this molecular cascade. 
 
Cells incubated with BCI only were added as well to monitor the effect of the small molecule on 
cells viability and a percentage of survival more than 96% was achieved for all cell lines (data not 
shown). Results were plotted as percentage of survival normalised against the untreated samples 
versus different concentrations of HTL001 and the relative regression curves of HTL001 (blue) or 
the combined treatment BCI+HTL001 (red) were illustrated (Figure 6.3-6). As it is shown on the 
graphs, the most sensitive cell line PEA1 treated with HTL001 failed to gain any benefit from the 
pre-exposure to BCI (Figure 6.3-6-a), however for both PEA2 and COV318 cell lines (Figure 
6.3-6-b/c) the pre-treatment was beneficial and showed a statistically significant difference. The 
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difference in the two dose-response curves was even more marked for the traditionally less 
susceptible cell line to HTL001, COV318. Table 6.3-2 below summarised the IC50 obtained: 
 
 
Cell line HTL001  BCI + HTL001 
PEA1 13.11 13.59 
PEA2 24.76 19.98 
COV318 65.32 47.22 
Table 6.3-2: IC5 0  of the commercial cell l ines exposed to HTL001 only or a combinati on of 
BCI and HTL001.  
The IC5 0 was calculated with GraphPad Prism version 7.03. Data set for curve fit and 
calculations are the results from MTS assays and expressed in μM.  
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Cells were seeded at 10000 cells/well in a 96 well plate and incubated O.N. Appropriate μM concentrations of B CI (10μM and 5μM for PEA1 , 
COV318 and PEA2 respectively) were then diluted in fresh growth media and applied to cells for 2 hours before washing and exposing them for 
further 2 hours to different concentrations of HTL001 (5 μM-100μM  range). End point of the experiment was an MTS assay to monitor cell  
viability. MTS reagent was diluted 1:10 in reduced serum RPMI (2%FBS) and incubated with cells for 2 - 3hrs before reading at 490nm on a plate 
reader Varioskan Flash (Thermo Scientific) . Blue and red lines are the curve fit of the data sets interpolated with GraphPad software. Errors bars 
represent SD calculated on three biological repetitions. HT = HTL001, BCI = DUSP1 inhibitor.
Figure 6.3-6: MTS assay of cell l ines PEA1, PEA2 and COV318 treated with HTL001 only or a combination of BCI and HTL001.  
202 
 
I have subsequently validated the results using Annexin V/7AAD on ovarian cancer cells exposed to 
HTL001 alone or in combination with BCI and confirmed that the cells died through apoptosis. The 
representative results in Figure 6.3-8 recapitulated the MTS assay findings: ovarian cancer cells 
treated with BCI alone were not affected in terms of cell viability. In contrast, the DUSP1 inhibitor 
BCI without creating any cytotoxicity, successfully modulated the response to HTL001, as observed 
by the increased percentage of cell death in the combination therapy as compared to cells treated 
with HTL001 only. The PEA1 cell line did not benefit from this combination, but a 30% and a 23% 
increase in cell death was achieved for PEA2 and COV318 respectively. In the summary bar chart of 
Annexin V assay results evaluated by flow cytometry from two independent biological repetitions 
(Figure 6.3-7), a statistical significant difference was not achieved when treating with a 
combination of BCI and HTL001 in all the cell lines tested, perhaps due to the high experimental 
variability and the number of repetitions limited to two. However, higher concentration of HTL001 
in combination with the same concentration of BCI showed a statistically significant difference 
(p=0.03) calculated with a t-test in the COV318 cells. 
 
 
 
Figure 6.3-7: Summary bar chart of Annexin V staining of ovarian cancer cell l ines treated 
with combination therapy.  
Cells were pre-treated with BCI for 2 hours (10μM for PEA1, COV318 and 5μM for PEA2) 
and exposed to 25μM of HTL001 . For COV318, a second higher concentration (50μM) was 
used as its proven stronger resistance to HTL001 . Results were expressed as percentage of 
double positive cells to Annexin V and 7AAD staining. Error bars indicate SD calculated 
from two independent repetitions. A t -test was used for statistical analysis. CNTL = 
untreated control T = HTL001, BCI = DUSP1 inhibitor.
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Cells were seeded in a 6 well plate and incubated O.N. Appropriate μM concentrations of BCI (10μM for PEA1, COV318 and 5μM for PEA2) 
were then diluted in fresh growth media and applied to cells for 2 hours before washing and exposing them for a further 2 hours to different 
concentrations of HTL001 (25μM for PEA1 and PEA2 and 50μM for COV318) before the end point Annexin V/7AAD staining. Reading by flow 
cytometry occurred within 24hrs. Each FACS plot shows 10000 events from one representative test.
Figure 6.3-8: Annexin V/7AAD staining of OC cell lines aft er treatment with combination therapy evaluated by flow cytometry.  
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6.4. Discussion 
In Chapter 6, the molecular mechanisms of HTL001 leading to a programmed cell death were 
explored. Identifying molecular regulators after drug treatment is a general approach in drug 
discovery to create the possibility of recognising biomarkers of response of a certain class of drugs 
and therefore to better stratify patients that will receive that compound or it is a strategy to target 
other elements of the signalling cascade for combination therapy using two or more anti-cancer 
agents with different mechanisms of action. 
First, an attempt to unravel the key players of the apoptotic cascade was made and to discover 
whether they were belonging to the intrinsic or extrinsic pathway or a combination of the two. 
HTL001 is an anti-cancer agent and a stress response should be expected in cells exposed to the 
drug, therefore kinases involved in the MAPK network (JNK1/2, p38 and ERK1/2) were considered 
as well as members of the AP1 complex. The AP1 complex is a dimer of enzymes with leucine motifs 
capable of DNA binding and activation of several gene targets according to cellular context and 
type of signal (cytokines, ligands) or insults (UV, inflammation, cytotoxic compounds) received by 
the cells. Transcription factors of the AP1 complex are members of JUN, FOS or ATF family and 
within the variety of functions that this complex can control, one is mediating apoptosis operating 
as a bridge between MAPKs signalling cascade and transcriptional activation of pro-apoptotic genes 
(for further details refer to Section 6.1.2). In addition bearing in mind that the caspases and FAS 
ligand families constitute a pre-existing machinery in the cells and they mainly undergo post-
transcriptional modifications, the hypothesis was that a sudden cytotoxic stress in a range of two 
hours would have strongly activated their the mRNA expression. The strong cytotoxic input would 
have changed the balance of the cell moving towards a death signal rather than survival 
orchestrated increasing the mRNA levels, which would then correspond to more protein level and 
more post-transcriptional activation in a cascade leading to more apoptosis. There are evidences 
from the literature, reviewed elegantly by Kumar and Cakouros [165] that even caspases and 
members of the FAS family could be transcriptionally modulated in some circumstances. For 
example it has been shown that caspase 8 is transcriptionally induced in some cases as its promoter 
contains a p53-responsive element. In cells lacking p53, E2F-1 can induce apoptosis through the 
transcription of p73, which belonging to the same p53 family shares some of its targets (Apaf-1 and 
BAX). Other groups indeed reported that loss of Retinoblastoma (RB) or forced E2F-1 expression 
results in direct transcriptional upregulation of several caspases. 
 
Transcriptional changes induced by the treatment of HTL001 in ovarian cancer cell lines were 
screened with a RT2 profiler array in a panel of 19 genes taken from the regulatory pathways 
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described above (Table 6.3-1).The timing of the experiment was set to two hours to be able to 
link the molecular changes happening in the cell after HTL001 exposure with the phenotype 
observed in the MTS assays showed in Chapter 3. Timing is certainly an essential parameter for this 
experimental design and definitely a limitation of this array is that the final output was a picture of 
the transcriptional changes occurring in the “surviving cells” in a relatively short time. More likely, 
having included several longer time points in the experiment and lower concentrations of HTL001 
would have given enough time for the expression of non- early response genes to fully understand 
the process. 
 
The explanation for such a downregulation in Caspase 3 was not clear, as the apoptotic process 
starts (Figure 6.3-1), but the downregulation seen in the ERKs family could be explained by a stop 
in the survival pathways promoted by ERK signalling and the activation of pro-apoptotic signalling 
driven by JNK1 in PEA1. Downregulated genes were also the anti-apoptotic genes BCL-2 and BCL2L1 
(BCL-XL) in line with the programmed cell death induced by HTL001. Among the upregulated genes 
were c-JUN, c-FOS, ATF3, TNF-α and DUSP1, commonly overexpressed in all cell lines and correlated 
to the intensity of differential transcriptional alterations and HTL001 sensitivity: high fold gene 
expression changes in PEA1 correlated to high sensitivity to HTL001, vice versa for COV318. The 
results recapitulated the previous findings of Morgan and colleagues in melanoma B16 cells [67] 
and in non-small-cell lung cancer cell line A549 [146], where upregulated genes after 2 hours 
treatment with HXR9 were Dusp1, Atf3 followed by c-Jun and c-Fos for mouse melanoma B16 and 
c-FOS and FOSB and EGR1 for lung cancer A549, screened by probing total RNA on whole genome 
arrays. 
Genes such as c-FOS, c-JUN, DUSP1 and ATF3 upregulated in ovarian cancer cells studied in this 
project and EGR1 for non-small-cell lung cancer cells belong to a family of immediate early response 
genes, whose expression is transient and immediate after cells insult to stress, generally in the 
setting of allergy and inflammation (reviewed in [166, 167]). An analogy to the inflammatory 
models can be made with ovarian cancer cells treated with HTL001, suggested also by the evidence 
of the TNF-α increase in the cell lines tested. TNF-α was in fact upregulated in response to HTL001 
in PEO series and PEA2 and very close to threshold in PEA1 (1.70 versus 2 set as threshold). The 
“TNF paradox” has been extensively explored in the literature [168]: according to cellular context, 
TNF is involved in proliferation and survival or inflammation and cell death. Pioneering studies in 
inflammation in immune cells characterised the signalling network of TNF and its ability to act as a 
“double sword”: in a simplified version, TNF can both mediate a gene transcription of NFkB for 
survival or for inflammation/cell death through the activation of the MAPKs via complex I (Figure 
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6.4-1). Moreover, FADD is the adaptor protein that can activate complex II in response to TNF, as 
well as, mediate death ligands FasL and TRAIL extrinsic apoptotic pathway signalling (for details see 
apoptosis overview Section 6.1.1). Unfortunately, FAS ligand expression could not be assessed due 
to a technical problem showing high Ct value (above 35) in the vehicle control and test sample, or 
vice versa suggesting the possibility of a null expression of the gene in a range of two hours which 
cannot be excluded. However, FasL shares 15-25% of homology with TNF as they belongs to the 
same TNF superfamily. It could be speculated an enrolment of the apoptotic extrinsic pathways in 
response to HTL001 treatment via a FasL/TNF signalling network, as well as, a simultaneous 
activation of gene transcription for acute stress response and apoptosis/necrosis via MAPKs. 
Finally, BIM (BCL2L11) was another pro-apoptosis key player upregulated in the RT2 profiler in PEA1 
cells as well as cells from the PEO series. Its overexpression could be perhaps explained due to a 
cross talk between the intrinsic and extrinsic apoptosis pathways operated by BID, due to a 
sustained and persistent stress response resulting in apoptosis. 
 
 
TNF superfamily comprise a large group of ligands, including TRAIL, FasL and TFN. TRAIL 
and FasL are known as death ligands, due to their ability to bind their associated death 
receptors and induce apoptosis. Upon binding of FasL/TRAIL, adaptor protein FADD forms 
a complex with pro-caspase 8, called DISC that cleaves caspase 8 into an active version 
leading to cell death via the extrinsic signalling pathway. TNF has a dual function and  acts 
as a scale between survival an d inflammation/cell death. After TNF binding, TNF receptor 
1 (TNF-R1) present on all  nucleated cells, is able to assemble two complexes: main acto rs 
Figure 6.4-1: TNF superfamily signalling network in inflammation and apoptosis/necrosis.  
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of complex I are TRADD able to recruit  TRAFs that in turns activate the MAPKs signalling 
pathways for transcriptional expression of genes related to inflammation and 
apoptosis/necrosis. RIP1 interacts with FADD to create complex II and start s the extrinsic 
apoptosis. Image taken from [169], open access under Creative Commons Licence.  
 
 
The upregulation seen for ATF3, c-FOS and DUSP1 at transcriptional level was validated at 
translation level (Figure 6.3-5). Despite PEA1 showing the highest fold changes in the 
overexpression of these genes, a greater ATF3 and DUSP1 protein concentration was observed in 
PEA2. c-FOS upregulation appeared constant across repetitions and typology of cell line. The data 
are an indication of a differential translation and post-transcriptional modifications occurring in the 
paired cell lines. 
 
After having confirmed ATF3, c-FOS and DUSP1 as reliable biomarkers upregulated in response to 
HTL001, the rest of the chapter focused on understanding the role of DUSP1 in response to HTL001 
treatment. Modulating the protein function to get further insights into the mechanism of action 
leading to apoptosis of HTL001 and, at the same time, identifying a possible attractive target for 
combinational therapy was the final purpose of the second part of the chapter. 
The role of DUSP1 in mediating HTL001 cell death was never explored before; previous work 
focused on c-FOS in quality of c-JUN binding partner and member of the AP1 transcriptional 
complex for activation of pro-apoptotic genes. For example, downregulation of c-FOS protein 
expression correlated with a partial rescue from apoptosis in melanoma cells suggesting c-FOS 
contribution in promoting apoptosis [67, 95]. DUSP1 is protein phosphatase that de-
phosphorylates precise members of the MAPKs family according to cell type and type of insult 
received by the cell. The choice of targeting a regulatory protein with a well-defined function, such 
as DUSP1, it would have let us to easier understand its biological modulation in the HTL001 
signalling, rather than targeting transcription factors as ATF3 and c-FOS that activate a consistent 
number of downstream genes and relative functions still completely not well characterised. There 
is also evidence from literature (already summarised in Section 6.1.3) that DUSP1 upregulation 
could be responsible for resistance of tumours to chemotherapy, radiotherapy and cytotoxic 
compounds, acting as a negative regulator of stress response and apoptosis signalling driven by 
MAPKs family. The hypothesis that DUSP1 overexpression was an intrinsic regulatory mechanism 
for protecting cancer cells from cell death in HTL001 treated cells, led us to inhibit DUSP1 function. 
We aimed then to confirm the negative feedback loop of DUSP1 on MAPKs signalling and therefore 
to re-sensitise ovarian cancer cell lines to HTL001 induced apoptosis. Given the availability of BCI 
[163], an allosteric inhibitor of DUSP1, an investigation of its selective inhibition in combination 
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with HTL001 and modulation of the molecular pathway was possible. Small molecules are also more 
attractive from a clinical point of view, therefore the approach of a chemical inhibition rather than 
a traditional knock down.  
 
The concentration of DUSP1 inhibitor (BCI) was optimised to avoid any signs of cytotoxicity (Figure 
6.3-3) and with the only purpose of modulating DUSP1 function and related MAPKs activity 
(Figure 6.3-4). Shutting down DUSP1 function of MAPKs de-phosphorylation led to an increased 
phosphorylation of its preferential targets p38 and JNK1 and JNK2, but it did not affect ERKs, 
indicating apoptosis via p38 and JNKs. It is noteworthy to mention that DUSP6 is another target of 
BCI inhibition with preferential ERKs targeting [163, 170], but the results here demonstrated ERKs 
phosphorylation status was not relevant with DUSPs activities. When using combination therapy of 
BCI followed by HTL001, a beneficial increase in the percentage of dying cells was achieved for PEA2 
and COV318, with statistically significant differences. However, no such increase in cell death was 
obtained from the PEA1 cell line following DUSP1 inhibition in combination with HTL001 as 
quantified by viability assays (Figure 6.3-6) and apoptosis assays (Figure 6.3-7 and Figure 
6.3-8). An explanation to this differential sensitivity to DUSP1 inhibition could rely on the diverse 
DUSP1 content observed in the two cell lines with a higher protein concentration in PEA2 (Figure 
6.3-5). 
A mechanism that could give insight to this differential sensitivity is the control of ERKs on DUSP1 
activity: DUSP1 phosphorylation at Ser359 and Ser364 operated by ERKs increase the protein half-
life, but does not affect its function [164]. It can be speculated that EKRs contribute to stabilise 
DUSP1 protein and avoid its degradation in PEA2 and COV318 cell lines. Therefore, one can expect 
that the more DUSP1 is expressed in the cell, the more the protein inhibition is efficacious. 
An evidence that supports the above statement is that DUSP1 inhibition in PEA2 was more efficient 
as confirmed by an enlarged activity of p38 and JNK1 and JNK2 indicated by a higher 
phosphorylated protein level. JNK2 phosphorylation in PEA1 was not even affected (Figure 6.3-4). 
 
To combine the findings of this chapter and evidence from the literature a provisional schematic 
signalling pathway for HTL001 was proposed (Figure 6.4-2). After treating ovarian cancer cell lines 
with HTL001 and blocking selective HOX/PBX interaction, a sustained stress response resulting in 
apoptosis is then triggered more likely through an activation either of the TNF signalling or the 
death ligands FasL/TRAIL and their relative receptors. TNF superfamily members share the 
molecular pathway that lead to the cleavage of pro-caspase 8 via complex II and activation of the 
extrinsic apoptotic pathway (Figure 6.4-2 - 1). In addition, TNF can also auto-amplify its pro-
apoptotic signal via gene regulation, including the upregulation of c-FOS, c-JUN, ATF3 and DUSP1 
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(Figure 6.4-2 - 2). Their activation is mediated by members of the MAPKs, in particular JNKs are 
responsible for c-JUN, while ERKs for c-FOS transcription. Translated c-FOS and c-JUN form the AP1 
complex to, in turn, regulate gene transcription of several TF and TNF (Figure 6.4-2 - 3). DUSP1 
controls the pro-apoptotic signal with a negative feedback loop, promoting the de-phosphorylation 
and in turn de-activation of p38 and JNKs (Figure 6.4-2 - 4). Pre-treating ovarian cancer cells with 
a DUSP1 inhibitor such as BCI, the inner intrinsic cell resistance driven by DUSP1 was removed and 
the apoptotic effects of HTL001 via MAPKs were enhanced. 
 
 
 
Figure 6.4-2: Schematic diagram of the proposed HTL001 signalling network leading to 
apoptosis and BCI inhibition on DUSP1.  
A detailed description of the mechanism of action can be found in the text. TF = 
transcription factors, TNFR = tumour necrosis factor receptor, FasLR = Fas ligand receptor.  
 
 
An analogue signalling network supporting the hypothesis was found in the work from Guo et al. 
[171] in rat mesangial cells. Cells treated with soluble TNF‐α strongly induced the mRNA expression 
and de novo protein synthesis of DUSP1. However, when pre-treating the cells with Ro318220, a 
DUSP1 inhibitor, the expression of DUSP1 was suppressed. Moreover, the inhibition of DUSP1 with 
Ro318220 caused an immediate sustained activation of JNK and ERK. Protein content of c-FOS and 
c-JUN was also increased after TNF‐α exposure. 
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It was not explored in our model how DUSP1 promoter was regulated in cells exposed to HTL001, 
but there is evidence from the literature that DUSP1 transcription is initiated by CREB due possibly 
to the presence of a cAMP responsive element (CRE) on the promoter. Kang et al. [161] in fact 
discovered that HeyA8 and SKOV3ip1 ovarian cancer cells treated with norepinephrine were 
upregulating DUSP1 mRNA expression. However, when cells were pre-treated with a CREB siRNA, 
DUSP1 expression showed a significant decrease, suggesting a control operated by CREB. Denkert 
et al. [155] demonstrated that DUSP1 mRNA was also inducible by the exposure of SKOV‐3 and 
OVCAR‐3 ovarian cancer cells to TNF‐α, but not by the stimulation with the phorbol ester TPA. TPA 
is a strong inducer of TRE (TPA responsive elements), therefore the findings were an indirect 
confirmation of Kang and colleagues results suggesting the presence of a CRE regulation on DUSP1 
promoter. 
 
6.4.1. Concluding remarks 
The data presented here and the vast amount of literature show a DUSP1 negative role in regulating 
MAPKs signalling and TNF driven apoptosis, therefore this phosphatase can be an attractive target 
for combination therapy in ovarian cancer. Its transcriptional and protein upregulation observed 
after incubation with HTL001, but also with common therapeutic as cisplatin [157, 172], paclitaxel 
[158, 161], gemcitabine [159] and novel therapeutics as Lapatinib [162] is an indication of an 
intrinsic protection to anti-cancer drugs. Understanding DUSP1 regulation and its close signalling 
network might give further insights to the mechanism of resistance operated by cancer cells and in 
a bigger picture, opens to a new clinical management of resistant and refractory ovarian cancer 
patients. It is noteworthy to mention that PEA1 and PEA2 cell lines used in this chapter are paired 
cell lines isolated from the same patient with poorly differentiated adenocarcinoma. PEA1 is a cell 
line established from peritoneal effusion prior to treatment with cisplatin and prednimustine 
(naïve), while PEA2 was collected on relapse. The diverse sensitivity to DUSP1 inhibition in the two 
cells and in particular in the cisplatin resistant cell line PEA2, could suggest intrinsic mechanisms of 
resistance developed in the relapsed patient that rely on DUSP1 and should be attention of further 
analysis. 
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CHAPTER 7 
 
7. General discussion 
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7.1. HOX genes as a target for therapy 
Despite the advantages achieved over the past years in the treatment of ovarian cancer, there is 
still an unmet need to identify new biomarkers for targeted therapies or as a prognostic markers. 
Successful stories as for example Bevacizumab or PARPi, approved by the FDA for the treatment of 
certain type of cancer, including ovarian carcinoma, often incur in mechanism of resistance with 
the progression of the disease. Lots of research at the moment is spent to understand how to 
overcome mechanism of resistance to PARPi as well as platinum resistance that occurs for 70% of 
the patients [173]. The identification of new therapeutic vulnerabilities is necessary for the 
treatment of ovarian cancer patients in the relapse setting. 
HOX genes are a group of transcription factors, the homeobox, generally expressed during 
development and silent in adulthood, playing a pivotal role in the embryo patterning. A set of 39 
genes in the mammals, with redundant functions, are tightly regulated in a spatial and temporal 
manner. There is a well-documented evidence of their re-activation in the context of cancer, 
including prostate, colorectal, breast and ovarian carcinoma to name few associated with 
documented oncogenic functions of proliferation, invasion, programmed cell death and DNA 
repair. 
As described in the Introduction, HOX gene represents an ideal target for drug discovery given their 
essential characteristics that a good therapeutic target should demonstrate including: 1) selective 
expression to pathologic tissue; 2) oncogenic functions and 3) the possibility to be additionally a 
valid prognostic marker for drug sensitivity. However, several limitations of the use of HOX genes 
have been addressed in this thesis and a new direction of future research for the HOX superfamily 
has been proposed in Section 1.7.4.  
The contribution of HOX genes during embryonic development is well documented, however only 
hints of their role as transcription factors during oncogenesis has been reported. Very little is in 
fact know about the interactome and signalling network of HOX genes and further research should 
move in this direction. Acting as transcription factors, HOX genes controls the regulation of several 
unknown downstream genes. Comprehensive analysis with the aid of advanced technologies such 
as chromatin immunoprecipitation studies (i.e. RIME) will help to map the HOX network. For 
example, the use of HXR9 as a net inhibitor of HOX-PBX interaction and a global exploration with 
RIME on and off treatment with HXR9 on cancer cells will help to 1) understand the chromatin 
binding site of HOX genes, 2) detect the top hits of genes possibly regulated by HOX and 3) identify 
possible players of the mechanism leading to apoptosis from the screen in the HXR9-treated cancer 
cells. Nevertheless, understanding not only what HOX genes control, but how HOX family is 
regulated is vital to open to new therapeutic strategies. Epigenetic modifications and miRNAs 
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modulate HOXs expression in a temporal and spatial manner and with some evidences that they 
are conserving the same mechanisms used during embryo development. Resolving how this HOX 
genes silencing or switch on happens in cancer cells could suggest indications on the use of 
epigenetic-modifying agents such as DNA methyltransferase (DNMT) and histone deacetylase 
(HDAC) inhibitors. 
7.2 HTL001, the next step in improving HXR9 
One of the most promising and the only reported up to now strategy for a net HOX inhibition is 
certainly HXR9, developed by Morgan and colleagues [67]. HXR9 is an 18 aminoacids peptide 
equipped with a poly-arginine for cell entry and a binding motifs mimicking the conserved YPWM 
hexapeptide across HOX paralogues for binding their co-factor PBX. The competitive inhibition of 
HOX-PBX interaction lead to apoptosis in cells overexpressing HOX genes (Chapter 0). HXR9 had 
been extensively tested in immortalised cell lines derived from a variety of carcinomas, including 
ovarian, breast, prostate and melanoma in vitro and in commercial ovarian cancer cells (SKOV3) 
injected in flank tumours in vivo, demonstrating tumour growth reduction [67-70]. 
In the present work, the HOX-PBX inhibition was further explored using an improved version of 
HXR9 designed by Prof R. Morgan. The new peptide HTL001, thanks to a few aminoacids changes, 
we hypothesised should have maintained the same mechanism of inhibition, but should have 
improved potency and pharmacological profile and a prediction of its potency would have been 
possible reading the HOX profiling. In Chapter 3, HTL001 was tested in parallel with HXR9 to assess 
its new behaviour on cancer cells. The results showed an overall improvement, but not significantly 
difference in its killing ability as compared to its counterpart HXR9 and proved in ovarian cancer 
cell lines and in primary cultures derived from ascites and tissue. The results also demonstrated 
that the mode of death of HTL001 that could still be considered a late apoptosis/necrosis. However, 
an MTS assay that measures mainly cell metabolism and an Annexin V assay have answered only 
partially to the question of the improved potency of HTL001 over HXR9. The mechanism of action 
of the two peptides as HOX target binding and disruption of HOX/PBX interaction were not really 
tested, so it is difficult to compare whether the peptides are really acting differently. The present 
work highlights the necessity to perform some reporter gene assays or immunoprecipitation 
studies to re-confirm the result found by Morgan et al. in their research on HOX-PBX disruption in 
melanoma [67]. It is important is fact to identify also possible off-targets binding of HTL001 and 
mechanistically link the phenotype observed in the cytotoxic assays to a genotype. 
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A linear Parson correlation for cell lines (PEA2, PEO4 and COV318) when blotting HTL001 IC50 and 
the mean of HOX paralogues 1 - 9 expression was found that could be predictive of drug sensitivity, 
but it cannot be applied to PEA1 and PEO1. An explanation behind this differential sensitivity to 
HTL001, maybe need to be found not looking at the HOX expression, but rather for the most 
common altered genes in OC to gain some insights from a mutational status analysis perspective. 
For example, PEO1 has a missense mutation for BRCA2 that is silent in its counterpart PEO4 and 
the loss of an effective DNA repair system component should sensitise the cells to the cytotoxic 
effect of HTL001 due to the accumulations of DNA damage. Other examples are reported in details 
in Section 3.4. Looking at the mutational status of the panel of ovarian cancer cell of this thesis to 
be able to link to the observed phenotype after HTL001 treatment, it is a new perspective suggested 
here for the first time. 
7.3 An innovative experimental model 
New experimental models to test therapeutic drugs that can predict the response of an individual 
patient to a single agent are still required due to the limitations of the current 2D and 3D models 
as summarised in Paragraph 4.1.1. We hypothesised that the use of a 3D model would provide 
better insights of drugs efficacy and guidance for a personalised medicine. Moreover, the promising 
results of HTL001 in vitro, set the basis for a rationale to trial the therapeutic peptide moving from 
monolayers of cells in culture (2D) to complete tri-dimensional platforms (Chapter 4).  The precision 
cut tissue slices model, in fact, uses tissue biopsy removed after surgery, maintaining tissue 
architecture and heterogeneity and it has the advantage of an ex vivo culture capable of 
recapitulating a clinical scenario. The organotypic model has been fairly used in the scientific 
community since the use of the Krumdieck chopper to prepare tissue slices, but the introduction 
of the Leica Vibratome greatly enhanced the viability of the precision cut tissue slices [123].  
The novelty in the present thesis was first the use of the organotypic model in the context of ovarian 
carcinoma and then the optimisation of the model. Only few articles have been published about 
preparing ovarian cancer tissue slices as a platform for drug testing and even less of them included 
the testing of a new target therapy with a comprehensive scoring system. Most of them focused 
on testing conventional chemotherapeutic with only a visual assessment via 
immunohistochemistry. To optimise the organotypic model first several parameters were 
systematically changed to understand behaviour and limitations of the ovarian carcinoma tissue 
slices in culture, then the culturing condition were changed with the publication from the work of 
Davies and colleagues [98]. The inclusion of their guidelines in the present work it is again 
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something limited to few studies and in their work the authors stressed on the importance to follow 
their recommended culturing condition to avoid to alter molecular pathways in the tissue slices 
only with the act of culturing. 
We demonstrated in this work how the organotypic culture can preserve viability up to less than 
one week and quantified it using a combination of marker for proliferation (Ki67) and apoptosis 
(cleaved caspase 3). The work provided a reliable platform for drug testing of common chemo-
therapeutics and novel compounds, such as cisplatin and HTL001. One of the limitation to bear in 
mind of the present platform is, however, the drug testing of therapeutics whose range of action 
is clinically incompatible with the timing of the organotypic culture. For example treatment with 
PARP inhibitors in vitro runs for a two week time frame to allow the accumulation of deleterious 
mutations over time, which would not find a correspondent testing on the precision cut tissue 
slices. Another limitation (or advantage in some cases for certain drug) is the lack of testing of 
systemic distribution of a therapeutic agent as precision cut tissue slices lack of an active blood or 
lymphatic circulation and immune system.  
7.4 Optimising HTL001 delivery 
Cisplatin demonstrated a variable cytotoxic activity on tissue slices that resembles also what can 
be seen in a clinical setting, in particular remembering that most of the cases presented were an 
aggressive type of OC and in high grade stage (HGS - III/IV). Moreover, most of the sample were 
also taken after heavy chemotherapy treatment pre-surgery that could have altered the original 
viability of the tumour, partly explaining the limited viability to less than one week observed in the 
tumour slices. 
Testing HTL001 on precision cut tissue slice was a lot more complex than testing cytotoxic drugs 
such as cisplatin. HTL001 revealed some limitations that still need to be solved. It is likely that this 
problem was related to several factors and one we could speculate being the untargeted 
mechanism of cell entry of the poly-arginine tail on the ovarian tissue slices. HTL001 might have 
been trapped by the thick connective tissue of non-tumour cells, preventing HTL001 action on 
cancer cells, as well as, by proteins present in the serum used as a supplement for growth media. 
There is a report from Kosuge et al. [174] that demonstrated a reduced cytosolic diffusion and the 
confinement to dot organisations when incubating poly-arginine peptides in media containing 
serum in HeLa cell line.  
The results in the present thesis highlighted the limit of a drug delivery relying on a poly-arginine 
strategy and future work should explore new strategies for HTL001 delivery. New modalities of 
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drug delivery could be combing HTL001 with localised ultrasound, for example. Focused ultrasound 
demonstrated to increase the uptake of therapeutic drugs at target tissue with minimal effects on 
its viability [175]. Other compounds such as the Pyrenebutyrate (PyB) were proven to increase the 
concentration of a poly-arginine peptide (R8) conjugated to a fluorescent dye on giant uni-lamellar 
vesicles. The concentration increase was correlating to a linear intensification of membrane 
interactions for cell entry. PyB proved also to enhance membrane fluidity to facilitate the peptide 
cellular entry [176]. Nevertheless, a new compound, HTL002, is currently under investigation in the 
Oncology Lab (personal communication from Prof Pandha). HTL002 is a small molecule mimicking 
HTL001 competitive inhibition of HOX-PBX interaction. Small molecules are becoming very 
attractive from a clinical point of view, therefore a chemical inhibition would be more effective 
than a cell penetrating peptide cargo to deliver the therapeutic effect. 
 
The hypothesis of the thesis that an alternative drug delivery strategy would have enhanced 
HTL001 bio-availability at target tissue, prompted us to investigate the use of viral therapy as a 
powerful method to enhance HTL001 concentration locally, avoiding off-target cytotoxicity and 
protecting the core peptide for inhibition from degradation or trapping (Chapter 5). Viral therapy 
was selected given the natural ability of recombinant virus to replicate in a cell to deliver multiple 
copies of the transgene and amplify the response to neighbour cells with a bystander effect. Adeno-
associated viruses were designated for the project for their proven track of safe profile in clinical 
trial phase I [177], the low immunogenicity and the small genome that allows for delivery of a small 
transgene in tandem (multiple copies). The features were perfectly matching HTL001 
characteristics needed for delivery. The pilot study of transfecting ovarian cancer cell lines with a 
plasmid for mammalian expression and two different expression cassettes for HTL001 translation 
and reporter tag (GFP), left open questions due to the low transfection efficacy of ovarian cancer 
cell lines PEA1 and PEA2, the lack of tangible cytotoxic effects and, overall, of a sensitive 
methodology to detect a small fragment such as HTL001 (2.6KDa). A short term goal for the project 
would be an analysis at mass spectrometry of the supernatant and the lysate of the transfected 
cells to overcome the lack of a specific antibody for HTL001 detection and to evaluate the presence 
of truncated products. The open questions to be addressed were, whether the self-cleavage 
operated by 2A peptides was happening and if the cause of an absence of tangible cytotoxic action 
was due to its low concentration or the lack of its translation. A long term goal might consider to 
prepare the recombinant rAAV2-HTL001 and directly infect ovarian cancer cells with the ultimate 
aim of neutralising transfection issues. Moreover, a new expression cassette design should be 
taken into account, perhaps inserting a smaller tag than GFP in the vector to reduce volumetric 
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interference of GFP on the binding motifs to PBX. For example, a histidine tag can be targeted with 
anti-histidine antibodies for downstream applications and removed post-translation when 
necessary with a TEV site. 
The novelty in the present thesis was the proposal that a lack of HTL001 efficacy observed on the 
tissue slices might be due to the limitation on the polyarginine strategy for peptide delivery and 
the work in Chapter 5 was an elegant approach that aimed at overcoming this issue. Despite the 
several initial drawbacks, the results here are setting the guidelines to plan further scientific 
investigation in this direction. Further work should include a revision of the strategy of transfection 
to optimise transfection efficacy, a revision of the expression cassette design strategy and an advice 
for an immediate transfection of HTL001 transgene in the dox-inducible TET vector to obtain 
detectable levels of HTL001 product at mass spectrometry. It is also imperative to prior test in 
cytotoxic and functional assays the biological activity of the resulting peptides (and their 
aminoacidic modifications) after translation to prove that the mechanism of inhibition still rely on 
a HOX-PBX disruption. 
7.5 Unravelling HTL001 molecular mechanism leading to apoptosis 
Another new aspect investigated during my PhD project was to understand the unknown molecular 
action of HTL001 leading cancer cells to undergo a programmed cell death. The identification of 
molecular regulators of a certain signalling pathway initiated by a drug allows researcher to target 
these elements with combination therapy to enhance the response or to use them as biomarkers 
to predict the response. Key players of the apoptotic cascade from intrinsic and extrinsic pathway, 
as well as, regulators of a stress response were included in qPCR array to screen transcriptional 
expression from total mRNA in ovarian cancer cell lines (Chapter 6). The hypothesis was that a 
sudden cytotoxic stress in a range of two hours, which is the working window of HTL001 (or HXR9), 
would have strongly activated the mRNA expression of the programmed cell death machinery. The 
strong cytotoxic input would have changed the balance of the cell moving towards a death signal 
rather than survival orchestrated increasing the mRNA levels of death receptors (Fas family) and 
Caspases family, which would then correspond to more protein level and more post-transcriptional 
activation in a cascade leading to more apoptosis. There are evidences from the literature [165] 
that even caspases and members of the FAS family could be transcriptionally modulated in some 
circumstances. For example, it has been shown that caspase 8 is transcriptionally induced in some 
cases as its promoter contains a p53-responsive element. In cells lacking p53, such as the HGS 
ovarian cancer cells, E2F-1 can induce apoptosis through the transcription of p73, which belonging 
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to the same p53 family shares some of its targets (Apaf-1 and BAX). Other groups indeed reported 
that loss of Retinoblastoma (RB) or forced E2F-1 expression results in direct transcriptional 
upregulation of several caspases. 
The timing of the experiment was set to two hours to be able to link the molecular changes 
happening in the cell after HTL001 exposure with the phenotype observed in the MTS assays 
showed in Chapter 3. Timing is certainly an essential parameter for this experimental design and 
definitely a limitation of this array is that the final output was a picture of the transcriptional 
changes occurring in the “surviving cells” in a relatively short time. More likely, having included 
several longer time points in the experiment and lower concentrations of HTL001 would have given 
probably enough time for the expression of non- early response genes to fully understand the 
process.  
Overall few genes were overexpressed and among them the most noticeable upregulated genes 
were c-JUN, c-FOS, ATF3 and DUSP1. The results were also validated at translation level and 
recapitulated earlier discovery from Morgan and colleagues, who found that melanoma B16 or lung 
cancer A549 cells exposed to HXR9 showed upregulation of c-FOS, c-JUN, DUSP1, ATF3 and EGR1. 
All of those genes belong to a class of immediate early response genes after cellular insult. The role 
of c-FOS in partially contributing to a related HTL001 cell death was documented before [67, 70-
72, 95] and discussed in Section 1.6.3. However, c-FOS together with its binding partner c-JUN 
forms the AP1 complex and plays a strategic role contributing to a large number of cellular 
functions such as proliferation, survival and apoptosis. Therefore it might be challenging to develop 
a specific target therapy without affecting other off-target molecular pathways. However, the 
specific function of DUSP1 as phosphatase to negatively regulate the MAPKs signalling system and 
the presence on the market of BCI, an allosteric inhibitor of DUSP1 function, prompted us to explore 
its role in the signalling cascade in the context of HTL001 treatment and eventually to identify 
DUSP1 as a target for combination therapy. Targeting DUSP1 with a small molecule allosteric 
inhibitor (BCI) demonstrated a beneficial increase in apoptosis for some ovarian cancer cells and 
we proposed it is due to the suppression of the negative feed-back of DUSP1 on the MAPKs 
pathway. The data indicated a possible mediation of HTL001 related apoptosis via the MAPKs 
signalling and suggest DUSP1 as a valid target for a combinational therapy, given its pro-apoptotic 
suppressor role. 
DUSP1 upregulation has a well proven correlation of resistance to certain chemotherapeutics, 
radiotherapy and novel compounds and several examples have been reported in Section 6.1.3. 
Recently a report from Racz et al. [178] demonstrated how reactive oxygen species-activated PARP-
1 via the of JNK and p38 kinases. However, inhibition of PARP with inhibitors upregulated the 
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expression of DUSP1, which in turn deregulated the phosphorylation and so activation of the 
MAPKs involved in the programmed cell death.  The protective role of DUSP1 upon PARP inhibitor 
exposure shows analogies with HTL001 treatment and, broadly, it suggests the use of DUSP1 
inhibitors in combinational therapies to mitigate the intrinsic resistance of cells to apoptosis.   
Nevertheless, Denkert et al. [155] reported gradual loss of DUSP1 expression with higher tumour 
grade in ovarian carcinoma primary tissue. Normal ovarian surface epithelium as well as benign 
adenomas expressed high protein content quantified with immunohistochemistry analysis. The 
decreased expression of DUSP1 in high grade ovarian carcinoma can be explained by a loss of 
DUSP1 protein, which corresponds to a loss of uncontrolled negative feedback regulation resulting 
in a sustained signalling of the MAPKs, in particular of the ERKs, which is generally associated with 
cell proliferation [156]. A re-increase in DUSP1 expression and protein level after HTL001 treatment 
might then correlate with the opportunity to evaluate HTL001 efficacy in cancer cells using DUSP1 
as a marker for prognosis.  
7.6 Final statement 
In conclusion the present thesis brought new perspectives on the therapeutic targeting of HOX 
genes. Years of research on extensively evaluating HOX expression and its selective apoptosis 
induced by HXR9 (HTL001) using mainly simples techniques as qPCR and Annexin V assays partly 
addressed the questions around HOXs gene targeting in a vast number of cell lines derived from 
solid malignancies in vitro and in vivo and the molecular mechanism of action of HTL001. The 
project here set solid bases to move forward an investigation to improve the pharmaceutical 
delivery of HTL001, explore new molecular targets related to its signalling network and estimated 
the drug efficacy  in an innovative experimental platform, as the organotypic culture, close to 
patients’ real responses. The work here also highlighted the limitations of the use of HOXs as 
therapeutic target and proposed new suggestions for future research direction with the aid of new 
technologies that will help to map the HOXs signalling network and HTL001 signalling pathway. 
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Appendix A - Patients’ details 
Sample name Type Stage Chemotherapy 
Patient 1 High grade serous (HGS) IIIc No chemotherapy 
Patient 2 HGS Iva Pre-surgery 
Patient 3 Endometrioid Ic No chemotherapy 
Patient 4 HGS IVb Pre-surgery 
Patient 5 HGS IIIc Post-surgery 
Patient 6 HGS and clear cells IIIc Pre-surgery 
Patient 7 HGS IVb Pre-surgery 
Patient 8 HGS IIIc Pre-surgery 
Patient 9 HGS IIIc Pre-surgery 
Patient 10 HGS IVa Pre-surgery 
Appendix A. Table summarising sample details including sample name, type of ovarian 
carcinoma and stage according to FIGO classification.  
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Appendix B - List of abstracts, conferences and publications 
 
I. Abstract and poster accepted for NCRI 2016 Liverpool and ESMO 2016 Copenhagen 
conferences: 
 
“Organotypic slice ovarian cancer model as a platform to test novel therapeutics”. 
G. Falgari, A. Michael, N. Annels, P. Ellis, W. Ashbourne, S. Butler Manuel and H.S. Pandha. 
 
Background: An effective way to test new drugs in a pre-clinical setting remains a challenging task. 
Ovarian cancer models are particularly difficult as the tumours are very heterogeneous and 
although progress has been made with testing cell lines derived from ascites- new platforms are 
needed. Precision cut tumour slices have been tested for many years and the technique is 
improving. Organotypic culture could potentially offer a platform to test drugs without having to 
rely on laboratory animal models. Testing individual tumour' sensitivity to cytotoxics would allow 
for a personalized approach to cancer treatment and would help to avoid some of the unnecessary 
toxicity. We have developed an organotypic slice ovarian cancer culture model that allows for 
testing cytotoxics and targeted agents on tissue taken directly from patients. 
Methods: Tumour tissue obtained from patients undergoing operation for ovarian cancer was 
biopsied using a core punch biopsy. The tumours were sliced on a vibrating microtome into 300 µm 
thick slices and cultivated in culture. Slices were harvested at various time points and fixed in 10% 
buffered formalin before embedding in paraffin. The viability, morphology, and proliferation index 
of the cultivated slices were analysed by immunochemistry (IHC) using H&E, ki67, cleaved Caspase 
3 assay and compared to the original tumour biopsy. The cultivated tumour slices were also treated 
with cisplatin and saline control. 
Results: Core punch biopsies were obtained from 18 high grade serous ovarian tumors and one 
endometroid tumour and cultured for up to seven days. The tissue viability assessed using ki67 
showed high proliferation rate at the start of the culture and low levels of apoptosis. The apoptosis 
index varied depending on the individual culture conditions and the number of necrotic cells have 
increased. The morphology of the tissue was retained throughout. Following administration of 
cisplatin we were able to observe clear signs of necrotic and apoptotic cell death. The platform is 
currently being used to test the effect of other cytotoxics as well as novel drugs. 
Conclusions: organotypic slice ovarian cancer model is a new way of assessing sensitivity to 
anticancer agents and has promising potential for use in personalized cancer treatment. 
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II. Abstract accepted for BGCS (British Gynaecological Cancer Society) conference 2018 in 
London and presented as a proffered paper: 
 
“Exploring the role of DUSP1 inhibition in chemo-resistant ovarian carcinoma cell lines”.  
G. Falgari, H. Pandha and A. Michael. 
 
Introduction: HTL001 is a synthetic peptide that disrupts the interaction between HOX proteins and 
PBX co-factors, and blocks PBX-dependent HOX functions. HOX genes are normally active during 
embryogenesis and later become over-expressed in several solid tumours, including ovarian 
carcinoma, promoting tumorigenesis and metastasis. HOX/PBX inhibition with HTL001 drives 
cancer cells through apoptosis. Our preliminary work shows that the treatment of ovarian cancer 
cell lines, PEA1 and PEA2, (platinum sensitive and resistant) with HTL001 induces a rapid spike in 
the gene and protein expression of DUSP1, C-FOS and ATF3.  DUSP1 (Dual-specificity phosphatase-
1) de-phosphorylates several MAPKs, including ERK1/2, p38 and JNK1/2 and acts as a negative 
regulator of several pathways involved in cell proliferation and stress response.  There is evidence 
that DUSP1 overexpression could be responsible for intrinsic resistance of tumours to 
chemotherapy, radiotherapy and cytotoxic compounds. We investigated whether the use of a 
DUSP1 inhibitor (BCI) could enhance the apoptosis efficiency of HTL001 by targeting the negative 
regulation of DUSP1. 
Methods: BCI was purchased from Axon Medchem. PEA1 and PEA2 cell lines were donated by Prof 
H. Gabra. DUSP1, C-FOS and ATF3 expression were assessed using a Qiagen RT2 profiler PCR array 
for apoptosis pathways and candidate targets were validated for protein expression with Western 
Blot. Metabolism of cells treated with HTL001, without or in combination with BCI, was performed 
through a MTS assay and mode of death was detected via an Annexin V assay. 
Results: treatment of PEA1 and PEA2 with HTL001 induced an overexpression of DUSP1, C-FOS and 
ATF3 protein. BCI was subsequently tested for its ability to inhibit DUSP1 dependent de-
phosphorylation of ERK1/2, p38 and JNK1/2 kinases at the dose ineffective on cell viability and was 
found to be more effective in platinum-resistant PEA2 cell line. The combined treatment of BCI and 
HTL001 increased the level of apoptosis, in particular in the platinum resistant cell line PEA2. 
Conclusions: DUSP1 works as a negative regulator of stress response towards cytotoxic agents and 
could be an interesting target for therapy in platinum resistant ovarian carcinoma. 
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III. Pending publication for Clinical Medicine Insights: Women's Health (short outline):  
 
“Exploring the role of DUSP1 in cancer chemoresistance”. 
G. Falgari, H. Pandha and A. Michael. 
 
Dual Specific Phosphatase -1 (DUSP1) is one of the 25 members of the family of tyrosine 
phosphatases. MKP-1 (MAPK phosphatase-1) is the alternative name given to the protein whose 
ATP-ase catalytic domain has the ability to de-phosphorylate the MAPKs proteins ERKs (1/2), JNKs 
(1/2), and p38. There is evidence of DUSP1 playing an important role in cytotoxic agents responses, 
inflammation and apoptosis, working as a negative regulator of the MAPK signalling pathways. 
The current review will explore the role of DUSP1 in the context of cancer chemoresistance, with a 
focus on gynaecological malignancies. Activation of DUSP1 molecular signalling network will be 
analysed in response to conventional therapies (cisplatin, paclitaxel, gemcitabine) and novel 
therapeutics (Lapatinib, HTL001 - unpublished data) and a correlation with cancer cells intrinsic 
mechanisms of resistance proposed. 
Concluding remarks will focus on the attention of the use of DUSP1 as a candidate target for drug 
discovery and combination therapy for the management of relapsed or refractory cancer patients. 
 
 
IV. Publication in progress: 
 
“HOX gene expression in colorectal cancer and its clinicopathological significance: a systematic 
review of the literature”. 
E. Martinou, G. Falgari, G. Simpson, I. Bagwan, R. Morgan, ND. Karanjia and H. Pandha.  
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